



(11) **EP 1 094 070 A2**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
25.04.2001 Bulletin 2001/17

(51) Int. Cl.⁷: **C07K 14/205, C12N 15/31**

(21) Application number: **00309125.3**

(22) Date of filing: **17.10.2000**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**
Designated Extension States:
AL LT LV MK RO SI

(72) Inventor:
**Rosey, Everett Lee,
Pfizer Central Research
Groton, Connecticut 06340 (US)**

(30) Priority: **22.10.1999 US 160922 P**

(74) Representative:
**Eddowes, Simon et al
Urquhart-Dykes & Lord,
30 Welbeck Street
London W1G 8ER (GB)**

(83) Declaration under Rule 28(4) EPC (expert
solution)


(71) Applicant: **Pfizer Products Inc.
Groton, Connecticut 06340 (US)**

(54) **Lawsonia intracellularis proteins, and related methods and materials**

(57) Isolated polynucleotide molecules contain a nucleotide sequence that encodes a *L. intracellularis* HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100 protein, a substantial portion of the sequences, or a homol-

ogous sequence. Related polypeptides, immunogenic compositions and assays are described.

FIG. 1



Entry into National Phase of PCT/EP2005/000562
Express Mail: EV 829030969 US
Attorney Docket: 1-2004.001 US

EP 1 094 070 A2

Description**FIELD OF THE INVENTION**

- 5 [0001] The present invention relates to protens derived from *Lawsonia intracellularis* and encompasses related proteins, nucleic acids, and immunogenic compositions. The immunogenic compositions are particularly useful in prevention of *L. intracellularis* infections in susceptible animals, such as pigs. The proteins, fragments, and nucleic acids can also be employed as diagnostic agents.

BACKGROUND OF THE INVENTION

- [0002] Commercially raised pigs are sensitive to a wide spectrum of intestinal diseases or syndromes that are collectively referred to as porcine proliferative enteropathy (PPE). These diseases include intestinal adenomatosis complex (Barker I. K. et al., 1985, In "Pathology of Domestic Animals," 3rd Edition, Vol. 2 p. 1-237, eds. K. V. F. Jubb et al. (Academic Press: Orlando)), porcine intestinal adenomatosis (PIA), necrotic enteritis (Rowland A. C. et al., 1976, *Veterinary Record* 97:178-180), proliferative haemorrhagic enteropathy (Love, R. J. et al., 1977, *Veterinary Record* 100: 473), regional ileitis (Jonsson, L. et al., 1976, *Acta Veterinaria Scandinavica* 17: 223-232), haemorrhagic bowel syndrome (O'Neil, I. P. A., 1970, *Veterinary Record* 87:742-747), porcine proliferative enteritis and *Campylobacter* spp - induced enteritis (Straw, B. E., 1990, *Journal of American Veterinary Medical Association* 197: 355-357).

- 20 [0003] One major type of PPE is non-haemorrhagic and is manifested by porcine intestinal adenomatosis (PIA). This form of PPE frequently causes growth retardation and mild diarrhea. Another important type of PPE is haemorrhagic. It is often fatal, and is manifested by proliferative haemorrhagic enteropathy (PHE) wherein the distal small intestine lumen becomes engorged with blood.

- [0004] While PPE in pigs is commercially most important, PPE is also a problem in the raising of hamsters (Stills, H. F., 1991, *Infection and Immunology* 59: 3227-3236), ferrets (Fox et al., 1989, *Veterinary Pathology* 26: 515-517), guinea pigs (Elwell et al., 1981, *Veterinary Pathology* 18: 136-139), rabbits (Schodeb et al., 1990, *Veterinary Pathology* 27: 73-80) and certain birds (Mason et al., 1998).

- [0005] The organism that causes PPE is the *Campylobacter*-like bacterium "*L. intracellularis*" (McOrist S et al., 1995, *International Journal Of Systematic Bacteriology* 45: 820-825). This organism is also known as heal symbiont intracellularis (Stills, 1991, *supra*). PPE-like diseases in pigs may also be caused by other species of *Campylobacter* (Gebhart et al., 1983, *American Journal of Veterinary Research* 44: 361-367).

- [0006] *L. intracellularis* is located in the cytoplasm of villi and intestinal crypt cells of infected animals, where it causes structural irregularities and enterocyte proliferation. Abscesses form as the villi and intestinal crypts become branched and fill with inflammatory cells.

- 35 [0007] Current control of PPE relies on the use of antibacterial compounds. There is, however, a need for alternative means of controlling *L. intracellularis* infection.

- [0008] International Patent Application No. PCT/AU96/00767 describes *L. intracellularis* polypeptides and immunogenic compositions that are useful as vaccines. There is, however, a need for additional compositions that confer resistance to *L. intracellularis* infection.

SUMMARY OF THE INVENTION

- 40 [0009] The present invention relates to an isolated polynucleotide molecule comprising a nucleotide sequence that is selected from the group consisting of:

- 45 a) a nucleotide sequence encoding *L. intracellularis* HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100 protein;
b) a nucleotide sequence that is a substantial part of the nucleotide sequence encoding the *L. intracellularis* HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100 protein; and
c) a nucleotide sequence that is homologous to the nucleotide sequence of a) or b).

- 50 [0010] In another aspect, the invention relates to a recombinant vector comprising these polynucleotide molecules, including those encoding a carrier or fusion partner such that expression of the recombinant vector results in a fusion protein comprising the carrier or fusion partner fused to a protein or polypeptide encoded by the nucleotide sequences described above. The invention also encompasses transformed host cells comprising these recombinant vectors and polypeptides produced by such transformed host cells.

- 55 [0011] In another aspect, the present invention relates to an isolated polypeptide that is selected from the group consisting of:

- (a) *L. intracellularis* HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100 protein;
- (b) a polypeptide having an amino acid sequence that is homologous to that of the *L. intracellularis* HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100 protein;
- (c) a polypeptide consisting of a substantial portion of the *L. intracellularis* HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100 protein or of the polypeptide having an amino acid sequence that is homologous to that of the *L. intracellularis* HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100 protein;
- (d) a fusion protein comprising the protein or polypeptide of (a), (b) or (c) fused to another protein or polypeptide; and
- (e) an analog or derivative of the protein or polypeptide of (a), (b), (c) or (d).

[0012] The present invention further provides a polynucleotide molecule comprising a nucleotide sequence of greater than 20 nucleotides having promoter activity and found within SEQ ID NO: 2 from about nt 2691 to about nt 2890.

[0013] The present invention further relates to a method of preparing any of these polypeptides, comprising culturing host cells transformed with a recombinant expression vector and recovering the expressed polypeptide from the cell culture. The vector comprises a polynucleotide molecule comprising a nucleotide sequence encoding any of the polypeptides, the nucleotide sequence being in operative association with one or more regulatory elements. Culturing is conducted under conditions conducive to expression of the polypeptide.

[0014] In yet another aspect, the invention relates to an isolated antibody that specifically reacts with any of the *L. intracellularis* HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100 proteins or polypeptides described above.

[0015] The invention also relates to an immunizing composition that comprises an immunologically effective amount of a protein, polypeptide, antibody, or polynucleotide of the invention in combination with a pharmaceutically acceptable carrier. The present invention encompasses a method of immunizing a PPE susceptible animal against *L. intracellularis* infection that comprises administering to the animal the immunizing composition.

[0016] The invention also relates to a kit for immunizing a PPE susceptible animal against a disease condition caused or exacerbated by *L. intracellularis* that comprises a container having therein an immunologically effective amount of one of the proteins, polypeptides, antibodies, or polynucleotides described above. The invention also relates to a kit for detecting the presence of *L. intracellularis*, an *L. intracellularis* specific amino acid or nucleotide sequence, or an anti- *L. intracellularis* antibody, comprising a container that has therein a protein, polypeptide, polynucleotide, or antibody of the invention.

BRIEF DESCRIPTION OF DRAWINGS

[0017]

Figure 1 shows the arrangement of gene cluster A, containing the genes encoding the LysS, YcfW, ABC1 and Omp100 proteins, and the arrangement of gene cluster B, encoding the PonA, HtrA, and HypC proteins.

Figure 2 shows an alignment of the YcfW amino acid sequence with the most similar sequence found in a search of the GenBank database.

Figure 3 shows an alignment of the ABC1 amino acid sequence with the most similar sequence found in a search of the GenBank database.

Figure 4 shows an alignment of the Omp100 amino acid sequence with the most similar sequence found in a search of the GenBank database.

Figure 5 shows an alignment of the PonA amino acid sequence with the most similar sequence found in a search of the GenBank database.

Figure 6 shows an alignment of the HtrA amino acid sequence with the most similar sequence found in a search of the GenBank database.

Figure 7 shows an alignment of the HypC amino acid sequence with the most similar sequence found in a search of the GenBank database.

Figure 8 shows an alignment of the Orf1 amino acid sequence with the most similar sequence found in a search of the GenBank database.

Figure 9 shows an alignment of the LysS amino acid sequence with the most similar sequence found in a search of the GenBank database.

DETAILED DESCRIPTION OF THE INVENTION

[0018] All patents, patent applications, and publications cited herein are hereby incorporated by reference in their entireties.

Polynucleotide Molecules

[0019] An isolated polynucleotide molecule of the present invention can have a nucleotide sequence derived from any species or strain of *Lawsonia*, but is preferably from the species *intracellularis*. Pathogenic strains or species of *Lawsonia* for use in practicing the present invention can be isolated from organs, tissues or body fluids of infected animals using isolation techniques as described below.

[0020] As used herein, the terms "polynucleotide molecule," "polynucleotide sequence," "coding sequence," "open-reading frame (ORF)," and the like, are intended to refer to both DNA and RNA molecules, which can either be single-stranded or double-stranded, and that can include one or more prokaryotic sequences, cDNA sequences, genomic DNA sequences including exons and introns, and chemically synthesized DNA and RNA sequences, and both sense and corresponding anti-sense strands. As used herein, the term "ORF" refers to the minimal nucleotide sequence required to encode a *Lawsonia* HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100 protein, without any intervening termination codons.

[0021] Production and manipulation of the polynucleotide molecules and oligonucleotide molecules disclosed herein are within the skill in the art and can be carried out according to recombinant techniques described, among other places, in Maniatis *et al.*, 1989, Molecular Cloning. A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Ausubel *et al.*, 1989, Current Protocols In Molecular Biology, Greene Publishing Associates & Wiley Interscience, NY; Sambrook *et al.*, 1989, Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Innis *et al.* (eds), 1995, PCR Strategies, Academic Press, Inc., San Diego; and Erlich (ed), 1992, PCR Technology, Oxford University Press, New York and all revisions of these references.

[0022] References herein to the nucleotide sequences shown in SEQ ID NOS: 1 AND 2, and to substantial portions thereof, are intended to also refer to the corresponding nucleotide sequences and substantial portions thereof, respectively, as present in the following plasmids contained in *E. coli* Top10 cells deposited by Pfizer Inc. at Central Research, Eastern Point Road, Groton, CT, 06340 with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD, 20852:

pER432 containing the *ponA* gene and accorded ATCC accession number PTA-635, deposited on September 9, 1999;

pER434 containing the *htrA* gene and accorded ATCC accession number PTA-636, deposited on September 9, 1999;

pER436 containing the *hypC* gene and accorded ATCC accession number PTA-637, deposited on September 9, 1999;

pER438 containing the *ycfW* and *abc1* genes and accorded ATCC accession number PTA-638, deposited on September 9, 1999;

pER440 containing the *omp100* gene and accorded ATCC accession number PTA-639, deposited on September 9, 1999; and

pT068 containing the *lysS* and *ycfW* genes and accorded ATCC accession number PTA-2232, deposited on July 14, 2000.

[0023] In addition, references herein to the amino acid sequences shown in SEQ ID NOS:3-9, and SEQ ID NO: 102, and to substantial portions and peptide fragments thereof, are intended to also refer to the corresponding amino acid sequences, and substantial portions and peptide fragments thereof, respectively, encoded by the corresponding protein encoding nucleotide sequences present in the plasmids listed above, unless otherwise indicated.

HtrA-Related Polynucleotide Molecules

[0024] The present invention provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding the HtrA protein from *L. intracellularis*. In a preferred embodiment, the HtrA protein has the amino acid sequence of SEQ ID NO: 7. In a further preferred embodiment, the isolated HtrA-encoding polynucleotide molecule of the present invention comprises a nucleotide sequence selected from the group consisting of the nucleotide sequence of SEQ ID NO: 2 from about nt 2891 to about nt 4315, which is the nucleotide sequence of the open reading frame (ORF) of the *htrA* gene, and the nucleotide sequence of the HtrA-encoding ORF of plasmid pER434 (ATCC accession number PTA-636).

[0025] The present invention further provides an isolated polynucleotide molecule having a nucleotide sequence that is homologous to the nucleotide sequence of a HtrA-encoding polynucleotide molecule of the present invention. The term "homologous" when used to refer to a HtrA-related polynucleotide molecule means a polynucleotide molecule having a nucleotide sequence: (a) that encodes the same protein as one of the aforementioned HtrA-encoding polynucleotide molecules of the present invention, but that includes one or more silent changes to the nucleotide sequence

according to the degeneracy of the genetic code; or (b) that hybridizes to the complement of a polynucleotide molecule having a nucleotide sequence that encodes the amino acid sequence of the *L. intracellularis* HtrA protein under at least moderately stringent conditions, *i.e.*, hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65°C, and washing in 0.2xSSC/0.1% SDS at 42°C (see Ausubel *et al.* (eds.), 1989, Current Protocols in Molecular Biology, Vol. 1, Green Publishing Associates, Inc., and John Wiley & Sons, Inc., New York, at p. 2.10.3), and that is useful in practicing the present invention. In a preferred embodiment, the homologous polynucleotide molecule hybridizes to the complement of a polynucleotide molecule having a nucleotide sequence that encodes the amino acid sequence of the *L. intracellularis* HtrA protein under highly stringent conditions, *i.e.*, hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% SDS, 1 mM EDTA at 65°C, and washing in 0.1xSSC/0.1% SDS at 68°C (Ausubel *et al.*, 1989, above), and is useful in practicing the present invention. In a more preferred embodiment, the homologous polynucleotide molecule hybridizes under highly stringent conditions to the complement of a polynucleotide molecule consisting of a nucleotide sequence selected from the group consisting of the HtrA encoding ORF of SEQ ID NO: 2, which is from about nt 2891 to about nt 4315. As noted above, reference to homologous polynucleotide molecules herein is also intended to refer to the complements of such molecules.

[0026] As used herein, a polynucleotide molecule is "useful in practicing the present invention" where the polynucleotide molecule can be used to amplify a *Lawsonia*-specific polynucleotide molecule using a standard amplification technique, such as the polymerase chain reaction, or as a diagnostic reagent to detect the presence of a *Lawsonia*-specific polynucleotide in a fluid or tissue sample from a *Lawsonia*-infected animal, or where the polynucleotide molecule encodes a polypeptide that is useful in practicing the invention, as described below.

[0027] Polynucleotide molecules of the present invention having nucleotide sequences that are homologous to the nucleotide sequence of a HtrA-encoding polynucleotide molecule of the present invention do not include polynucleotide molecules that have been described from bacteria such as *E. coli*, *S. typhimurium*, *C. jejuni*, *H. influenzae*, *B. melitensis*, *B. abortus*, *C. trachomatis*, *Y. enterocolitica*, *Rickettsia*, *B. burgdorferi*, and *B. subtilis*. The *L. intracellularis* HtrA protein encoded by SEQ ID NO: 2 has 39.6% identity of amino acid sequence with the *B. abortus* HtrA protein. The *L. intracellularis* protein is 474 residues in length and the *B. abortus* protein is 513 residues in length. The *L. intracellularis* protein is 35.4% identical to that of *H. influenzae*.

[0028] The homologous nucleotide sequence of the molecule of the invention preferably comprises a sequence that has more than 50%, more preferably more than about 90%, even more preferably more than about 95%, and most preferably more than about 99% sequence identity to the molecule of SEQ ID NO: 2, which is from about nt 2891 to about nt 4315, wherein sequence identity is determined by use of the BLASTN algorithm (GenBank, National Center for Biotechnology Information).

[0029] In another embodiment, the polynucleotide has a homologous sequence that is more than about 50% of the length of the nucleotide sequence encoding the *L. intracellularis* HtrA protein. In another embodiment the sequence is more than 70%, in another embodiment the sequence is more than 90%, and in another embodiment more than about 98%, of the length of the nucleotide sequence encoding the *L. intracellularis* protein. In yet another embodiment, the isolated polynucleotide that has a homologous sequence is equal in length to the sequence encoding the *L. intracellularis* HtrA protein.

[0030] In yet another embodiment, the nucleotide sequence that is homologous to the *L. intracellularis* HtrA protein encoding sequence has between 1 and 50, more preferably between 1 and 25, and most preferably between 1 and 5 nucleotides inserted, deleted, or substituted with respect to the sequence of SEQ ID NO: 2 which is from about nt 2891 to about nt 4315.

[0031] The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide that is homologous to the *L. intracellularis* HtrA protein. As used herein to refer to polypeptides that are homologous to the *L. intracellularis* HtrA protein, the term "homologous" refers to a polypeptide otherwise having the amino acid sequence of the *L. intracellularis* HtrA protein, but in which one or more amino acid residues has been substituted with a different amino acid residue, where the resulting polypeptide is useful in practicing the present invention. Conservative amino acid substitutions are well-known in the art. Rules for making such substitutions include those described by Dayhof, M.D., 1978, Nat. Biomed. Res. Found., Washington, D.C., Vol. 5, Sup. 3, among others. More specifically, conservative amino acid substitutions are those that generally take place within a family of amino acids that are related in acidity, polarity, or bulkiness of their side chains. Genetically encoded amino acids are generally divided into four groups: (1) acidic = aspartate, glutamate; (2) basic = lysine, arginine, histidine; (3) non-polar = alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar = glycine, asparagine, glutamine, cysteine, serine, threonine, and tyrosine. Phenylalanine, tryptophan and tyrosine are also jointly classified as aromatic amino acids. One or more replacements within any particular group, *e.g.*, of a leucine with an isoleucine or valine, or of an aspartate with a glutamate, or of a threonine with a serine, or of any other amino acid residue with a structurally related amino acid residue, *e.g.*, an amino acid residue with similar acidity, polarity, bulkiness of side chain, or with similarity in some combination thereof, will generally have an insignificant effect on the function or immunogenicity of the polypeptide. In a preferred embodiment, the homologous polypeptide has at least about

50%, more preferably at least about 70%, and even more preferably at least about 90% sequence identity, and most preferably at least 95% sequence identity to SEQ ID NO: 7.

[0032] In another embodiment, the polynucleotide encodes an isolated polypeptide consisting of the *L. intracellularis* HtrA protein having between 1 and 10, and more preferably between 1 and 5, amino acids inserted, deleted, or substituted, including combinations thereof. In a more particular example of this embodiment, the polynucleotide encodes an isolated polypeptide having between 1 and 5 amino acids conservatively substituted for the HtrA sequence of SEQ ID NO: 7.

[0033] As used herein, a polypeptide is "useful in practicing the present invention" where the polypeptide can be used as a diagnostic reagent to detect the presence of *Lawsonia*-specific antibodies in a blood, serum, or other biological fluid sample from an animal that has developed an immune response to *Lawsonia*. The polypeptide is also useful if it can be used to induce an immune response in an animal against *Lawsonia*.

[0034] The present invention further provides a polynucleotide molecule consisting of a substantial portion of any of the aforementioned *Lawsonia* HtrA-related polynucleotide molecules of the present invention. As used herein, a "substantial portion" of a HtrA-related polynucleotide molecule means a polynucleotide molecule consisting of less than the complete nucleotide sequence of the HtrA-related polynucleotide molecule, but comprising at least about 5%, more preferably at least about 10%, and even more preferably at least about 20%, and most preferably at least about 50% of the nucleotide sequence of the HtrA-related polynucleotide molecule, and that is useful in practicing the present invention. Such polynucleotide molecules include, for example polynucleotide molecules encoding peptide fragments of the HtrA protein.

[0035] In addition to the nucleotide sequences of any of the aforementioned HtrA-related polynucleotide molecules, polynucleotide molecules of the present invention can further comprise, or alternatively may consist of, nucleotide sequences selected from those that naturally flank the HtrA ORF or gene *in situ* in *L. intracellularis*, and include the nucleotide sequences shown in SEQ ID NO: 2 from about nt 2691 to about nt 2890 and from about nt 4316 to about nt 4580, or substantial portions thereof.

PonA -Related Polynucleotide Molecules

[0036] The present invention provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding the PonA protein from *L. intracellularis*. In a preferred embodiment, the PonA protein has the amino acid sequence of SEQ ID NO: 6. In a further preferred embodiment, the isolated PonA-encoding polynucleotide molecule of the present invention comprises a nucleotide sequence selected from the group consisting of the nucleotide sequence of SEQ ID NO: 2 from about nt 252 to about nt 2690 (the nucleotide sequence of the open reading frame (ORF) of the PonA gene) and the nucleotide sequence of the PonA-encoding ORF of plasmid pER432 (ATCC accession number PTA-635).

[0037] The present invention further provides an isolated polynucleotide molecule having a nucleotide sequence that is "homologous" to the nucleotide sequence of a PonA-encoding polynucleotide molecule of the present invention, as that term is correspondingly defined above with respect to HtrA related polynucleotide molecules. In a preferred embodiment, the homologous polynucleotide molecule hybridizes to the complement of a polynucleotide molecule having a nucleotide sequence that encodes the amino acid sequence of the *L. intracellularis* PonA protein under highly stringent conditions. In a more preferred embodiment, the homologous polynucleotide molecule hybridizes under highly stringent conditions to the complement of a polynucleotide molecule consisting of a nucleotide sequence of SEQ ID NO: 2 from about nt 252 to about nt 2690.

[0038] Polynucleotide molecules of the present invention having nucleotide sequences that are homologous to the nucleotide sequence of a PonA-encoding polynucleotide molecule of the present invention do not include known polynucleotide molecules encoding PonA proteins of *Neisseria flavescens*, *N. gonorrhoeae*, and *N. meningitidis*.

[0039] The homologous nucleotide sequence of the molecule of the invention preferably comprises a sequence that has more than 50%, more preferably more than about 90%, even more preferably more than about 95%, and most preferably more than about 99% sequence identity to the molecule of SEQ ID NO: 2, which is from about nt 252 to about nt 2690, wherein sequence identity is determined by use of the BLASTN algorithm (GenBank, National Center for Biotechnology Information).

[0040] In another embodiment, the polynucleotide has a homologous sequence that is more than about 50% of the length of the nucleotide sequence encoding the *L. intracellularis* PonA protein. In another embodiment, the sequence is more than 90%, and in another embodiment more than about 98%, of the length of the nucleotide sequence encoding the *L. intracellularis* protein. In yet another embodiment, the isolated polynucleotide that has a homologous sequence is equal in length to the sequence encoding the *L. intracellularis* PonA protein.

[0041] In yet another embodiment, the nucleotide sequence that is homologous to the *L. intracellularis* PonA protein encoding sequence has between 1 and 50, more preferably between 1 and 25, and most preferably between 1 and 5 nucleotides inserted, deleted, or substituted with respect to the sequence of SEQ ID NO: 2.

[0042] The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide that is "homologous" to the *L. intracellularis* PonA protein, as that term is correspondingly described with respect to the HtrA protein above. In a preferred embodiment, the homologous polypeptide has at least about 50%, more preferably at least about 70%, and even more preferably at least about 90% sequence identity, and most preferably at least 95% sequence identity to SEQ ID NO: 6.

[0043] In another embodiment, the polynucleotide encodes an isolated polypeptide consisting of the *L. intracellularis* PonA protein having between 1 and 10, and more preferably between 1 and 5, amino acids inserted, deleted, or substituted, including combinations thereof. In a more particular example of this embodiment, the polynucleotide encodes an isolated polypeptide having between 1 and 5 amino acids conservatively substituted for the PonA sequence of SEQ ID NO: 6.

[0044] The present invention further provides a polynucleotide molecule consisting of a "substantial portion" of any of the aforementioned *Lawsonia* PonA-related polynucleotide molecules of the present invention, as that term is correspondingly described above with respect to the HtrA protein.

[0045] In addition to the nucleotide sequences of any of the aforementioned PonA-related polynucleotide molecules, polynucleotide molecules of the present invention can further comprise, or alternatively may consist of, nucleotide sequences selected from those that naturally flank the *ponA* ORF or gene *in situ* in *L. intracellularis*, and include the nucleotide sequences shown in SEQ ID NO: 2 from about nt 126 to about nt 251 and from about nt 2691 to about nt 2890, or substantial portions thereof.

HypC -Related Polynucleotide Molecules

[0046] The present invention provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding the HypC protein from *L. intracellularis*. In a preferred embodiment, the HypC protein has the amino acid sequence of SEQ ID NO: 8. In a further preferred embodiment, the isolated HypC-encoding polynucleotide molecule of the present invention comprises a nucleotide sequence selected from the group consisting of the nucleotide sequence of SEQ ID NO: 2 from about nt 4581 to about nt 4829, and the nucleotide sequence of the HypC-encoding ORF of plasmid pER436 (ATCC accession number PTA-637).

[0047] The present invention further provides an isolated polynucleotide molecule having a nucleotide sequence that is "homologous" to the nucleotide sequence of a HypC-encoding polynucleotide molecule of the present invention, as that term is correspondingly defined above with respect to HtrA related polynucleotide molecules. In a preferred embodiment, the homologous polynucleotide molecule hybridizes to the complement of a polynucleotide molecule having a nucleotide sequence that encodes the amino acid sequence of the *L. intracellularis* HypC protein under highly stringent conditions. In a more preferred embodiment, the homologous polynucleotide molecule hybridizes under highly stringent conditions to the complement of a polynucleotide molecule consisting of a nucleotide sequence selected from the group consisting of the ORF of SEQ ID NO: 2 from about nt 4581 to about nt 4829.

[0048] Polynucleotide molecules of the present invention having nucleotide sequences that are homologous to the nucleotide sequence of a HypC-encoding polynucleotide molecule of the present invention do not include polynucleotide molecules encoding HypC or HypD proteins of *Desulfovibrio gigas* and *Rizobium leguminosarum*.

[0049] The homologous nucleotide sequence of the molecule of the invention preferably comprises a sequence that has more than 50%, more preferably more than about 90%, even more preferably more than about 95%, and most preferably more than about 99% sequence identity to the molecule of SEQ ID NO: 2, which is from about nt 4581 to about nt 4829, wherein sequence identity is determined by use of the BLASTN algorithm (GenBank, National Center for Biotechnology Information).

[0050] In another embodiment, the polynucleotide has a homologous sequence that is more than about 50% of the length of the nucleotide sequence encoding the *L. intracellularis* HypC protein. In another embodiment, the sequence is more than 90%, and in another embodiment more than about 98%, of the length of the nucleotide sequence encoding the *L. intracellularis* HypC protein. In yet another embodiment, the isolated polynucleotide that has a homologous sequence is equal in length to the sequence encoding the *L. intracellularis* HypC protein.

[0051] In yet another embodiment, the nucleotide sequence that is homologous to the *L. intracellularis* HypC protein encoding sequence has between 1 and 50, more preferably between 1 and 25, and most preferably between 1 and 5 nucleotides inserted, deleted, or substituted with respect to the sequence of SEQ ID NO: 2.

[0052] The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide that is "homologous" to the *L. intracellularis* HypC protein, as that term is correspondingly described with respect to the HtrA protein above. In a preferred embodiment, the homologous polypeptide has at least about 50%, more preferably at least about 70%, and even more preferably at least about 90% sequence identity, and most preferably at least 95% sequence identity to SEQ ID NO: 8.

[0053] In another embodiment, the polynucleotide encodes an isolated polypeptide consisting of the *L. intracellularis* HypC protein having between 1 and 10, and more preferably between 1 and 5, amino acids inserted,

deleted, or substituted, including combinations thereof. In a more particular example of this embodiment, the polynucleotide encodes an isolated polypeptide having between 1 and 5 amino acids conservatively substituted for the HypC sequence of **SEQ ID NO: 8**.

[0054] The present invention further provides a polynucleotide molecule consisting of a "substantial portion" of any of the aforementioned *Lawsonia HypC*-related polynucleotide molecules of the present invention, as that term is correspondingly described above with respect to the HtrA protein.

[0055] In addition to the nucleotide sequences of any of the aforementioned *HypC*-related polynucleotide molecules, polynucleotide molecules of the present invention can further comprise, or alternatively may consist of, nucleotide sequences selected from those that naturally flank the *hypC* ORF or gene *in situ* in *L. intracellularis*, and include the nucleotide sequences shown in **SEQ ID NO: 2** from about nt 4316 to about nt 4580 and from about nt 4830 to about nt 4911, or substantial portions thereof.

LysS -Related Polynucleotide Molecules

[0056] The present invention provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding a LysS protein from *L. intracellularis*. In a preferred embodiment, the LysS protein has the amino acid sequence of **SEQ ID NO: 102**. In a further preferred embodiment, the isolated LysS-encoding polynucleotide molecule of the present invention comprises a nucleotide sequence selected from the group consisting of the nucleotide sequence of **SEQ ID NO: 1** from about nt 165 to about nt 1745 of the nucleotide sequence of the *lysS* gene, and the nucleotide sequence of the LysS-encoding ORF of plasmid pT068 (ATCC accession number PTA-2232).

[0057] The present invention further provides an isolated polynucleotide molecule having a nucleotide sequence that is "homologous" to the nucleotide sequence of a LysS-encoding polynucleotide molecule of the present invention, as that term is correspondingly defined above with respect to HtrA related polynucleotide molecules. In a preferred embodiment, the homologous polynucleotide molecule hybridizes to the complement of a polynucleotide molecule having a nucleotide sequence that encodes the amino acid sequence of the *L. intracellularis* LysS protein under highly stringent conditions. In a more preferred embodiment, the homologous polynucleotide molecule hybridizes under highly stringent conditions to the complement of a polynucleotide molecule consisting of a nucleotide sequence of **SEQ ID NO: 1** from about nt 165 to about nt 1745.

[0058] The homologous nucleotide sequence of the molecule of the invention preferably comprises a sequence that has more than 50%, more preferably more than about 90%, even more preferably more than about 95%, and most preferably more than about 99% sequence identity to the molecule of **SEQ ID NO: 1** from about nt 165 to about nt 1745, wherein sequence identity is determined by use of the BLASTN algorithm (GenBank, National Center for Biotechnology Information).

[0059] In another embodiment, the polynucleotide has a homologous sequence that is more than about 50% of the length of the nucleotide sequence encoding the *L. intracellularis* LysS protein. In another embodiment, the sequence is more than 90%, and in another embodiment more than about 98%, of the length of the nucleotide sequence encoding the *L. intracellularis* LysS protein. In yet another embodiment, the isolated polynucleotide that has a homologous sequence is equal in length to the sequence encoding the *L. intracellularis* LysS protein.

[0060] In yet another embodiment, the nucleotide sequence that is homologous to the *L. intracellularis* LysS protein encoding sequence has between 1 and 50, more preferably between 1 and 25, and most preferably between 1 and 5 nucleotides inserted, deleted, or substituted with respect to the sequence of **SEQ ID NO: 1**.

[0061] The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide that is "homologous" to the *L. intracellularis* LysS protein, as that term is correspondingly described with respect to the HtrA protein above. In a preferred embodiment, the homologous polypeptide has at least about 50%, more preferably at least about 70%, and even more preferably at least about 90% sequence identity, and most preferably at least 95% sequence identity to **SEQ ID NO: 102**.

[0062] In another embodiment, the polynucleotide encodes an isolated polypeptide consisting of the *L. intracellularis* LysS protein having between 1 and 10, and more preferably between 1 and 5, amino acids inserted, deleted, or substituted, including combinations thereof. In a more particular example of this embodiment, the polynucleotide encodes an isolated polypeptide having between 1 and 5 amino acids conservatively substituted for the LysS sequence of **SEQ ID NO: 102**.

[0063] The present invention further provides a polynucleotide molecule consisting of a "substantial portion" of any of the aforementioned *Lawsonia lysS*-related polynucleotide molecules of the present invention, as that term is correspondingly described above with respect to the HtrA protein.

[0064] In addition to the nucleotide sequences of any of the aforementioned *lysS*-related polynucleotide molecules, polynucleotide molecules of the present invention can further comprise, or alternatively may consist of, nucleotide sequences selected from those that naturally flank the *lysS* ORF or gene *in situ* in *L. intracellularis*.

YcfW -Related Polynucleotide Molecules

[0065] The present invention provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding the YcfW protein from *L. intracellularis*. In a preferred embodiment, the YcfW protein has the amino acid sequence of SEQ ID NO: 3. In a further preferred embodiment, the isolated YcfW-encoding polynucleotide molecule of the present invention comprises a nucleotide sequence selected from the group consisting of the nucleotide sequence of SEQ ID NO: 1 from about nt 1745 to about nt 3028 of the nucleotide sequence of the YcfW gene, and the nucleotide sequence of the YcfW-encoding ORF of plasmids pER438 (ATCC accession number PTA-638) and pT068 (ATCC accession number PTA-2232). The present invention further provides an isolated polynucleotide molecule having a nucleotide sequence that is "homologous" to the nucleotide sequence of a YcfW-encoding polynucleotide molecule of the present invention, as that term is correspondingly defined above with respect to HtrA related polynucleotide molecules. In a preferred embodiment, the homologous polynucleotide molecule hybridizes to the complement of a polynucleotide molecule having a nucleotide sequence that encodes the amino acid sequence of the *L. intracellularis* YcfW protein under highly stringent conditions. In a more preferred embodiment, the homologous polynucleotide molecule hybridizes under highly stringent conditions to the complement of a polynucleotide molecule consisting of a nucleotide sequence of SEQ ID NO: 1 from about nt 1745 to about nt 3028.

[0066] The homologous nucleotide sequence of the molecule of the invention preferably comprises a sequence that has more than 50%, more preferably more than about 90%, even more preferably more than about 95%, and most preferably more than about 99% sequence identity to the molecule of SEQ ID NO: 1 from about nt 1745 to about nt 3028, wherein sequence identity is determined by use of the BLASTN algorithm (GenBank, National Center for Biotechnology Information).

[0067] In another embodiment, the polynucleotide has a homologous sequence that is more than about 50% of the length of the nucleotide sequence encoding the *L. intracellularis* YcfW protein. In another embodiment, the sequence is more than 90%, and in another embodiment more than about 98%, of the length of the nucleotide sequence encoding the *L. intracellularis* YcfW protein. In yet another embodiment, the isolated polynucleotide that has a homologous sequence is equal in length to the sequence encoding the *L. intracellularis* YcfW protein.

[0068] In yet another embodiment, the nucleotide sequence that is homologous to the *L. intracellularis* YcfW protein encoding sequence has between 1 and 50, more preferably between 1 and 25, and most preferably between 1 and 5 nucleotides inserted, deleted, or substituted with respect to the sequence of SEQ ID NO: 1.

[0069] The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide that is "homologous" to the *L. intracellularis* YcfW protein, as that term is correspondingly described with respect to the HtrA protein above. In a preferred embodiment, the homologous polypeptide has at least about 50%, more preferably at least about 70%, and even more preferably at least about 90% sequence identity, and most preferably at least 95% sequence identity to SEQ ID NO: 3.

[0070] In another embodiment, the polynucleotide encodes an isolated polypeptide consisting of the *L. intracellularis* YcfW protein having between 1 and 10, and more preferably between 1 and 5, amino acids inserted, deleted, or substituted, including combinations thereof. In a more particular example of this embodiment, the polynucleotide encodes an isolated polypeptide having between 1 and 5 amino acids conservatively substituted for the YcfW sequence of SEQ ID NO: 3.

[0071] The present invention further provides a polynucleotide molecule consisting of a "substantial portion" of any of the aforementioned *Lawsonia* YcfW-related polynucleotide molecules of the present invention, as that term is correspondingly described above with respect to the HtrA protein.

[0072] In addition to the nucleotide sequences of any of the aforementioned YcfW-related polynucleotide molecules, polynucleotide molecules of the present invention can further comprise, or alternatively may consist of, nucleotide sequences selected from those that naturally flank the ycfW ORF or gene *in situ* in *L. intracellularis*.

ABC1 -Related Polynucleotide Molecules

[0073] The present invention provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding the ABC1 protein from *L. intracellularis*. In a preferred embodiment, the ABC1 protein has the amino acid sequence of SEQ ID NO: 4. In a further preferred embodiment, the isolated ABC1-encoding polynucleotide molecule of the present invention comprises a nucleotide sequence selected from the group consisting of the nucleotide sequence of SEQ ID NO: 1 from about nt 3031 to about nt 3738 (the nucleotide sequence of the open reading frame (ORF) of the ABC1 gene) and the nucleotide sequence of the ABC1-encoding ORF of plasmid pER438 (ATCC accession number PTA-638).

[0074] The present invention further provides an isolated polynucleotide molecule having a nucleotide sequence that is "homologous" to the nucleotide sequence of an ABC1-encoding polynucleotide molecule of the present invention, as that term is correspondingly defined above with respect to HtrA related polynucleotide molecules. In a preferred

embodiment, the homologous polynucleotide molecule hybridizes to the complement of a polynucleotide molecule having a nucleotide sequence that encodes the amino acid sequence of the *L. intracellularis* ABC1 protein under highly stringent conditions. In a more preferred embodiment, the homologous polynucleotide molecule hybridizes under highly stringent conditions to the complement of a polynucleotide molecule consisting of a nucleotide sequence selected from the group consisting of the ORE of SEQ ID NO: 1, which is from about nt 3031 to about nt 3738.

[0075] Polynucleotide molecules of the present invention having nucleotide sequences that are homologous to the nucleotide sequence of a ABC1-encoding polynucleotide molecule of the present invention do not include polynucleotide molecules encoding ABC1 proteins of *Neisseria flavescens*, *N. gonorrhoeae*, and *N. meningitidis*.

[0076] The nucleotide sequence of the molecule of the invention preferably comprises a sequence that has more than 50%, more preferably more than about 90%, even more preferably more than about 95%, and most preferably more than about 99% sequence identity to the molecule of SEQ ID NO: 1 from about nt 3031 to about nt 3738, wherein sequence identity is determined by use of the BLASTN algorithm (GenBank, National Center for Biotechnology Information).

[0077] In another embodiment, the polynucleotide has a homologous sequence that is more than about 50% of the length of the nucleotide sequence encoding the *L. intracellularis* ABC1 protein. In another embodiment, the sequence is more than 90%, and in another embodiment more than about 98%, of the length of the nucleotide sequence encoding the *L. intracellularis* ABC1 protein. In yet another embodiment, the isolated polynucleotide that has a homologous sequence is equal in length to the sequence encoding the *L. intracellularis* ABC1 protein.

[0078] In yet another embodiment, the nucleotide sequence that is homologous to the *L. intracellularis* ABC1 protein encoding sequence has between 1 and 50, more preferably between 1 and 25, and most preferably between 1 and 5 nucleotides inserted, deleted, or substituted with respect to the sequence of SEQ ID NO: 1.

[0079] The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide that is "homologous" to the *L. intracellularis* ABC1 protein, as that term is correspondingly described with respect to the HtrA protein above. In a preferred embodiment, the homologous polypeptide has at least about 50%, more preferably at least about 70%, and even more preferably at least about 90% sequence identity, and most preferably at least 95% sequence identity to SEQ ID NO: 1.

[0080] In another embodiment, the polynucleotide encodes an isolated polypeptide consisting of the *L. intracellularis* ABC1 protein having between 1 and 10, and more preferably between 1 and 5, amino acids inserted, deleted, or substituted, including combinations thereof. In a more particular example of this embodiment, the polynucleotide encodes an isolated polypeptide having between 1 and 5 amino acids conservatively substituted for the ABC1 sequence of SEQ ID NO: 4.

[0081] The present invention further provides a polynucleotide molecule consisting of a "substantial portion" of any of the aforementioned *Lawsonia ABC1*-related polynucleotide molecules of the present invention, as that term is correspondingly described above with respect to the HtrA protein.

[0082] In addition to the nucleotide sequences of any of the aforementioned *ABC1*-related polynucleotide molecules, polynucleotide molecules of the present invention can further comprise, or alternatively may consist of, nucleotide sequences selected from those that naturally flank the *abc1* ORF or gene *in situ* in *L. intracellularis*, and include the flanking nucleotide sequences shown in SEQ ID NO: 1.

Omp100 -Related Polynucleotide Molecules

[0083] The present invention provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding the Omp100 protein from *L. intracellularis*. In a preferred embodiment, the Omp100 protein has the amino acid sequence of SEQ ID NO: 5. In a further preferred embodiment, the isolated Omp100-encoding polynucleotide molecule of the present invention comprises a nucleotide sequence selected from the group consisting of the nucleotide sequence of SEQ ID NO: 1 from about nt 3695 to about nt 6385 (the nucleotide sequence of the open reading frame (ORF) of the *Omp100* gene), and the nucleotide sequence of the Omp100-encoding ORF of plasmid pER440 (ATCC accession number PTA-639).

[0084] The present invention further provides an isolated polynucleotide molecule having a nucleotide sequence that is "homologous" to the nucleotide sequence of a Omp100-encoding polynucleotide molecule of the present invention, as that term is correspondingly defined above with respect to HtrA related polynucleotide molecules. In a preferred embodiment, the homologous polynucleotide molecule hybridizes to the complement of a polynucleotide molecule having a nucleotide sequence that encodes the amino acid sequence of the *L. intracellularis* Omp100 protein under highly stringent conditions. In a more preferred embodiment, the homologous polynucleotide molecule hybridizes under highly stringent conditions to the complement of a polynucleotide molecule consisting of a nucleotide sequence selected from the group consisting of the ORF of SEQ ID NO: 1, which is from about nt 3695 to about nt 6385.

[0085] Polynucleotide molecules of the present invention having nucleotide sequences that are homologous to the nucleotide sequence of a Omp100-encoding polynucleotide molecule of the present invention do not include polynucle-

otide molecules encoding any of the following proteins listed in the GenBank database: YaeT (Accn. U70214 or AE000127) of *E. coli*; Oma90 (Accn. AF120927) of *Shigella flexneri*; Omp85 (Accn. AF021245) of *Neisseria meningitidis*; D15 (Accn. U60834) of *Haemophilus influenzae* (D15), and Oma87 (Accn. U60439) of *Pasteurella multocida*.

5 [0086] The nucleotide sequence of the molecule of the invention preferably comprises a homologous sequence that has more than 50%, more preferably more than about 90%, even more preferably more than about 95%, and most preferably more than about 99% sequence identity to the molecule of SEQ ID NO: 1 from about nt 3695 to about nt 6385, wherein sequence identity is determined by use of the BLASTN algorithm (GenBank, National Center for Biotechnology Information).

10 [0087] In another embodiment, the polynucleotide has a homologous sequence that is more than about 50% of the length of the nucleotide sequence encoding the *L. intracellularis* Omp100 protein. In another embodiment, the sequence is more than 90%, and in another embodiment more than about 98%, of the length of the nucleotide sequence encoding the *L. intracellularis* Omp100 protein. In yet another embodiment, the isolated polynucleotide that has a homologous sequence is equal in length to the sequence encoding the *L. intracellularis* Omp100 protein.

15 [0088] In yet another embodiment, the nucleotide sequence that is homologous to the *L. intracellularis* Omp100 protein encoding sequence has between 1 and 50, more preferably between 1 and 25, and most preferably between 1 and 5 nucleotides inserted, deleted, or substituted with respect to the sequence of SEQ ID NO: 5.

[0089] The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide that is "homologous" to the *L. intracellularis* Omp100 protein, as that term is correspondingly described with respect to the HtrA protein above. In a preferred embodiment, the homologous polypeptide has at least about 50%, more preferably at least about 70%, and even more preferably at least about 90% sequence identity, and most preferably at least 95% sequence identity to SEQ ID NO: 5.

20 [0090] In another embodiment, the polynucleotide encodes an isolated polypeptide consisting of the *L. intracellularis* Omp100 protein having between 1 and 10, and more preferably between 1 and 5, amino acids inserted, deleted, or substituted, including combinations thereof. In a more particular example of this embodiment, the polynucleotide encodes an isolated polypeptide having between 1 and 5 amino acids conservatively substituted for the Omp100 sequence of SEQ ID NO: 5.

[0091] The present invention further provides a polynucleotide molecule consisting of a "substantial portion" of any of the aforementioned *Lawsonia* Omp100-related polynucleotide molecules of the present invention, as that term is correspondingly described above with respect to the HtrA protein.

30 [0092] In addition to the nucleotide sequences of any of the aforementioned Omp100-related polynucleotide molecules, polynucleotide molecules of the present invention can further comprise, or alternatively may consist of, nucleotide sequences selected from those that naturally flank the *omp100* ORF or gene *in situ* in *L. intracellularis*, and include the nucleotide sequences shown in SEQ ID NO: 1.

35 Promoter Sequences

[0093] The present invention also relates to a polynucleotide molecule comprising a nucleotide sequence greater than 20 nucleotides having promoter activity and found within SEQ ID NO: 2 from about nt 2691 to about nt 2890, or its complement. As further discussed below in the Examples, it has been determined that this region of the *Lawsonia* sequence contains a temperature responsive promoter for the *htrA* gene. In a preferred embodiment, the polynucleotide comprises the sequence of about nt 2797 to nt 2829.

40 [0094] The present invention also relates to oligonucleotides having promoter activity that hybridize under moderately stringent, and more preferably under highly stringent conditions, to the complement of the nucleotide sequence greater than 20 nucleotides having promoter activity and found within SEQ ID NO: 2 from about nt 2691 to about nt 2890. Preferably the oligonucleotide having promoter activity hybridizes under moderately stringent or highly stringent conditions to the complement of the polynucleotide comprising the sequence from about nt 2797 to nt 2829. In another embodiment, the invention encompasses an oligonucleotide having promoter activity having between 1 and 25, and most preferably between 1 and 5 nucleotides inserted, deleted, or substituted with respect to the sequence of SEQ ID NO: 2 which is from about nt 2691 to about nt 2890.

50 [0095] The functional sequences having promoter activity of the present invention are useful for a variety of purposes including for controlling the recombinant expression of any of the genes of the present invention, or of other genes or coding sequences, in host cells of *L. intracellularis* or in host cells of any other species of *Lawsonia*, or in any other appropriate host cell. Such other genes or coding sequences can either be native or heterologous to the recombinant host cell. The promoter sequence can be fused to the particular gene or coding sequence using standard recombinant techniques as known in the art so that the promoter sequence is in operative association therewith, as "operative association" is defined below. By using the promoter, recombinant expression systems can, for example, be constructed and used to screen for compounds and transcriptional factors that can modulate the expression of the genes

of *Lawsonia* or other bacteria. In addition, such promoter constructs can be used to express heterologous polypeptides in *Lawsonia*, *E. coli*, or other appropriate host cells.

Oligonucleotide Molecules

5

[0096] The present invention further provides oligonucleotide molecules that hybridize to any one of the aforementioned polynucleotide molecules of the present invention, or that hybridize to a polynucleotide molecule having a nucleotide sequence that is the complement of any one of the aforementioned polynucleotide molecules of the present invention. Such oligonucleotide molecules are preferably at least about 10 nucleotides in length, and more preferably
10 from about 15 to about 30 nucleotides in length, and hybridize to one or more of the aforementioned polynucleotide molecules under highly stringent conditions, *i.e.*, washing in 6xSSC/0.5% sodium pyrophosphate at about 37°C for ~14-base oligos, at about 48°C for ~17-base oligos, at about 55°C for ~20-base oligos, and at about 60°C for ~23-base oligos. Other hybridization conditions for longer oligonucleotide molecules of the present invention can be determined by the skilled artisan using standard techniques. In a preferred embodiment, an oligonucleotide molecule of the present
15 invention is complementary to a portion of at least one of the aforementioned polynucleotide molecules of the present invention.

[0097] The oligonucleotide molecules of the present invention are useful for a variety of purposes, including as primers in amplification of a *Lawsonia*-specific polynucleotide molecule for use, *e.g.*, in differential disease diagnosis, or to act as antisense molecules useful in gene regulation. Suitably designed primers can also be used to detect the
20 presence of *Lawsonia*-specific polynucleotide molecules in a sample of animal tissue or fluid, including brain tissue, lung tissue, intestinal tissue, placental tissue, blood, cerebrospinal fluid, feces, mucous, urine, amniotic fluid, *etc.* The oligonucleotide molecule specifically reacts with the *Lawsonia* organism; this is generally accomplished by employing a sequence of sufficient length. The production of a specific amplification product can support a diagnosis of *Lawsonia* infection, while lack of an amplified product can point to a lack of infection. Methods for conducting amplifications, such
25 as the polymerase chain reaction (PCR), are described, among other places, in Innis *et al.* (eds), 1995, above; and Erlich (ed), 1992, above. Other amplification techniques known in the art, *e.g.*, the ligase chain reaction, can alternatively be used. The sequences of the polynucleotide molecules disclosed herein can also be used to design primers for use in isolating homologous genes from other species or strains of *Lawsonia* or other bacterial cells.

[0098] Specific though non-limiting embodiments of oligonucleotide molecules useful in practicing the present
30 invention include oligonucleotide molecules selected from the group consisting of SEQ ID NOS: 10-101 and the complements thereof.

Recombinant Expression Systems Cloning And Expression Vectors

[0099] The present invention further encompasses methods and compositions for cloning and expressing any of
35 the polynucleotide molecules of the present invention, including cloning vectors, expression vectors, transformed host cells comprising any of said vectors, and novel strains or cell lines derived therefrom. In a preferred embodiment, the present invention provides a recombinant vector comprising a polynucleotide molecule having a nucleotide sequence encoding the HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100 protein of *L. intracellularis*. In specific embodiments,
40 the present invention provides plasmid pER432 containing the *ponA* gene (ATCC accession number PTA-635), plasmid pER434 containing the *htrA* gene (ATCC accession number PTA-636), plasmid pER436 containing the *hypC* gene (ATCC accession number PTA-637), plasmid pT068 containing the *lysS* and *ycfW* genes (ATCC accession number PTA-2232), plasmid pER438 containing the *ycfW* and *abc1* genes (ATCC accession number PTA-638), and plasmid pER440 containing the Omp100 gene (ATCC accession number PTA-639). The invention also encompasses recombinant
45 vectors and transformed cells employed to obtain polypeptides of the invention.

[0100] Recombinant vectors of the present invention, particularly expression vectors, are preferably constructed so that the coding sequence for the polynucleotide molecule of the invention is in operative association with one or more regulatory elements necessary for transcription and translation of the coding sequence to produce a polypeptide. As used herein, the term "regulatory element" includes but is not limited to nucleotide sequences that encode inducible and
50 non-inducible promoters, enhancers, operators, ribosome-binding sites, and other elements known in the art that serve to drive and/or regulate expression of polynucleotide coding sequences. Also, as used herein, the coding sequence is in "operative association" with one or more regulatory elements where the regulatory elements effectively regulate and allow for the transcription of the coding sequence or the translation of its mRNA, or both.

[0101] Methods are well-known in the art for constructing recombinant vectors containing particular coding
55 sequences in operative association with appropriate regulatory elements, and these can be used to practice the present invention. These methods include *in vitro* recombinant techniques, synthetic techniques, and *in vivo* genetic recombination. See, *e.g.*, the techniques described in Maniatis *et al.*, 1989, above; Ausubel *et al.*, 1989, above; Sambrook *et al.*, 1989, above; Innis *et al.*, 1995, above; and Erlich, 1992, above.

[0102] A variety of expression vectors are known in the art which can be utilized to express the HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100 coding sequences of the present invention, including recombinant bacteriophage DNA, plasmid DNA, and cosmid DNA expression vectors containing the particular coding sequences. Typical prokaryotic expression vector plasmids that can be engineered to contain a polynucleotide molecule of the present invention include pUC8, pUC9, pBR322 and pBR329 (Biorad Laboratories, Richmond, CA), pPL and pKK223 (Pharmacia, Piscataway, NJ), pQE50 (Qiagen, Chatsworth, CA), and pGEM-T EASY (Promega, Madison, WI), among many others. Typical eukaryotic expression vectors that can be engineered to contain a polynucleotide molecule of the present invention include an ecdysone-inducible mammalian expression system (Invitrogen, Carlsbad, CA), cytomegalovirus promoter-enhancer-based systems (Promega, Madison, WI; Stratagene, La Jolla, CA, Invitrogen), and baculovirus-based expression systems (Promega), among others.

[0103] The regulatory elements of these and other vectors can vary in their strength and specificities. Depending on the host/vector system utilized, any of a number of suitable transcription and translation elements can be used. For instance, when cloning in mammalian cell systems, promoters isolated from the genome of mammalian cells, e.g., mouse metallothionein promoter, or from viruses that grow in these cells, e.g., vaccinia virus 7.5K promoter or Moloney murine sarcoma virus long terminal repeat, can be used. Promoters obtained by recombinant DNA or synthetic techniques can also be used to provide for transcription of the inserted sequence. In addition, expression from certain promoters can be elevated in the presence of particular inducers, e.g., zinc and cadmium ions for metallothionein promoters. Non-limiting examples of transcriptional regulatory regions or promoters include for bacteria, the β -gal promoter, the T7 promoter, the TAC promoter, λ left and right promoters, trp and lac promoters, trp-lac fusion promoters, etc.; for yeast, glycolytic enzyme promoters, such as ADH-I and -II promoters, GPK promoter, PGI promoter, TRP promoter, etc.; and for mammalian cells, SV40 early and late promoters, adenovirus major late promoters, among others. The present invention further provides a polynucleotide molecule comprising the nucleotide sequence of the promoter of the *htrA* gene of *L. intracellularis*, which can be used to express any of the coding sequences of the present invention in *Lawsonia*, *E. coli*, or other suitable hosts.

[0104] Specific initiation signals are also required for sufficient translation of inserted coding sequences. These signals typically include an ATG initiation codon and adjacent sequences. In cases where the polynucleotide molecule of the present invention including its own initiation codon and adjacent sequences are inserted into the appropriate expression vector, no additional translation control signals may be needed. However, in cases where only a portion of a coding sequence is inserted, exogenous translational control signals, including the ATG initiation codon, may be required. These exogenous translational control signals and initiation codons can be obtained from a variety of sources, both natural and synthetic. Furthermore, the initiation codon must be in phase with the reading frame of the coding regions to ensure in-frame translation of the entire insert.

[0105] Expression vectors can also be constructed that will express a fusion protein comprising a protein or polypeptide of the present invention. Such fusion proteins can be used, e.g., to raise antisera against a *Lawsonia* protein, to study the biochemical properties of the *Lawsonia* protein, to engineer a *Lawsonia* protein exhibiting different immunological or functional properties, or to aid in the identification or purification, or to improve the stability, of a recombinantly-expressed *Lawsonia* protein. Possible fusion protein expression vectors include but are not limited to vectors incorporating sequences that encode β -galactosidase and trpE fusions, maltose-binding protein fusions (pMal series; New England Biolabs), glutathione-S-transferase fusions (pGEX series; Pharmacia), polyhistidine fusions (pET series; Novagen Inc., Madison, WI), and thioredoxin fusions (pTrxFus; Invitrogen, Carlsbad, CA). Methods are well-known in the art for constructing expression vectors encoding these and other fusion proteins.

[0106] The fusion protein can be useful to aid in purification of the expressed protein. In non-limiting embodiments, e.g., a HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100-maltose-binding fusion protein can be purified using amylose resin; a HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100-glutathione-S-transferase fusion protein can be purified using glutathione-agarose beads; and a HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100-polyhistidine fusion protein can be purified using divalent nickel resin. Alternatively, antibodies against a carrier protein or peptide can be used for affinity chromatography purification of the fusion protein. For example, a nucleotide sequence coding for the target epitope of a monoclonal antibody can be engineered into the expression vector in operative association with the regulatory elements and situated so that the expressed epitope is fused to a *Lawsonia* protein of the present invention. In a non-limiting embodiment, a nucleotide sequence coding for the FLAG™ epitope tag (International Biotechnologies Inc.), which is a hydrophilic marker peptide, can be inserted by standard techniques into the expression vector at a point corresponding to the amino or carboxyl terminus of the HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100 protein. The expressed HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100 protein-FLAG™ epitope fusion product can then be detected and affinity-purified using commercially available anti-FLAG™ antibodies.

[0107] The expression vector can also be engineered to contain polylinker sequences that encode specific protease cleavage sites so that the expressed *Lawsonia* protein can be released from the carrier region or fusion partner by treatment with a specific protease. For example, the fusion protein vector can include a nucleotide sequence encoding a thrombin or factor Xa cleavage site, among others.

[0108] A signal sequence upstream from and in the same reading frame with the *Lawsonia* coding sequence can be engineered into the expression vector by known methods to direct the trafficking and secretion of the expressed protein. Non-limiting examples of signal sequences include those from α -factor, immunoglobulins, outer membrane proteins, penicillinase, and T-cell receptors, among others.

5 [0109] To aid in the selection of host cells transformed or transfected with a recombinant vector of the present invention, the vector can be engineered to further comprise a coding sequence for a reporter gene product or other selectable marker. Such a coding sequence is preferably in operative association with the regulatory elements, as described above. Reporter genes that are useful in practicing the invention are well-known in the art and include those encoding chloramphenicol acetyltransferase (CAT), green fluorescent protein, firefly luciferase, and human growth hormone, among others. Nucleotide sequences encoding selectable markers are well-known in the art, and include those that encode gene products conferring resistance to antibiotics or anti-metabolites, or that supply an auxotrophic requirement. Examples of such sequences include those that encode thymidine kinase activity, or resistance to methotrexate, ampicillin, kanamycin, chloramphenicol, zeocin, pyrimethamine, aminoglycosides, or hygromycin, among others.

15

Transformation Of Host Cells

[0110] The present invention further provides transformed host cells comprising a polynucleotide molecule or recombinant vector of the present invention, and cell lines derived therefrom. Host cells useful in practicing the invention can be eukaryotic or prokaryotic cells. Such transformed host cells include but are not limited to microorganisms, such as bacteria transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA vectors, or yeast transformed with a recombinant vector, or animal cells, such as insect cells infected with a recombinant virus vector, e.g., baculovirus, or mammalian cells infected with a recombinant virus vector, e.g., adenovirus or vaccinia virus, among others. For example, a strain of *E. coli* can be used, such as, e.g., the DH5 α strain available from the ATCC, Rockville, MD, USA (Accession No. 31343), or from GIBCO BRL, Gaithersburg, MD. Eukaryotic host cells include yeast cells, although mammalian cells, e.g., from a mouse, hamster, cow, monkey, or human cell line, among others, can also be utilized effectively. Examples of eukaryotic host cells that can be used to express a recombinant protein of the invention include Chinese hamster ovary (CHO) cells (e.g., ATCC Accession No. CCL-61), NIH Swiss mouse embryo cells NIH/3T3 (e.g., ATCC Accession No. CRL-1658), and Madin-Darby bovine kidney (MDBK) cells (ATCC Accession No. CCL-22). Transfected cells can express the polynucleotide of the invention by chromosomal integration, or episomally.

[0111] The recombinant vector of the invention is preferably transformed or transfected into one or more host cells of a substantially homogeneous culture of cells. The vector is generally introduced into host cells in accordance with known techniques, such as, e.g., by protoplast transformation, calcium phosphate precipitation, calcium chloride treatment, microinjection, electroporation, transfection by contact with a recombined virus, liposome-mediated transfection, DEAE-dextran transfection, transduction, conjugation, or microprojectile bombardment, among others. Selection of transformants can be conducted by standard procedures, such as by selecting for cells expressing a selectable marker. e.g., antibiotic resistance, associated with the recombinant expression vector.

[0112] Once an expression vector is introduced into the host cell, the integration and maintenance of the polynucleotide molecule of the present invention, either in the host cell genome or episomally, can be confirmed by standard techniques, e.g., by Southern hybridization analysis, restriction enzyme analysis, PCR analysis including reverse transcriptase PCR (rt-PCR), or by immunological assay to detect the expected protein product. Host cells containing and/or expressing a polynucleotide molecule of the present invention can be identified by any of at least four general approaches that are well-known in the art, including: (i) DNA-DNA, DNA-RNA, or RNA-antisense RNA hybridization; (ii) detecting the presence of "marker" gene functions; (iii) assessing the level of transcription as measured by the expression of specific mRNA transcripts in the host cell; or (iv) detecting the presence of mature polypeptide product, e.g., by immunoassay, as known in the art.

Expression And Purification Of Recombinant Polypeptides

50 [0113] Once a polynucleotide molecule of the present invention has been stably introduced into an appropriate host cell, the transformed host cell is clonally propagated, and the resulting cells are grown under conditions conducive to the maximum production of the encoded polypeptide. Such conditions typically include growing transformed cells to high density. Where the expression vector comprises an inducible promoter, appropriate induction conditions such as, e.g., temperature shift, exhaustion of nutrients, addition of gratuitous inducers (e.g., analogs of carbohydrates, such as isopropyl- β -D-thiogalactopyranoside (IPTG)), accumulation of excess metabolic by-products, or the like, are employed as needed to induce expression.

[0114] Where the polypeptide is retained inside the host cells, the cells are harvested and lysed, and the product is substantially purified or isolated from the lysate under extraction conditions known in the art to minimize protein degradation.

dition such as, e.g., at 4°C, or in the presence of protease inhibitors, or both. Where the polypeptide is secreted from the host cells, the exhausted nutrient medium can simply be collected and the polypeptide substantially purified or isolated therefrom.

[0115] The polypeptide can be substantially purified or isolated from cell lysates or culture medium, as necessary, using standard methods, including but not limited to one or more of the following methods: ammonium sulfate precipitation, size fractionation, ion exchange chromatography, HPLC, density centrifugation, and affinity chromatography. If the polypeptide lacks biological activity, it can be detected as based, e.g., on size, or reactivity with a polypeptide-specific antibody, or by the presence of a fusion tag. For use in practicing the present invention, the polypeptide can be in an unpurified state as secreted into the culture fluid or as present in a cell lysate, but is preferably substantially purified or isolated therefrom. As used herein, a polypeptide is "substantially purified" where the polypeptide constitutes at least about 20 wt% of the protein in a particular preparation. Also, as used herein, a polypeptide is "isolated" where the polypeptide constitutes at least about 80 wt% of the protein in a particular preparation. In another embodiment of the invention, the protein is present in a preparation in at least about a 1000x higher concentration than its natural counterpart is normally found in a preparation of *L. intracellularis* cell lysate.

Polypeptides

[0116] Thus, the present invention encompasses a substantially purified or isolated polypeptide encoded by a polynucleotide of the present invention. In a non-limiting embodiment, the polypeptide is a HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100 *L. intracellularis* protein. In a preferred embodiment, the *L. intracellularis* HtrA, PonA, HypC, LysS, YcfW, ABC1, and Omp100 proteins have the amino acid sequences of SEQ ID NOS: 3-8 or SEQ ID NO: 102. In another embodiment, the polypeptides are substantially free of other *Lawsonia* proteins.

[0117] The present invention further provides polypeptides that are homologous to any of the aforementioned *L. intracellularis* proteins, as the term "homologous" is defined above for polypeptides. Polypeptides of the present invention that are homologous to the proteins of the invention do not include polypeptides having the amino acid sequences of non-*Lawsonia* proteins described herein. The polypeptide of the invention, in one embodiment, has more than 70%, preferably more than about 90%, and most preferably more than about 95% amino acid sequence identity to the *Lawsonia* proteins, wherein sequence identity is determined by use of the BLASTP algorithm (GenBank, NCBI).

[0118] In another embodiment, the polypeptide consists of the *L. intracellularis* HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100 protein having between 1 and 10, and more preferably between 1 and 5, amino acids inserted, deleted, or substituted, including combinations thereof. In a more particular example of this embodiment, the isolated polypeptide has between 1 and 5 amino acids conservatively substituted in the amino acid sequence of the HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100 protein.

[0119] The present invention further provides polypeptides consisting of a substantial portion of any one of the aforementioned polypeptides of the present invention. As used herein, a "substantial portion" of a polypeptide of the present invention, or "peptide fragment," means a polypeptide consisting of less than the complete amino acid sequence of the corresponding full-length polypeptide, but comprising at least about 5%, more preferably at least about 20%, even more preferably at least about 50%, and most preferably at least about 95% of the amino acid sequence thereof, and that is useful in practicing the present invention. Particularly preferred are peptide fragments that are immunogenic, i.e., capable of inducing an immune response which results in production of antibodies that react specifically against the corresponding full-length *Lawsonia* polypeptide.

[0120] In another embodiment, the polypeptide of the invention comprises an epitope of HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100 protein that is specifically reactive with anti-*Lawsonia* antibodies. The epitope is preferably more than 8, more preferably more than 12, and most preferably, more than 20 amino acids of the protein sequence.

[0121] The present invention further provides fusion proteins comprising any of the polypeptides of the invention fused to a carrier or fusion partner as known in the art.

[0122] The present invention further provides a method of preparing any of the polypeptides described above, comprising culturing a host cell transformed with a recombinant expression vector, said recombinant expression vector comprising a polynucleotide molecule comprising a nucleotide sequence encoding the particular polypeptide, which polynucleotide molecule is in operative association with one or more regulatory elements, under conditions conducive to the expression of the polypeptide, and recovering the expressed polypeptide from the cell culture.

Use Of Polypeptides

[0123] Once a polypeptide of the present invention of sufficient purity has been obtained, it can be characterized by standard methods, including by SDS-PAGE, size exclusion chromatography, amino acid sequence analysis, immunological activity, biological activity, etc. The polypeptide can be further characterized using hydrophilicity analysis (see, e.g., Hopp and Woods, 1981, Proc. Natl. Acad. Sci. USA 78:3824), or analogous software algorithms, to identify hydro-

phobic and hydrophilic regions. Structural analysis can be carried out to identify regions of the polypeptide that assume specific secondary structures. Biophysical methods such as X-ray crystallography (Engstrom, 1974, *Biochem. Exp. Biol.* 11: 7-13), computer modeling (Fletterick and Zoller (eds), 1986, in: Current Communications in Molecular Biology, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY), and nuclear magnetic resonance (NMR) can be used to map and study potential sites of interaction between the polypeptide and other putative interacting proteins/receptors/molecules. Information obtained from these studies can be used to design deletion mutants and vaccine compositions, and to design or select therapeutic or pharmacologic compounds that can specifically block the biological function of the polypeptide *in vivo*.

[0124] Polypeptides of the present invention are useful for a variety of purposes, including as components of vaccine compositions to protect PPE susceptible animals against PPE; or as diagnostic reagents, *e.g.*, using standard techniques such as ELISA assays, to screen for *Lawsonia*-specific antibodies in blood or serum samples from animals; or as antigens to raise polyclonal or monoclonal antibodies, as described below, which antibodies are useful as diagnostic reagents, *e.g.*, using standard techniques such as Western blot assays, to screen for *Lawsonia*-specific proteins in cell, tissue or fluid samples from an animal.

Analogs And Derivatives Of Polypeptides

[0125] A polypeptide of the present invention can be modified at the protein level to improve or otherwise alter its biological or immunological characteristics. One or more chemical modifications of the polypeptide can be carried out using known techniques to prepare analogs therefrom, including but not limited to any of the following: substitution of one or more L-amino acids of the polypeptide with corresponding D-amino acids, amino acid analogs, or amino acid mimics, so as to produce, *e.g.*, carbazates or tertiary centers; or specific chemical modification, such as, *e.g.*, proteolytic cleavage with trypsin, chymotrypsin, papain or V8 protease, or treatment with NaBH₄ or cyanogen bromide, or acetylation, formylation, oxidation or reduction, *etc.* Alternatively or additionally, polypeptides of the present invention can be modified by genetic recombination techniques.

[0126] A polypeptide of the present invention can be derivatized by conjugation thereto of one or more chemical groups, including but not limited to acetyl groups, sulfur bridging groups, glycosyl groups, lipids, and phosphates, and/or by conjugation to a second polypeptide of the present invention, or to another protein, such as, *e.g.*, serum albumin, keyhole limpet hemocyanin, or commercially activated BSA, or to a polyamino acid (*e.g.*, polylysine), or to a polysaccharide, (*e.g.*, sepharose, agarose, or modified or unmodified celluloses), among others. Such conjugation is preferably by covalent linkage at amino acid side chains and/or at the N-terminus or C-terminus of the polypeptide. Methods for carrying out such conjugation reactions are well-known in the field of protein chemistry.

[0127] Derivatives useful in practicing the claimed invention also include those in which a water-soluble polymer such as, *e.g.*, polyethylene glycol, is conjugated to a polypeptide of the present invention, or to an analog or derivative thereof, thereby providing additional desirable properties while retaining, at least in part, the immunogenicity of the polypeptide. These additional desirable properties include, *e.g.*, increased solubility in aqueous solutions, increased stability in storage, increased resistance to proteolytic dehydration, and increased *in vivo* half-life. Water-soluble polymers suitable for conjugation to a polypeptide of the present invention include but are not limited to polyethylene glycol homopolymers, polypropylene glycol homopolymers, copolymers of ethylene glycol with propylene glycol, wherein said homopolymers and copolymers are unsubstituted or substituted at one end with an alkyl group, polyoxyethylated polyols, polyvinyl alcohol, polysaccharides, polyvinyl ethyl ethers, and α,β -poly[2-hydroxyethyl]-DL-aspartamide. Polyethylene glycol is particularly preferred. Methods for making water-soluble polymer conjugates of polypeptides are known in the art and are described in, among other places, U.S. Patent 3,788,948; U.S. Patent 3,960,830; U.S. Patent 4,002,531; U.S. Patent 4,055,635; U.S. Patent 4,179,337; U.S. Patent 4,261,973; U.S. Patent 4,412,989; U.S. Patent 4,414,147; U.S. Patent 4,415,665; U.S. Patent 4,609,546; U.S. Patent 4,732,863; U.S. Patent 4,745,180; European Patent (EP) 152,847; EP 98,110; and Japanese Patent 5,792,435, which patents are incorporated herein by reference.

Antibodies

[0128] The present invention further provides isolated antibodies directed against a polypeptide of the present invention. In a preferred embodiment, antibodies can be raised against a HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100 protein from *L. intracellularis* using known methods. Various host animals selected from pigs, cows, horses, rabbits, goats, sheep, or mice, can be immunized with a partially or substantially purified, or isolated, *L. intracellularis* protein, or with a homolog, fusion protein, substantial portion, analog or derivative thereof, as these are described above. An adjuvant, such as described below, can be used to enhance antibody production.

[0129] Polyclonal antibodies can be obtained and isolated from the serum of an immunized animal and tested for specificity against the antigen using standard techniques. Alternatively, monoclonal antibodies can be prepared and isolated using any technique that provides for the production of antibody molecules by continuous cell lines in culture.

These include but are not limited to the hybridoma technique originally described by Kohler and Milstein (Nature, 1975, 256: 495-497); the human B-cell hybridoma technique (Kosbor *et al.*, 1983, Immunology Today 4:72; Cote *et al.*, 1983, Proc. Natl. Acad. Sci. USA 80: 2026-2030); and the EBV-hybridoma technique (Cole *et al.*, 1985, Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). Alternatively, techniques described for the production of single chain antibodies (see, e.g., U.S. Patent 4,946,778) can be adapted to produce *L. intracellularis* antigen-specific single chain antibodies. These publications are incorporated herein by reference.

[0130] Antibody fragments that contain specific binding sites for a polypeptide of the present invention are also encompassed within the present invention, and can be generated by known techniques. Such fragments include but are not limited to F(ab')₂ fragments, which can be generated by pepsin digestion of an intact antibody molecule, and Fab fragments, which can be generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries can be constructed (Huse *et al.*, 1989, Science 246: 1275-1281) to allow rapid identification of Fab fragments having the desired specificity to the *L. intracellularis* protein.

[0131] Techniques for the production and isolation of monoclonal antibodies and antibody fragments are well-known in the art, and are additionally described, among other places, in Harlow and Lane, 1988, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, and in J. W. Goding, 1986, Monoclonal Antibodies: Principles and Practice, Academic Press, London, which are incorporated herein by reference.

Targeted Mutation Of *Lawsonia* Genes

[0132] Based on the disclosure of the polynucleotide molecules of the present invention, genetic constructs can be prepared for use in disabling or otherwise mutating a *Lawsonia* *htrA*, *ponA*, *lysS*, *ycfW*, *hypC*, *abc1*, or *omp100* gene (which gene is hereinafter referred to as the "*Lawsonia* gene"). The *Lawsonia* gene can be mutated using an appropriately designed genetic construct. For example, the *Lawsonia* gene can be mutated using a genetic construct of the present invention that functions to: (a) delete all or a portion of the coding sequence or regulatory sequence of the *Lawsonia* gene; or (b) replace all or a portion of the coding sequence or regulatory sequence of the *Lawsonia* gene with a different nucleotide sequence; or (c) insert into the coding sequence or regulatory sequence of the *Lawsonia* gene one or more nucleotides, or an oligonucleotide molecule, or polynucleotide molecule, which can comprise a nucleotide sequence from *Lawsonia* or from a heterologous source; or (d) carry out some combination of (a), (b) and (c). Alternately, constructs can be employed to alter the expression of the *Lawsonia* gene or the stability of its encoded protein.

[0133] *Lawsonia* cells in which a *Lawsonia* gene has been mutated are, for example, useful in practicing the present invention where mutating the gene reduces the pathogenicity of the *Lawsonia* cells carrying the mutated gene compared to cells of the same strain of *Lawsonia* where the gene has not been so mutated, and where such *Lawsonia* cells carrying the disabled gene can be used in a vaccine composition, particularly in a modified live vaccine, to induce or contribute to the induction of, a protective response in an animal against PPE. In a preferred embodiment, the mutation serves to partially or completely disable the *Lawsonia* gene, or partially or completely disable the protein encoded by the *Lawsonia* gene. In this context, a *Lawsonia* gene or protein is considered to be partially or completely disabled if either no protein product is made (for example, the gene is deleted), or a protein product is made that can no longer carry out its normal biological function or can no longer be transported to its normal cellular location, or a product is made that carries out its normal biological function but at a significantly reduced rate. *Lawsonia* cells in which the *Lawsonia* gene has been mutated are also useful to increase expression of that gene or the stability of its encoded protein. Mutations are particularly useful that result in a detectable decrease in the pathogenicity of cells of a pathogenic strain of *Lawsonia*. The invention also encompasses cells expressing proteins and polypeptides of the invention where such cells are constitutive mutants.

[0134] In a non-limiting embodiment, a genetic construct of the present invention is used to mutate a wild-type *Lawsonia* gene by replacement of the coding sequence of the wild-type gene, or a promoter or other regulatory region thereof, or a portion thereof, with a different nucleotide sequence such as, e.g., a mutated coding sequence or mutated regulatory region, or portion thereof. Mutated *Lawsonia* gene sequences for use in such a genetic construct can be produced by any of a variety of known methods, including by use of error-prone PCR, or by cassette mutagenesis. For example, oligonucleotide-directed mutagenesis can be employed to alter the coding sequence or promoter sequence of a wild-type *Lawsonia* gene in a defined way, e.g., to introduce a frame-shift or a termination codon at a specific point within the sequence. Alternatively or additionally, a mutated nucleotide sequence for use in the genetic construct of the present invention can be prepared by insertion or deletion of the coding sequence or promoter sequence of one or more nucleotides, oligonucleotide molecules or polynucleotide molecules, or by replacement of a portion of the coding sequence or promoter sequence with one or more different nucleotides, oligonucleotide molecules or polynucleotide molecules. Such oligonucleotide molecules or polynucleotide molecules can be obtained from any naturally occurring source or can be synthetic. The inserted or deleted sequence can serve simply to disrupt the reading frame of the *Lawsonia* gene, or can further encode a heterologous gene product such as a selectable marker.

[0135] Alternatively or additionally, random mutagenesis can be used to produce a mutated *Lawsonia* gene sequence for use in a genetic construct of the present invention. Random mutagenesis can be carried out by any suitable techniques such as, e.g., by exposing cells carrying a *Lawsonia* gene to ultraviolet radiation or x-rays, or to chemical mutagens such as N-methyl-N'-nitrosoguanidine, ethyl methane sulfonate, nitrous acid or nitrogen mustards, and then selecting for cells carrying a mutation in the particular gene. See, e.g., Ausubel, 1989, above, for a review of mutagenesis techniques.

[0136] Mutations to produce modified *Lawsonia* cells that are useful in practicing the present invention can occur anywhere in the *Lawsonia* gene, including in the ORF, or in the promoter or other regulatory region, or in any other sequences that naturally comprise the gene or ORF, or that alter expression of the gene or the stability of its encoded protein. Such *Lawsonia* cells include mutants in which a modified form of the protein normally encoded by the *Lawsonia* gene is produced, or in which no protein normally encoded by the *Lawsonia* gene is produced, and can be null, conditional, constitutive, or leaky mutants.

[0137] Alternatively, a genetic construct of the present invention can comprise nucleotide sequences that naturally flank the *Lawsonia* gene or ORF *in situ*, with only a portion or no nucleotide sequences from the coding region of the gene itself. Such a genetic construct would be useful, e.g., to delete the entire *Lawsonia* gene or ORF.

[0138] In one embodiment, a genetic construct of the present invention comprises a polynucleotide molecule that can be used to disable a *Lawsonia* gene, comprising: (a) a polynucleotide molecule having a nucleotide sequence that is otherwise the same as a nucleotide sequence encoding a HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100 protein from *L. intracellularis*, but which nucleotide sequence further comprises one or more disabling mutations; or (b) a polynucleotide molecule comprising a nucleotide sequence that naturally flanks the ORF of a *Lawsonia* gene *in situ*. Once transformed into cells of a strain of *Lawsonia*, the polynucleotide molecule of the genetic construct is specifically targeted to the particular *Lawsonia* gene by homologous recombination, and thereby either replaces the gene or portion thereof or inserts into the gene. As a result of this recombination event, the *Lawsonia* gene otherwise native to that particular strain of *Lawsonia* is disabled.

[0139] In another embodiment, a genetic construct employs a mutation that alters expression, e.g., by constitutively expressing or overexpressing the HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100 protein. Such a mutation can be useful, for example, to weaken the host cells. The construct can also employ a mutation that increases stability of the protein to, e.g., attenuate the host cell.

[0140] For targeted gene mutation through homologous recombination, the genetic construct is preferably a plasmid, either circular or linearized, comprising a mutated nucleotide sequence as described above. In a non-limiting embodiment, at least about 200 nucleotides of the mutated sequence are used to specifically direct the genetic construct of the present invention to the particular targeted *Lawsonia* gene for homologous recombination, although shorter lengths of nucleotides can also be effective. In addition, the plasmid preferably comprises an additional nucleotide sequence encoding a reporter gene product or other selectable marker that is constructed so that it will insert into the *Lawsonia* genome in operative association with the regulatory element sequences of the native *Lawsonia* gene to be disrupted. Reporter genes that can be used in practicing the invention are well-known in the art and include those encoding CAT, green fluorescent protein, and β -galactosidase, among others. Nucleotide sequences encoding selectable markers are also well-known in the art, and include those that encode gene products conferring resistance to antibiotics or anti-metabolites, or that supply an auxotrophic requirement. Examples of such sequences include those that encode pyrimethamine resistance, or neomycin phosphotransferase (which confers resistance to aminoglycosides), or hygromycin phosphotransferase (which confers resistance to hygromycin).

[0141] Methods that can be used for creating the genetic constructs of the present invention are well-known in the art, and include *in vitro* recombinant techniques, synthetic techniques, and *in vivo* genetic recombination, as described, among other places, in Maniatis *et al.*, 1989, above; Ausubel *et al.*, 1989, above; Sambrook *et al.*, 1989, above; Innis *et al.*, 1995, above; and Erlich, 1992, above.

[0142] *Lawsonia* cells can be transformed or transfected with a genetic construct of the present invention in accordance with known techniques, such as, e.g., by electroporation. Selection of transformants can be carried out using standard techniques, such as by selecting for cells expressing a selectable marker associated with the construct. Identification of transformants in which a successful recombination event has occurred and the particular target gene has been altered can be carried out by genetic analysis, such as by Southern blot analysis, or by Northern analysis to detect a lack of mRNA transcripts encoding the particular protein, or cells lacking the particular protein, as determined, e.g., by immunological analysis, by the appearance of a novel phenotype, such as reduced pathogenicity, by PCR assay, or by some combination thereof.

[0143] In a further non-limiting embodiment, the genetic construct of the present invention can additionally comprise a different gene or coding region from *Lawsonia* or from a different pathogen that infects the animal, which gene or coding region encodes an antigen useful to induce, or contribute to the induction of, a separate and distinct protective immune response in the animal upon vaccination with the modified live *Lawsonia* cells of the present invention. This additional gene or coding region can be further engineered to contain a signal sequence that leads to secretion of the

encoded antigen from the modified live *Lawsonia* cell, thereby allowing for the antigen to be displayed to the immune system of the vaccinated animal.

[0144] The present invention thus provides modified live *Lawsonia* cells in which the *htrA*, *ponA*, *hypC*, *lysS*, *ycfW*, *abc1*, or *omp100* gene has been mutated. In addition, the present invention provides a method of preparing modified live *Lawsonia* cells, comprising: (a) transforming cells of *Lawsonia* with a genetic construct of the invention; (b) selecting transformed cells in which the *htrA*, *ponA*, *hypC*, *lysS*, *ycfW*, *abc1*, or *omp100* gene has been mutated by the genetic construct; and (c) selecting from among the cells of step (b) those cells that can be used in a vaccine to protect a PPE susceptible animal against PPE. The invention also encompasses killed cell compositions prepared from such modified *Lawsonia* cells.

Culturing *Lawsonia* Bacteria

[0145] *Lawsonia* bacterium for use in the present invention can be cultured and maintained *in vitro* using methods described e.g. by Joens et al., 1997, *Am. J. Vet. Res.* 58:1125-1131; Lawson et al., 1993, *Journal of Clinical Microbiology* 31:1136-1142; and McOrist et al., 1995, *supra*.

Anti-*Lawsonia* Vaccines

[0146] The present invention further provides a vaccine against PPE, comprising an immunologically effective amount of a protein or polypeptide of the present invention, and a pharmaceutically acceptable carrier. In a preferred embodiment, the vaccine comprises a HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100 *L. intracellularis* protein.

[0147] The present invention further provides a vaccine against PPE, comprising an immunologically effective amount of one or more polynucleotide molecules of the present invention, and a pharmaceutically acceptable carrier. In a preferred embodiment, the vaccine comprises a polynucleotide molecule having a nucleotide sequence encoding *L. intracellularis* HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100.

[0148] The present invention further provides a vaccine against PPE, comprising an immunologically effective amount of modified *Lawsonia* bacteria of the present invention, and a pharmaceutically acceptable carrier. In one embodiment, the modified *Lawsonia* cells for use in the vaccine of the present invention are live *L. intracellularis* bacteria which express a HtrA⁺, PonA⁺, HypC⁺, LysS⁺, YcfW⁺, ABC1⁺, or Omp100⁺ phenotype. Alternatively, the vaccine of the present invention can comprise any of such modified *Lawsonia* cells of the present invention that have been inactivated. Inactivation of modified *Lawsonia* cells can be carried out using any techniques known in the art, including by chemical treatment, such as with binary ethylenimine (BEI), or beta-propiolactone, or formaldehyde, or by freeze-thawing or heat treatment, or by homogenization of cells, or by a combination of these types of techniques. Vaccines prepared from homogenized, modified *Lawsonia* cells can consist of either the entire unfractionated cell homogenate, or an immunologically effective subfraction thereof.

[0149] As used herein, the term "immunologically effective amount" refers to that amount of antigen, e.g., protein, polypeptide, polynucleotide molecule, or modified cells, capable of inducing a protective response against PPE when administered to a member of a PPE susceptible animal species after either a single administration, or after multiple administrations.

[0150] The phrase "capable of inducing a protective response" is used broadly herein to include the induction or enhancement of any immune-based response in the animal in response to vaccination, including either an antibody or cell-mediated immune response, or both, that serves to protect the vaccinated animal against PPE. The terms "protective response" and "protect" as used herein to refer not only to the absolute prevention of PPE or absolute prevention of infection by *Lawsonia*, but also to any detectable reduction in the degree or rate of infection by such a pathogen, or any detectable reduction in the severity of the disease or any symptom or condition resulting from infection by the pathogen, including, e.g., any detectable reduction in the rate of formation, or in the absolute number, of lesions formed in one or more tissues, or the transmission of infection to other animals, in the vaccinated animal as compared to an unvaccinated infected animal of the same species.

[0151] In a further preferred embodiment, the vaccine of the present invention is a combination vaccine for protecting a PPE susceptible animal against PPE and, optionally, one or more other diseases or pathological conditions that can afflict the animal, which combination vaccine comprises an immunologically effective amount of a first component comprising a polypeptide, polynucleotide molecule, or modified *Lawsonia* cells of the present invention; an immunologically effective amount of a second component that is different from the first component, and that is capable of inducing, or contributing to the induction of, a protective response against a disease or pathological condition that can afflict the PPE susceptible animal; and a pharmaceutically acceptable carrier.

[0152] The second component of the combination vaccine is selected based on its ability to induce, or contribute to the induction of, a protective response against either PPE or another disease or pathological condition that can afflict members of the relevant species, as known in the art. Any antigenic component that is useful in a vaccine composition

in the particular species can be used as the second component of the combination vaccine. Such antigenic components include but are not limited to those that provide protection against pathogens selected from the group consisting of *Leptospira* spp., *Campylobacter* spp., *Staphylococcus aureus*, *Streptococcus agalactiae*, *Streptococcus suis*, *Mycoplasma* spp., *Klebsiella* spp., *Salmonella* spp., rotavirus, coronavirus, rabies, *Pasteurella hemolytica*, *Pasteurella multocida*, *Clostridia* spp., *Tetanus* toxoid, *E. coli*, *Cryptosporidium* spp., *Eimeria* spp., *Trichomonas* spp., *Serpulina* (*Brachyspira*) *hyodysenteriae*, *Actinobacillus pleuropneumoniae*, *Actinobacillus suis*, *Salmonella choleraesuis*, *Erysipelothrix rhusiopathiae*, *Leptospira* sp., *Staphylococcus hyicus*, *Haemophilus parasuis*, *Bordetella bronchiseptica*, *Mycoplasma hyopneumoniae*, porcine reproductive and respiratory syndrome virus, swine influenza virus, porcine immunodeficiency virus, transmissible gastroenteritis virus, porcine parvovirus, encophalomyocarditis virus, coronavirus, pseudorabies virus, circovirus and other eukaryotic parasites.

[0153] In one embodiment, the combination vaccine of the present invention comprises a combination of two or more components selected from the group consisting of an immunologically effective amount of a protein or polypeptide of the present invention, an immunologically effective amount of a polynucleotide molecule of the present invention, and an immunologically effective amount of modified *Lawsonia* cells of the present invention.

[0154] The vaccines of the present invention can further comprise one or more additional immunomodulatory components including, e.g., an adjuvant or cytokine, as described below.

[0155] The present invention further provides a method of preparing a vaccine against PPE, comprising combining an immunologically effective amount of a *L. intracellularis* protein or polypeptide, or polynucleotide molecule, or modified *Lawsonia* cells, of the present invention, with a pharmaceutically acceptable carrier, in a form suitable for administration to a PPE susceptible animal. In a preferred embodiment, the protein is *L. intracellularis* HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100, the polynucleotide molecule preferably comprises a nucleotide sequence encoding *L. intracellularis* HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100 protein and the modified *Lawsonia* bacteria has an HtrA⁺, PonA⁺, HypC⁺, LysS⁺, YcfW⁺, ABC1⁺, or Omp100⁺ phenotype.

[0156] A vaccine comprising modified live *Lawsonia* cells of the present invention can be prepared using an aliquot of culture fluid containing said *Lawsonia* cells, either free in the medium or residing in mammalian host cells, or both, and can be administered directly or in concentrated form to the PPE susceptible animal. Alternatively, modified live *Lawsonia* cells can be combined with a pharmaceutically acceptable carrier, with or without an immunomodulatory agent, selected from those known in the art and appropriate to the chosen route of administration, preferably where at least some degree of viability of the modified live *Lawsonia* cells in the vaccine composition is maintained.

[0157] Vaccine compositions of the present invention can be formulated following accepted convention to include pharmaceutically acceptable carriers, such as standard buffers, stabilizers, diluents, preservatives, and/or solubilizers, and can also be formulated to facilitate sustained release. Diluents include water, saline, dextrose, ethanol, glycerol, and the like. Additives for isotonicity include sodium chloride, dextrose, mannitol, sorbitol, and lactose, among others. Stabilizers include albumin, among others. Suitable other vaccine vehicles and additives, including those that are particularly useful in formulating modified live vaccines, are known or will be apparent to those skilled in the art. See, e.g., Remington's *Pharmaceutical Science*, 18th ed., 1990, Mack Publishing, which is incorporated herein by reference.

[0158] The vaccine of the present invention can further comprise one or more additional immunomodulatory components such as, e.g., an adjuvant or cytokine, among others. Non-limiting examples of adjuvants that can be used in the vaccine of the present invention include the RIBI adjuvant system (Ribi Inc., Hamilton, MT), alum, mineral gels such as aluminum hydroxide gel, oil-in-water emulsions, water-in-oil emulsions such as, e.g., Freund's complete and incomplete adjuvants, Block co polymer (CytRx, Atlanta GA), QS-21 (Cambridge Biotech Inc., Cambridge MA), SAF-M (Chiron, Emeryville CA), AMPHIGEN[®] adjuvant, saponin, Quil A or other saponin fraction, monophosphoryl lipid A, Avridine lipid-amine adjuvant, and protein adjuvants such as *Vibrio cholera* toxin and *E. coli* labile toxin. Specific non-limiting examples of oil-in-water emulsions useful in the vaccine of the invention include modified SEAM62 and SEAM 1/2 formulations. Modified SEAM62 is an oil-in-water emulsion containing 5% (v/v) squalene (Sigma), 1% (v/v) SPAN[®] 85 detergent (ICI Surfactants), 0.7% (v/v) TWEEN[®] 80 detergent (ICI Surfactants), 2.5% (v/v) ethanol, 200 µg/ml Quil A, 100 µg/ml cholesterol, and 0.5% (v/v) lecithin. Modified SEAM 1/2 is an oil-in-water emulsion comprising 5% (v/v) squalene, 1% (v/v) SPAN[®] 85 detergent, 0.7% (v/v) Tween 80 detergent, 2.5% (v/v) ethanol, 100 µg/ml Quil A, and 50 µg/ml cholesterol. Other immunomodulatory agents that can be included in the vaccine include, e.g., one or more interleukins, interferons, or other known cytokines. Where the vaccine comprises modified live *Lawsonia* cells, the adjuvant is preferably selected based on the ability of the resulting vaccine formulation to maintain at least some degree of viability of the modified live *Lawsonia* cells.

[0159] Where the vaccine composition comprises a polynucleotide molecule, the polynucleotide molecule can either be DNA or RNA, although DNA is preferred, and is preferably administered to a PPE susceptible animal to be protected against PPE in an expression vector construct, such as a recombinant plasmid or viral vector, as known in the art. Examples of recombinant viral vectors include recombinant adenovirus vectors and recombinant retrovirus vectors. The vaccine formulation can also comprise a non-viral DNA vector, such as a DNA plasmid-based vector. The polynucleotide molecule may be associated with lipids to form, e.g., DNA-lipid complexes, such as liposomes or coch-

leates. See, e.g., International Patent Publication WO 93/24640.

[0160] An expression vector useful as a vaccinal agent in a DNA vaccine preferably comprises a nucleotide sequence encoding one or more antigenic *Lawsonia* proteins, or a substantial portion of such a nucleotide sequence, in operative association with one or more transcriptional regulatory elements required for expression of the *Lawsonia* coding sequence in a eukaryotic cell, such as, e.g., a promoter sequence, as known in the art. In a preferred embodiment, the regulatory element is a strong viral promoter such as, e.g., a viral promoter from RSV or CMV. Such an expression vector also preferably includes a bacterial origin of replication and a prokaryotic selectable marker gene for cloning purposes, and a polyadenylation sequence to ensure appropriate termination of the expressed mRNA. A signal sequence may also be included to direct cellular secretion of the expressed protein.

[0161] The requirements for expression vectors useful as vaccinal agents in DNA vaccines are further described in U.S. Patent 5,703,055, U.S. Patent 5,580,859, U.S. Patent 5,589,466, International Patent Publication WO 98/35562, and in various scientific publications, including Ramsay *et al.*, 1997, *Immunol. Cell Biol.* 75:360-363; Davis, 1997, *Cur. Opin. Biotech.* 8:635-640; Maniackan *et al.*, 1997, *Critical Rev. Immunol.* 17:139-154; Robinson, 1997, *Vaccine* 15(8):785-787; Lai and Bennett, 1998, *Critical Rev. Immunol.* 18:449-484; and Vogel and Sarver, 1995, *Clin. Microbiol. Rev.* 8(3):406-410, among others.

[0162] Where the vaccine composition comprises modified live *Lawsonia* cells, the vaccine can be stored cold, frozen, or lyophilized. Where the vaccine composition instead comprises a protein, polypeptide, polynucleotide molecule, or inactivated modified *Lawsonia* cells of the present invention, the vaccine may be stored cold, frozen, or in lyophilized form to be rehydrated prior to administration using an appropriate diluent.

[0163] The vaccine of the present invention can optionally be formulated for sustained release of the antigen. Examples of such sustained release formulations include antigen in combination with composites of biocompatible polymers, such as, e.g., poly(lactic acid), poly(lactic-co-glycolic acid), methylcellulose, hyaluronic acid, collagen and the like. The structure, selection and use of degradable polymers in drug delivery vehicles have been reviewed in several publications, including A. Domb *et al.*, 1992, *Polymers for Advanced Technologies* 3: 279-292, which is incorporated herein by reference. Additional guidance in selecting and using polymers in pharmaceutical formulations can be found in the text by M. Chasin and R. Langer (eds), 1990, "Biodegradable Polymers as Drug Delivery Systems" in: Drugs and the Pharmaceutical Sciences, Vol. 45, M. Dekker, NY, which is also incorporated herein by reference. Alternatively, or additionally, the antigen can be microencapsulated to improve administration and efficacy. Methods for microencapsulating antigens are well-known in the art, and include techniques described, e.g., in U.S. Patent 3,137,631; U.S. Patent 3,959,457; U.S. Patent 4,205,060; U.S. Patent 4,606,940; U.S. Patent 4,744,933; U.S. Patent 5,132,117; and International Patent Publication WO 95/28227, all of which are incorporated herein by reference.

[0164] Liposomes can also be used to provide for the sustained release of antigen. Details concerning how to make and use liposomal formulations can be found in, among other places, U.S. Patent 4,016,100; U.S. Patent 4,452,747; U.S. Patent 4,921,706; U.S. Patent 4,927,637; U.S. Patent 4,944,948; U.S. Patent 5,008,050; and U.S. Patent 5,009,956, all of which are incorporated herein by reference.

[0165] The present invention further provides a method of vaccinating a PPE susceptible animal against PPE, comprising administering to the animal an immunogenically effective amount of a vaccine of the present invention. The vaccine is preferably administered parenterally, e.g., either by subcutaneous or intramuscular injection. However, the vaccine can also be administered by intraperitoneal or intravenous injection, or by other routes, including, e.g., orally, intranasally, rectally, vaginally, intra-ocularly, or by a combination of routes, and also by delayed release devices as known in the art. The skilled artisan can determine optimal routes of vaccine administration, and recognize acceptable formulations for the vaccine composition according to the chosen route of administration.

[0166] An effective dosage can be determined by conventional means, starting with a low dose of antigen, and then increasing the dosage while monitoring its effects. Numerous factors may be taken into consideration when determining an optimal dose per animal. Primary among these is the species, size, age and general condition of the animal, the presence of other drugs in the animal, the virulence of a particular strain of *Lawsonia* against which the animal is being vaccinated, and the like. The actual dosage is preferably chosen after consideration of the results from other animal studies.

[0167] The dose amount of a protein or polypeptide of the present invention in a vaccine of the present invention preferably ranges from about 1 µg to about 10 mg, more preferably from about 50 µg to about 1 mg, and most preferably from about 100 µg to about 0.5 mg. The dose amount of a *Lawsonia* polynucleotide molecule of the present invention in a vaccine of the present invention preferably ranges from about 50 µg to about 1 mg. The dose amount of modified *Lawsonia* cells of the present invention in a vaccine of the present invention preferably ranges from about 1×10^3 to about 1×10^8 cells/ml, and more preferably from about 1×10^5 to about 1×10^7 cells/ml. A suitable dosage size ranges from about 0.1 ml to about 10 ml, and more preferably from about 1 ml to about 5 ml. The dose amounts of these antigens are also applicable to combination vaccines of the present invention. Where the second component of the combination vaccine is an antigen other than a *Lawsonia* protein, polypeptide, polynucleotide or modified cell of the present invention, the dose amount of the second component for use in the combination vaccine can be determined from prior

vaccine applications of that second component, as known in the art.

[0168] The vaccine of the present invention is useful to protect animals, especially pigs, against PPE. The vaccine can be administered to any suitable animals, including, without limitation, hamsters, ferrets, guinea pigs, deer, and bovine, equine, and avian species. The vaccine of the invention can be administered at any time during the life of a particular animal depending upon several factors including, e.g., the timing of an outbreak of PPE among other animals, etc. The vaccine can be administered to animals of weaning age or younger, or to more mature animals. Effective protection may require only a primary vaccination, or one or more booster vaccinations may also be needed. One method of detecting whether adequate immune protection has been achieved is to determine seroconversion and antibody titer in the animal after vaccination. The timing of vaccination and the number of boosters, if any, is preferably determined by a veterinarian based on analysis of all relevant factors, some of which are described above.

[0169] In one embodiment, a protein or polypeptide of the invention, e.g., HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100 *L. intracellularis* protein, or combinations thereof, is administered in a formulation containing 100µg of polypeptide, and 25µg of *E. coli* labile toxin as adjuvant, in 1 ml of buffered solution. The formulation is, for example, administered intramuscularly to pigs at between 5 and 7 days of age, and readministered 14 days later.

[0170] The present invention further provides a kit for vaccinating a PPE susceptible animal against PPE, comprising a container having an immunologically effective amount of a polypeptide, polynucleotide molecule, or modified *Lawsonia* cells of the present invention, or a combination thereof. The kit can optionally comprise a second container having a pharmaceutically acceptable carrier or diluent. In a preferred embodiment, the polypeptide is the HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100 *L. intracellularis* protein; the polynucleotide molecule preferably has a nucleotide sequence that encodes the HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100 *L. intracellularis* protein and the modified *Lawsonia* cells preferably are live or inactivated cells that express an HtrA⁺, PonA⁺, HypC⁺, LysS⁺, YcfW⁺, ABC1⁺, or Omp100⁺ phenotype.

[0171] The invention also relates to a kit for detecting the presence of *L. intracellularis*, an *L. intracellularis* specific amino acid or nucleotide sequence, or an anti- *L. intracellularis* antibody, that contains a protein, polypeptide, polynucleotide, or antibody of the invention. The kit can also contain means for detecting the protein, polypeptide, polynucleotide, or antibody of the invention including, for example, an enzyme, fluorescent, or radioactive label attached to the protein, polypeptide, polynucleotide, or antibody, or attached to a moiety that binds to the protein, polypeptide, polynucleotide, or antibody.

[0172] The following examples are illustrative only, and not intended to limit the scope of the present invention.

EXAMPLES

Example 1: Molecular cloning of *L. intracellularis* chromosomal Region A

Isolation of DNA and construction of DNA libraries

[0173] Template DNA was purified from pig intestinal mucosa isolated from the ileum of pigs experimentally infected with *L. intracellularis*. DNA purification from homogenized intestinal mucosa was performed according to (1) the method of Nollau *et al.* (Nollau *et al.*, 1996, BioTechniques 20: 784-788) or (2) phenol extraction and sodium acetate-ethanol precipitation of DNA. To facilitate cloning of *L. intracellularis* gene sequences, several genomic libraries were constructed. These libraries were specifically modified by ligation of a known sequence (Vectorette II™, Genosys Biotechnologies, Inc., The Woodlands, TX) to the 5' and 3' ends of restricted DNA fragments. Vectorette™ libraries were constructed by separately digesting aliquots of *L. intracellularis*-infected pig mucosal DNA extract with restriction endonucleases *Hind*III, *Eco*RI, *Dra*I or *Hpa*I at 37° overnight. The reaction was then spiked with additional fresh restriction enzyme and adjusted to 2 mM ATP, 2 mM DTT final concentration. Vectorette™ tailing was carried out by addition of T₄ DNA Ligase (400 U) plus 3 pMol of the appropriate compatible Vectorette™ linker (*Hind*III Vectorette™: *Hind*III digested DNA; *Eco*RI: *Eco*RI digested DNA; Blunt: *Dra*I, *Hpa*I digested DNA). The mixture was incubated for three cycles at 20°, 60 min; and 37°, 30 min to complete the tailing reaction then adjusted to 200 µl with water and stored at -20°.

Molecular cloning of genomic Region A encoding LysS, YcfW, ABC1, and Omp100 proteins

[0174] Identification of genomic Region A (shown in Fig. 1) was accomplished by genomic walking and phage library screening processes. Screening of the *Hind*III, *Eco*RI, *Dra*I, and *Hpa*I Vectorette™ libraries was carried out to obtain DNA fragments located adjacent to gene (*amiB*) from *L. intracellularis* having homology to bacterial N-acetylmuramoyl-L-alanine amidases involved in cell wall autolysis. Oligonucleotide primers ER159 (SEQ ID NO: 37), ER161 (SEQ ID NO: 38), and ER162 (SEQ ID NO: 39) were designed based on the nucleotide sequence of *amiB*. All three primers were designed to bind the (-) strand within this region to allow amplification of DNA located upstream of the gene encoding *AmiB*.

[0175] For polymerase chain amplification of a fragment of the *omp100* gene, oligonucleotides ER159 (SEQ ID NO: 37), ER161 (SEQ ID NO: 38), and ER162 (SEQ ID NO: 39) were used in combination with a Vectorette™ specific primer (ER70) (SEQ ID NO: 33) in 50 µl reactions containing 1x PCR Buffer II (Perkin Elmer), 1.5 mM MgCl₂, 200 µM each deoxy-NTP, 50 pMol each primer, and 2.5 U AmpliTaq™ Gold (Perkin Elmer) thermostable polymerase. Multiple single reactions were performed with 4 µl of the Vectorette™ libraries as DNA template. Amplification was carried out as follows: denaturation (95° 9 min); 40 cycles of denaturation (95° 30 sec), annealing (65° 30 sec), and polymerization (72° 2.5 min); followed by a final extension at 72° for 7 minutes.

[0176] The amplified products were visualized by separation on a 1.2% agarose gel (Sigma). An approximately 2.5 kb product resulted from amplification of the *HpaI* Vectorette™ library when either ER159 or ER162 were used in combination with the Vectorette™-specific primer, ER70. This fragment represented a 1.9 kb region immediately upstream of the *L. intracellularis* gene encoding AmiB. The PCR product was purified following agarose gel electrophoresis using JETsorb™ kit (GENOMED, Inc., Research Triangle Park, NC) and cloned into pCR2.1 Topo (Invitrogen, Carlsbad, CA) to generate plasmid pER393. The insert was partially sequenced using vector specific primers. The sequence obtained was analyzed by the BLASTx algorithm (Altschul et al., 1990, *J. Mol. Biol.* 215:403-10) and shown to partially encode a protein with similarity to an approximately 85 kDa protein in the GenBank database. The reported proteins from *Neisseria meningitidis*, *Haemophilus influenzae*, and *Pasteurella multocida* were Omp85, protective surface antigen D15, and Oma87, respectively.

[0177] Based on the newly identified sequence of this partial gene fragment (encoding about the C-terminal 2/3 of the Omp100 protein) specific primers ER174 (SEQ ID NO: 46) and ER175 (SEQ ID NO: 47) were designed to obtain additional 5' flanking sequences by a second round of screening the Vectorette™ libraries by PCR amplification. Oligonucleotides ER174 (SEQ ID NO: 46) and ER175 (SEQ ID NO: 47) were used in combination with primer ER70 (SEQ ID NO: 33) in 50 µl reactions containing 1x PCR Buffer II (Perkin Elmer), 1.5 mM MgCl₂, 200 µM each deoxy-NTP, 50 pMol each primer, and 2.5 U AmpliTaq Gold (Perkin Elmer) thermostable polymerase. Multiple single reactions were performed with 2 µl of the Vectorette™ *EcoRI* and *DraI* libraries as DNA template. Amplification was carried out as follows: denaturation (95° 9 min); 35 cycles of denaturation (95° 30 sec), annealing (62° 30 sec), and polymerization (72° 2.5 min); followed by a final extension at 72° for 7 minutes.

[0178] Screening of the *EcoRI* and *DraI* Vectorette™ libraries by PCR (employing either ER174 or ER175 in combination with ER70) resulted in successful amplification of an approximately 1.4 kb fragment from the *EcoRI* Vectorette™ library. The PCR product was purified following agarose gel electrophoresis using JETsorb™ kit and cloned into pCR2.1 Topo to generate plasmid pER394. Sequence analysis of the insert termini within pER394 using ER175 and a vector specific primer confirmed this fragment was contiguous (e.g. overlapped) with the fragment insert within pER393 and allowed determination of the 5' end of the *omp100* gene. This analysis also indicated the presence of an additional partial ORF having homology to the ATP-binding cassette (ABC) superfamily of transporter proteins. Accordingly, the encoded partial protein was designated ABC1.

[0179] Based on the newly identified nucleotide sequence of this partial gene fragment (encoding about the C-terminal 1/2 of the ABC1 protein) specific primer ER188 (SEQ ID NO: 55) was designed to obtain additional 5' flanking sequence by a third round of screening the Vectorette™ libraries by PCR amplification. Oligonucleotide ER188 (SEQ ID NO: 55) was used in combination with primer ER70 (SEQ ID NO: 33) in 50 µl reactions containing 1x PCR Buffer II, 1.5 mM MgCl₂, 200 µM each deoxy-NTP, 50 pMol each primer, and 2.5 U AmpliTaq™ Gold thermostable polymerase. Multiple single reactions were performed with 4 µl of the Vectorette™ *HindIII*, *DraI*, and *HpaI* libraries as DNA template. Amplification was carried out as follows: denaturation (95° 9 min); 30 cycles of denaturation (95° 30 sec), annealing (60° 30 sec), and polymerization (72° 2.5 min); followed by a final extension at 72° for 7 minutes.

[0180] Screening of the *HindIII*, *DraI*, and *HpaI* Vectorette™ libraries by PCR (employing ER188 in combination with ER70) resulted in successful amplification of an approximately 0.8 kb fragment from the *HindIII* Vectorette™ library. The PCR product was purified following agarose gel electrophoresis using JETsorb™ kit and cloned into pCR2.1 Topo to generate plasmid pER395. Sequence analysis of the insert termini within pER395 using ER188 and vector specific primers confirmed this fragment was contiguous (e.g. overlapped) with the fragment insert within pER394 and allowed determination of the 5' end of the *abc1* gene. An additional partial ORF was identified upstream of the *abc1* gene. The encoded protein was designated YcfW based on its homology with the conserved protein, YcfW, found in numerous bacteria.

[0181] The region encoding the remaining portion of the *ycfW* ORF was obtained by screening a Lambda ZAP Express™ phage library created by partial *Tsp509I* digestion of *L. intracellularis* genomic DNA. The phage library was plated onto XL1 -Blue MRF⁺ *E. coli* cells in the presence of 10 mM MgSO₄, IPTG, and X-Gal. Clear plaques were picked and phage inserts were amplified using the Expand Long Template PCR System™ as recommended by the supplier (Boehringer Mannheim, Indianapolis, IN). The T3 and T7 phage specific primers were used in PCR conditions consisting of denaturation (94° 2 min); 25 cycles of denaturation (94° 10 sec), annealing (50° 30 sec), and polymerization (68° 6 min); followed by a final extension at 68° for 7 min. Resulting PCR products were end-sequenced using the T3 and T7 primers and compared to genes in the GeneBank database by BLASTx analysis. One phage, designated clone A21,

contained an approximately 6.1 kb insert encompassing 2.8 kb which overlapped the previously identified *ycfW*, *ABC1*, and *omp100* DNA sequence. Accordingly this clone was used to determine the DNA sequence encoding the N-terminus of the YcfW protein. An additional ORF was identified upstream of the *ycfW* gene. This gene encoded a protein which shares homology with several lysyl-tRNA synthetases and was designated *lysS*.

5 [0182] The preliminary nucleotide sequence for the *omp100* and C-terminal portion of the *abc1* genes was obtained by sequencing the inserts within pER393 and pER394. Preliminary nucleotide sequence encoding the C-terminal 141 amino acid portion of YcfW and amino-terminal portion of ABC1 was obtained by sequencing the insert within pER395. Preliminary nucleotide sequence encoding the *lysS* and N-terminal portion of the *ycfW* gene was obtained by
 10 sequencing the PCR product representing the insert contained in phage clone A21. The primers employed for preliminary sequencing included the vector-specific M13 forward, M13 reverse, phage T3 and T7 primers in addition to ER159 (SEQ ID NO: 37), ER169 (SEQ ID NO: 41), ER170 (SEQ ID NO: 42), ER176 (SEQ ID NO: 48), and ER177 (SEQ ID NO: 49) for pER393; ER175 (SEQ ID NO: 47), ER185 (SEQ ID NO: 52), ER186 (SEQ ID NO: 53), and ER187 (SEQ ID NO: 54) for pER394; ER188 (SEQ ID NO: 55) for pER395; and ER246 (SEQ ID NO: 97), ER254 (SEQ ID NO: 98), ER255 (SEQ ID NO: 99), ER256 (SEQ ID NO: 100), and ER257 (SEQ ID NO: 101) for phage clone A21.

Specific PCR amplification of subgenomic DNA fragments encompassing *L. intracellularis* Region A

[0183] Results of the cloning and preliminary sequencing from the genomic fragments contained in plasmids pER393, pER394, pER395 and phage clone A21 were used to design oligonucleotide primers for the specific amplification of overlapping subgenomic fragments directly from *L. intracellularis*-infected pig mucosal DNA extracts. DNA
 20 extraction was carried out according to the methods described above. This approach was preferred based on the desire to eliminate introduction of sequencing artifacts due to possible mutations arising during the cloning of gene fragments in *E. coli*. Oligonucleotides ER246 (SEQ ID NO: 97) and ER254 (SEQ ID NO: 98), which flank the *lysS* and N-terminal ¾ of *ycfW*; oligonucleotides ER229 (SEQ ID NO: 73) and ER206 (SEQ ID NO: 66), which flank the *abc1* gene; and
 25 ER231 (SEQ ID NO: 75) and ER232 (SEQ ID NO: 76), which flank the *omp100* gene, were used to specifically amplify this region from the mucosal DNA extract. The *lysS* gene was amplified in a PCR reaction containing 2 µl mucosal DNA extract as template, 1x PC2 buffer (Ab Peptides, Inc.), 200 µM each dNTP, 50 pMol each primer, 7.5 U KlenTaq1 and 0.15 U cloned *Pfu* thermostable polymerases in a 50 µl final sample volume. Conditions for amplification consisted of denaturation at 94° for 5 minutes followed by 30 cycles of denaturation (94° 1 minute), annealing (55° 30 seconds), and
 30 polymerization (72° 3 minutes). A final extension at 72° for 7 minutes completed the amplification of the targeted 2.6 kb region. The *abc1* gene was amplified in triplicate PCR reactions containing 1 µl mucosal DNA extract as template, 1x PC2 buffer, 200 µM each dNTP, 50 pMol each primer, 7.5 U KlenTaq1 and 0.15 U cloned *Pfu* thermostable polymerases in a 50 µl final sample volume. Conditions for amplification consisted of denaturation at 95° for 5 min followed by 33 cycles of denaturation (94° 1 min), annealing (58° 30 sec), and polymerization (72° 80 sec). A final extension at 72°
 35 for 10 minutes completed the amplification of the targeted gene region. The *omp100* gene was amplified in quadruplicate PCR reactions containing 2 µl mucosal DNA extract as template, 1x PC2 buffer, 200 µM each dNTP, 50 pMol each primer, 7.5 U KlenTaq1 and 0.15 U cloned *Pfu* thermostable polymerases in a 50 µl final sample volume. Conditions for amplification consisted of denaturation at 94° for 5 min followed by 35 cycles of denaturation (94° 30 sec), annealing (60° 30 sec), and polymerization (72° 3 min). A final extension at 72° for 7 minutes completed the amplification of the
 40 targeted gene region. Following amplification, each of the samples were pooled if appropriate and the specific product was purified by agarose gel electrophoresis prior to direct sequence analysis using DyeDeoxy™ termination reactions on an ABI automated DNA sequencer (Lark Technologies, Inc., Houston, TX).

[0184] Synthetic oligonucleotide primers were used to sequence both DNA strands of the amplified products from *L. intracellularis*. The primers used for sequence analysis included: AP58.1 (SEQ ID NO: 26), AP58.2 (SEQ ID NO: 27),
 45 AP59.1 (SEQ ID NO: 28), AP59.2 (SEQ ID NO: 29), AP59.3 (SEQ ID NO: 30), AP59.4 (SEQ ID NO: 31), AP59.5 (SEQ ID NO: 32), ER159 (SEQ ID NO: 37), ER169 (SEQ ID NO: 41), ER170 (SEQ ID NO: 42), ER175 (SEQ ID NO: 47), ER176 (SEQ ID NO: 48), ER177 (SEQ ID NO: 49), ER185 (SEQ ID NO: 52), ER186 (SEQ ID NO: 53), ER187 (SEQ ID NO: 54), ER188 (SEQ ID NO: 55), ER205 (SEQ ID NO: 65), ER206 (SEQ ID NO: 66), ER217 (SEQ ID NO: 71), ER229 (SEQ ID NO: 73), ER230 (SEQ ID NO: 74), RA138 (SEQ ID NO: 79), RA139 (SEQ ID NO: 80), RA140 (SEQ ID NO: 81), AP182.1 (SEQ ID NO: 83), AP182.2 (SEQ ID NO: 84), AP182.3 (SEQ ID NO: 85), AP182.4 (SEQ ID NO: 86), AP182.5 (SEQ ID NO: 87), AP182.6 (SEQ ID NO: 88), AP182.7 (SEQ ID NO: 89), AP182.8 (SEQ ID NO: 90), AP182.9 (SEQ ID NO: 91), AP182.10 (SEQ ID NO: 92), AP182.11 (SEQ ID NO: 93), AP182.12 (SEQ ID NO: 94), AP182.13 (SEQ ID NO: 95), AP182.14 (SEQ ID NO: 96), ER246 (SEQ ID NO: 97), ER254 (SEQ ID NO: 98), ER255 (SEQ ID NO: 99), ER256 (SEQ ID NO: 100), and ER257 (SEQ ID NO: 101).

55 [0185] The nucleotide sequence of the *L. intracellularis* genomic Region A is listed in SEQ ID NO: 1. The deduced amino acid sequences of the encoded LysS, YcfW, ABC1, and Omp100 proteins within this region are presented in SEQ ID NO: 102, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5, respectively.

Molecular analysis of the *L. intracellularis* genes and gene products specified by Region A

[0186] The *L. intracellularis* chromosomal Region A identified upstream of the *amiB* gene encodes proteins designated LysS, YcfW, ABC1, and Omp100 (Fig. 1). These genes are encoded by the same DNA strand and are very closely arranged. This organization suggests these genes may be part of an operon and are likely translationally coupled in the case of LysS/YcfW and ABC1/Omp100. The *lysS* ORF likely initiates from an atypical TTG initiation codon and would extend from nucleotide 165-1745 of SEQ ID NO: 1. This gene encodes a deduced 526 amino acid protein, designated LysS (SEQ ID NO: 102), having a theoretical molecular weight of about 60,628 daltons. The *ycfW* ORF extends from nucleotide 1745-3028 of the reported sequence (SEQ ID NO: 1). This gene encodes a deduced 427 amino acid protein, designated YcfW (SEQ ID NO: 3), having a theoretical molecular weight of about 46,957 daltons. The *abc1* ORF extends from nucleotide 3031-3738 of SEQ ID NO: 1, and encodes a deduced 235 amino acid protein, ABC1 (SEQ ID NO: 4), having a theoretical molecular weight of about 25,618 daltons. Further downstream but overlapping this ORF by 44 nucleotides is an additional large open reading frame. This ORF, which was designated *omp100*, extends from nucleotide 3695-6388 of SEQ ID NO: 1. The *omp100* gene encodes a deduced 896 amino acid protein which was designated Omp100 (SEQ ID NO: 5). The Omp100 protein has a theoretical molecular weight of about 101,178 daltons.

Similarity of *L. intracellularis* LysS protein to lysyl-tRNA synthetases

[0187] The deduced amino acid sequence of the LysS protein (SEQ ID NO: 102) was compared to other proteins reported in GeneBank by the BLASTp algorithm (Altschul, S.F. et al., 1997, *Nucleic Acids Res.* 25:3389-3402) and aligned by the CLUSTAL W algorithm (Thompson, J.D. et al., 1994, *Nucleic Acids Res.* 22:4673-4680). As shown in Figure 9, this analysis indicated that LysS shares similarity with members of the cytoplasmic lysyl-tRNA synthetase family. The *L. intracellularis* LysS protein shares 47% identity with the lysyl-tRNA synthetase protein (Accn. AB012100) from *Bacillus stearothermophilus*. Consistent with its cytoplasmic location no secretion signal sequence was identified near the predicted N-terminus of this protein.

Similarity of *L. intracellularis* YcfW and ABC1 proteins to other hypothetical proteins

[0188] The YcfW protein shares limited homology with a family of conserved hypothetical proteins approximately 40-45 kDa in size. Members of this family are reported to be transmembrane or integral membrane proteins. A structural prediction comparison of representative proteins from this family was carried out using TMPred (EMBnet - European Molecular Biology Network; <http://www.ch.embnet.org/index.html>). The TMPred program makes a prediction of membrane-spanning regions and their orientation. The algorithm is based on the statistical analysis of TMbase, a database of naturally occurring transmembrane proteins. (Hofmann & Stoffel, 1993, *Biol. Chem. Hoppe-Seyler* 347:166). This analysis indicates that homologs within this protein family have three strong transmembrane domains clustered near the C-terminus of the protein. We have noted an extremely well conserved domain at the very carboxyl-terminal four amino acids (LRYE) of representatives from this family. The observation that the C-terminal region contains multiple transmembrane domains while the extreme C-terminus is highly conserved suggests a universal functional requirement associated with this region of the YcfW family of homologous proteins. The *L. intracellularis* YcfW protein presented in SEQ ID NO: 3 also contains three C-terminal transmembrane domains in addition to the extreme C-terminal amino acids (LRYE). In addition to the three carboxyl domains above, TMPred analysis indicates that residues 19-44 of the YcfW protein are likely to form a transmembrane region. The amino terminus of YcfW was also examined by the PSORT (Ver. 6.4) computer algorithm using networks trained on known secretion signal sequences. This analysis indicates that residues 29-45 are likely to form a transmembrane region (P. Klein et al., 1985, *Biochim. Biophys. Acta*, 815:468) which is predicted to act as an uncleavable signal sequence (D. J. McGeoch, *Virus Research*, 3:271, 1985 and G. von Heijne, *Nucl. Acids Res.*, 14:4683, 1986). As shown in Fig. 2, the 427 amino acid *L. intracellularis* YcfW protein shares 32% identity with a 415 residue hypothetical protein (Accn. AJ235272) from *Rickettsia prowazekii*.

[0189] The deduced amino acid sequence of the ABC1 protein (SEQ ID NO: 4) was compared to other known proteins reported in GenBank by the BLASTp algorithm. An especially well conserved region (GASGSGKS) was identified near the amino terminus of ABC1. This region corresponds to the nucleotide-binding motif A (P-loop) present in ABC-type transporters. The ABC-type proteins consist of a very large superfamily of proteins which have a wide variety of cellular functions. The majority of these proteins are classified as ABC-type proteins based on regional homology within the nucleotide-binding motif and are generally thought to be involved in cellular transport functions. Figure 3 shows an alignment of ABC1 with that of YcfV from *E. coli*, (Accn. AE000212) which shares about 45% identical amino acid residues. The *E. coli* YcfV protein is a probable ABC-type transport protein.

Similarity of *L. intracellularis* Omp100 protein to 85 kDa proteins

- [0190] Examination of the amino terminus of Omp100 indicates that amino acids 1-25 are hydrophobic and positively charged which is characteristic of signal sequences (von Heijm, 1985, *J. Mol. Biol.* 184:99-105). The SignalP (Ver. 1.1) computer algorithm (Nielsen, H., et al., 1997, *Prot. Engineering*, 10:1-6; <http://www.cbs.dtu.dk/services/signalP/>), using networks trained on known signal sequences, predicted the most likely cleavage site between amino acids 25 and 26. Thus amino acids 1-25 are predicted to be removed from Omp100 during the outer membrane localization process. The Omp100 C-terminal amino acid is predicted to be a phenylalanine residue, a feature consistent with the correct localization of outer membrane proteins (Struyve, M., 1991, *J. Mol. Biol.* 218:141-148).
- [0191] The deduced amino acid sequence of the Omp100 protein (SEQ ID NO: 5) was compared to other known proteins reported in GenBank by the BLASTp algorithm (Altschul, S.F et al., 1997, *Nucleic Acids Res.* 25:3389-3402) and aligned by the CLUSTAL W algorithm (Thompson, J.D. et al., 1994, *Nucleic Acids Res.* 22:4673-4680). As shown in Figure 4, this analysis indicated Omp100 shares limited similarity with an approximately 85 kDa protein in the GenBank database (designated U70214). Alignment of the C-terminal ends of Omp100 and this hypothetical protein (YaeT, Accn. U70214 or AE000127) from *E. coli* indicate these proteins share about 23% identical residues. Other reported proteins include those identified from *Shigella flexneri* (Oma90), *Neisseria meningitidis* (Omp85), *Haemophilus influenzae* (D15), and *Pasteurella multocida* (Oma87), among others. The NH₂ terminal portion including amino acids 1-139 does not align with any known protein. An additional search of GenBank with the BLASTp algorithm using only the region encompassing amino acids 1-200 of the encoded Omp100 protein failed to detect any known Omp85-like proteins. This data indicates that the amino terminal portion of Omp100 is entirely unique to *L. intracellularis*.

Example 2: Molecular cloning of *L. intracellularis* chromosomal Region B

Molecular cloning of genomic Region B encoding PonA, HtrA, HypC, and ORF1 proteins.

- [0192] Identification of genomic Region B (shown in Figure 1) was accomplished by a genomic walking process similar to that described for identification of genomic Region A. Screening of the *Hind*III, *Eco*RI, *Dra*I, and *Hpa*I Vectorette™ libraries was carried out to obtain DNA fragments located adjacent to gene *flgE* from *L. intracellularis* which encodes a protein with homology to the flagellar hook protein of other bacteria. Oligonucleotide primers ER142 (SEQ ID NO: 34), ER153 (SEQ ID NO: 35), and ER158 (SEQ ID NO: 36) were designed based on the known nucleotide sequence 3' of *flgE*. All three primers were designed to bind the (+) strand within this region to allow amplification of DNA located downstream of the gene encoding *FlgE*.
- [0193] For polymerase chain amplification of a fragment of the *ponA* gene, oligonucleotides ER142 (SEQ ID NO: 34), ER153 (SEQ ID NO: 35), and ER158 (SEQ ID NO: 36) were used in combination with a Vectorette™ specific primer (ER70) (SEQ ID NO: 33) in 50 µl reactions containing 1x PCR Buffer II, 1.5 mM MgCl₂, 200 µM each deoxy-NTP, 50 pMol each primer, and 2.5 U AmpliTaq™ Gold thermostable polymerase. Multiple single reactions were performed with 4 µl of the Vectorette™ libraries as DNA template. Amplification annealing temperatures, extension times, and number of cycles varied between experiments and were carried out over the following ranges: denaturation (95° 9 min); 35-40 cycles of denaturation (95° 30 sec), annealing (50-60° 30 sec), and polymerization (72° 2.5-3 min); followed by a final extension at 72° for 7 minutes.
- [0194] The amplified products were visualized by separation on a 1.2% agarose gel. An approximately 1.2 kb product resulted from amplification of the *Dra*I Vectorette™ library when ER158 (SEQ ID NO: 36) was used in combination with the Vectorette™-specific primer, ER70. Conditions leading to specific amplification of this product included denaturation (95° 9 min); 40 cycles of denaturation (95° 30 sec), annealing (60° 30 sec), and polymerization (72° 2.5 min); followed by a final extension at 72° for 7 minutes. This fragment represented a 1.4 kb region immediately downstream of the *L. intracellularis* gene encoding *FlgE*. The PCR product was purified following agarose gel electrophoresis using a JETsorb™ kit and cloned into pCR2.1 Topo to generate plasmid pER390. The insert was partially sequenced using ER70 and ER158 primers. The sequence obtained was analyzed by the BLASTx algorithm (Altschul, S. F. et al., 1990) and shown to encode a polypeptide with similarity to the amino terminal one half of penicillin-binding proteins in the GenBank database.
- [0195] Based on the newly identified sequence of this partial gene, primer ER163 (SEQ ID NO: 40) was designed to obtain additional 3' flanking sequences by a second round of screening the Vectorette™ libraries. Oligonucleotide ER163 (SEQ ID NO: 40) was used in combination with primer ER70 (SEQ ID NO: 33) in 50 µl reactions containing 1x PCR Buffer II, 1.5 mM MgCl₂, 200 µM each deoxy-NTP, 50 pMol each primer, and 2.5 U AmpliTaq Gold thermostable polymerase. Multiple single reactions were performed with 2 µl of the Vectorette™ *Hind*III, *Eco*RI and *Hpa*I libraries as DNA template. Amplification was carried out as follows: denaturation (95° 9 min); 30 cycles of denaturation (95° 30 sec), annealing (62° 30 sec), and polymerization (72° 1.5 min); followed by a final extension at 72° for 7 minutes.
- [0196] A 2.7 kb fragment was amplified from the *Hind*III Vectorette™ library. The PCR product was purified following

agarose gel electrophoresis using JETsorb™ kit and cloned into pCR2.1 Topo to generate plasmid pER392. Sequence analysis of the cloned insert termini using vector specific primers confirmed this fragment was contiguous with the fragment insert within pER390. This analysis also indicated the presence of an additional partial ORF corresponding to approximately the NH₂-terminal 400 residues of the HtrA protein family of serine proteases. Accordingly, the encoded partial protein was designated HtrA.

[0197] A third round of genomic walking was carried out to identify additional sequence within the *htrA* ORF. Specific primer ER173 (SEQ ID NO: 45) was designed based on the known sequence near the 3' end of the insert within pER392. Oligonucleotide ER173 (SEQ ID NO: 45) was used in combination with primer ER70 (SEQ ID NO: 33) in 50 µl reactions as above. Multiple single reactions were performed with 2 µl of the Vectorette™ *DraI* and *HpaI* libraries as DNA template. Amplification (denaturation (95° 9 min); 35 cycles of denaturation (95° 30 sec), annealing (62° 30 sec), and polymerization (72° 2.5 min); followed by a final extension at 72° for 7 minutes) resulted in production of a 0.3 kb fragment from the *DraI* library. The PCR product was purified following agarose gel electrophoresis using a JETsorb™ kit, cloned into pCR2.1 Topo, and the insert sequenced on both strands using vector specific primers. Sequence and BLASTx analysis indicated that the *htrA* ORF remained open through the 3' end of the cloned fragment and that an additional 10 amino acids would be expected to remain before the end of the encoded HtrA protein.

[0198] A final round of genomic walking was carried out to identify the remainder of the *htrA* ORF and 3' flanking region. Specific primer ER189 (SEQ ID NO: 56) was designed based on the known sequence near the 3' end of the *htrA* ORF. Oligonucleotide ER189 (SEQ ID NO: 56) was used in combination with primer ER70 (SEQ ID NO: 33) in 50 µl reactions as above. Multiple single reactions were performed with 4 µl of the Vectorette™ *HindIII*, *EcoRI*, and *HpaI* libraries as DNA template. Amplification was carried out as follows: denaturation (95° 9 min); 30 cycles of denaturation (95° 30 sec), annealing (60° 30 sec), and polymerization (72° 2.5 min); followed by a final extension at 72° for 7 minutes. Amplification resulted in production of an approximately 1 kb fragment from the *EcoRI* library. The PCR product was purified following agarose gel electrophoresis using a JETsorb™ kit and cloned into pCR2.1 Topo to generate pER396. Sequence analysis of the insert termini within pER396 using vector specific primers allowed determination of the 3' end of the *htrA* gene. An additional small ORF was identified downstream of the *htrA* gene. The encoded protein was designated HypC based on its homology with the HypC protein found in other bacteria. Further downstream from *hypC* is an additional partial ORF, designated *orf1*, which is encoded by the opposite DNA strand. This truncated 177 amino acid polypeptide was designated ORF1.

[0199] The preliminary nucleotide sequence for the *ponA*, *htrA*, *hypC*, and C-terminal portion of the *orf1* genes was obtained by sequencing the inserts within pER390, pER392 and pER396. The primers employed for preliminary sequencing included the vector-specific M13 forward and M13 reverse primers in addition to ER193 (SEQ ID NO: 59) and ER194 (SEQ ID NO: 60) for pER390; ER171 (SEQ ID NO: 43), ER172 (SEQ ID NO: 44), ER178 (SEQ ID NO: 50), ER179 (SEQ ID NO: 51), ER190 (SEQ ID NO: 57), and ER191 (SEQ ID NO: 58) for pER392; and ER195 (SEQ ID NO: 61) and ER196 (SEQ ID NO: 62) for pER396.

Specific PCR amplification of subgenomic DNA fragments encompassing *L. intracellularis* Region B

[0200] Results of the cloning and preliminary sequencing from the genomic fragments contained in plasmids pER390, pER392, and pER396 were used to design oligonucleotide primers for the specific amplification of overlapping subgenomic fragments directly from *L. intracellularis*-infected pig mucosal DNA extracts (methods described above for DNA extraction were employed). This approach was preferred based on the desire to eliminate introduction of sequencing artifacts due to possible mutations arising during the cloning of gene fragments in *E. coli*. Oligonucleotides ER228 (SEQ ID NO: 72) and ER190 (SEQ ID NO: 57), which flank the *ponA* gene; oligonucleotides ER207 (SEQ ID NO: 67) and RA134 (SEQ ID NO: 78), which flank the *htrA* gene; and oligonucleotides ER189 (SEQ ID NO: 56) and ER196 (SEQ ID NO: 62), which flank the *hypC* gene were used to specifically amplify this region from the mucosal DNA extract. The endpoints of these fragments overlap thereby allowing specific amplification of subgenomic DNA fragments which are contiguous followed by subsequent confirmation by comparing the terminal nucleotide sequences present in each unique, overlapping DNA fragment. Accordingly, the final sequence represents the complete *L. intracellularis* genomic Region B.

[0201] The overlapping *ponA*, *htrA*, and *hypC* gene regions were amplified in triplicate PCR reactions each containing 1 µl mucosal DNA extract as template, 1x PC2 buffer (Ab Peptides, Inc.), 200 µM each dNTP, 50 pMol each primer, 7.5 U KlenTaq1 and 0.15 U cloned *Pfu* thermostable polymerases in a 50 µl final sample volume. Conditions for amplification of *ponA* consisted of denaturation at 95° for 5 min followed by 33 cycles of denaturation (95° 30 sec), annealing (62° 30 sec), and polymerization (72° 3 min). Conditions for amplification of *htrA* consisted of denaturation at 94° for 5 min followed by 33 cycles of denaturation (95° 30 sec), annealing (58° 30 sec), and polymerization (72° 3 min). Conditions for amplification of *hypC* consisted of denaturation at 94° for 5 min followed by 33 cycles of denaturation (95° 30 sec), annealing (62° 30 sec), and polymerization (72° 80 sec). A final extension at 72° for 7 minutes completed the amplification of each of the targeted gene regions. Following amplification, each of the samples were pooled

separately and the specific product was purified by agarose gel electrophoresis prior to direct sequence analysis using DyeDeoxy™ termination reactions on an ABI automated DNA sequencer (Lark Technologies, Inc., Houston, TX).

[0202] Synthetic oligonucleotide primers were used to sequence both DNA strands of the amplified products from *L. intracellularis*. The primers used for sequence analysis included: AP55.1 (SEQ ID NO: 10), AP55.2 (SEQ ID NO: 11), AP55.3 (SEQ ID NO: 12), AP55.4 (SEQ ID NO: 13), AP55.5 (SEQ ID NO: 14), AP55.6 (SEQ ID NO: 15), AP55.7 (SEQ ID NO: 16), AP55.8 (SEQ ID NO: 17), AP55.9 (SEQ ID NO: 18), AP55.10 (SEQ ID NO: 19), AP55.11 (SEQ ID NO: 20), AP56.1 (SEQ ID NO: 21), AP56.2 (SEQ ID NO: 22), AP56.3 (SEQ ID NO: 23), AP57.1 (SEQ ID NO: 24), AP57.2 (SEQ ID NO: 25), ER158 (SEQ ID NO: 36), ER163 (SEQ ID NO: 40), ER171 (SEQ ID NO: 43), ER172 (SEQ ID NO: 44), ER173 (SEQ ID NO: 45), ER178 (SEQ ID NO: 50), ER179 (SEQ ID NO: 51), ER189 (SEQ ID NO: 56), ER190 (SEQ ID NO: 57), ER191 (SEQ ID NO: 58), ER193 (SEQ ID NO: 59), ER194 (SEQ ID NO: 60), ER195 (SEQ ID NO: 61), ER196 (SEQ ID NO: 62), ER203 (SEQ ID NO: 63), ER204 (SEQ ID NO: 64), ER207 (SEQ ID NO: 67), ER208 (SEQ ID NO: 68), ER213 (SEQ ID NO: 69), ER228 (SEQ ID NO: 72), RA133 (SEQ ID NO: 77), RA134 (SEQ ID NO: 78), and RA171 (SEQ ID NO: 82).

[0203] The nucleotide sequence of the *L. intracellularis* genomic Region B is listed in SEQ ID NO: 2. The deduced amino acid sequences of the encoded PonA, HtrA, HypC, and ORF1 proteins within this region are presented in SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8, and SEQ ID NO: 9, respectively.

Molecular analysis of the *L. intracellularis* genes and gene products specified by Region B

[0204] The *L. intracellularis* chromosomal Region B identified downstream of the *flgE* gene encodes proteins designated PonA, HtrA, HypC, and a partial "ORF1" protein (Fig. 1). A portion of the *flgE* ORF is presented here and extends from nucleotide 1-125 (SEQ ID NO: 2). The *ponA* ORF extends from nucleotide 252-2690 of SEQ ID NO: 2, and encodes a deduced 812 amino acid protein, PonA (SEQ ID NO: 6), having a theoretical molecular weight of about 90,263 daltons. An alternative in-frame translation initiation codon is present at nucleotide 276 which, if utilized, would encode a slightly smaller 804 amino acid protein having a theoretical molecular weight of about 89,313 daltons. The *htrA* ORF extends from nucleotide 2981-4315 of SEQ ID NO: 2, and encodes a deduced 474 amino acid protein, HtrA (SEQ ID NO: 7), having a theoretical molecular weight of about 50,478 daltons. The small *hypC* ORF extends from nucleotide 4581-4829 of SEQ ID NO: 2, and encodes a deduced 82 amino acid protein, HypC (SEQ ID NO: 8), having a theoretical molecular weight of about 8,888 daltons. Further downstream and transcribed in the opposite orientation is an additional open reading frame. This ORF, which was designated "orf1", extends from nucleotide 4912-5445 at the 3' end of SEQ ID NO: 2. This ORF remains open through the 3' end of SEQ ID NO: 2 and thus encodes the C-terminal 177 amino acids of a truncated protein having a theoretical molecular weight of at least about 20,345 daltons. As shown in Fig. 8, the encoded ORF1 protein (SEQ ID NO: 9) shares limited homology with a 205 amino acid hypothetical protein encoded by gene "MJ1123" (Accn. U67555) from the *Methanococcus jannaschii* genome.

Similarity of *L. intracellularis* HypC protein to hydrogenase maturation proteins

[0205] The HypC protein shares homology with the hyp/hup family of hydrogenase maturation proteins. Hydrogenase, which catalyzes the reversible oxidation of molecular hydrogen, is involved in many relevant anaerobic processes where hydrogen is oxidized or produced (Adams, M.W.W., et al., 1980, *Biochem. Biophys. Acta* 594:105-176). The HypC protein is required for the maturation of catalytically active hydrogenase isozymes in *E. coli*. The precise role of HypC in this process is unknown but hydrogenase maturation involves nickel insertion, protein folding, C-terminal proteolytic processing, membrane integration, and reductive activation (Lutz, S., et al., 1991, *Mol. Microbiol.* 5:123-135; Przybyla, A.E., et al., 1992, *FEMS Microbiol. Rev.* 88:109-136). The HypC protein is 41% identical to the *Desulfovibrio gigas* 82 amino acid HynD protein (Accn. AJ223669, as shown in Figure 7) and 39% identical to the 75 amino acid HypC protein from *Rizobium leguminosarum*.

Similarity of *L. intracellularis* PonA protein to penicillin binding proteins

[0206] The *ponA* ORF encodes a deduced 812 amino acid protein, having a theoretical molecular weight of about 90,263 daltons. An alternative in-frame methionine codon is present which encodes a slightly smaller 804 amino acid protein having a theoretical molecular weight of about 89,313 daltons. Similar in-frame methionine codons have been identified in other characterized *ponA* ORF's. For example, PonA homologs from *Neisseria flavescens* (Accn. AF087677), *N. gonorrhoeae* (Accn. U72876), and *N. meningitidis* (Accn. U80933) contain amino-terminal in-frame methionine codons separated by 8, 6, and 6 codons, respectively. As with *L. intracellularis*, the neisserial *ponA* genes are preceded by indiscernable ribosome binding sites thus further complicating prediction of the true initiating methionine. N-terminal sequencing of the *N. gonorrhoeae* FA19 PonA protein indicated the second methionine was the preferred start site in this strain (Ropp et al., 1997, *J. Bacteriol.* 179:2783-2787). The upstream methionine codon was

used as the putative initiation site for the encoded PonA protein from *L. intracellularis*.

[0207] A structural prediction of the PonA protein was carried out using TMPred. The TMPred program makes a prediction of membrane-spanning regions and their orientation (K. Hofmann & W. Stoffel, 1993. TMbase - A database of membrane spanning proteins segments. *Biol. Chem. Hoppe-Seyler* 347:166). This analysis indicates that PonA has a strong transmembrane domain at the NH₂-terminus of the protein. The amino terminus of PonA was examined by the PSORT (Ver. 6.4) computer algorithm using networks trained on known signal sequences. This analysis indicates that residues 16-32 are likely to form a transmembrane region (P. Klein et al., 1985, *Biochim. Biophys. Acta*, 815:468) which is predicted to act as an uncleavable signal sequence (D. J. McGeoch, *Virus Research*, 3:271, 1985 and G. von Heijne, *Nucl. Acids Res.*, 14:4683, 1986). Thus the amino terminus of PonA is predicted to anchor the protein to the bacterial inner membrane, which is similar to the method of localization of other penicillin-binding proteins.

[0208] The PonA protein shares homology with Class A high-molecular-mass penicillin-binding proteins (PBP's) identified in other bacteria. Penicillin-binding proteins are bacterial cytoplasmic membrane proteins involved in the final steps of peptidoglycan synthesis. The Class A proteins generally exhibit two types of enzymatic activities: the glycosyl-transferase, which polymerizes the glycan strand and the transpeptidase, which cross-links these strands by their peptide side chains. These reactions are catalyzed either on the outer surface of the cytoplasmic membrane or further outside and the major fraction of the proteins involved in peptidoglycan synthesis is therefore localized in the periplasm. The deduced amino acid sequence of the PonA protein (SEQ ID NO: 6) was compared to other known proteins reported in GenBank by the BLASTp algorithm (Altschul, S.F et al., 1997, *supra*) and aligned by the CLUSTAL W algorithm (Thompson et al., 1994, *supra*). As shown in Figure 5, this analysis indicated PonA is most similar to a penicillin-binding protein from *Neisseria flavescens* (Accn. AF087677). PonA shares features characteristic of class A high-molecular-mass PBPs. The sequence including amino acids 124-134 (RQGGSTITQQV) corresponds to a highly conserved consensus amino acid sequence known as the QGAST box (Popham et al., 1994, *J. Bacteriol.* 176:7197-7205) found in all class A high-molecular-mass PBPs. Within the C-terminal half of PonA, three regions can be found that are highly conserved in all members of the penicilloyl serine transferase superfamily. These regions include the SXXK tetrad containing the active site serine at residues 507-510 (SAFK), the SXN triad at residues 565-567 (SRN), and the KT(S)G tetrad at residues 688-691 (KTG). These motifs are thought to be brought close together in the folded protein to form the transpeptidase domain active-site pocket that interacts with β -lactam antibiotics.

Similarity of *L. intracellularis* HtrA protein to periplasmic serine protease proteins

[0209] Examination of the amino terminus of HtrA indicates that amino acids 1-26 are hydrophobic and positively charged which is characteristic of signal sequences (von Heijm, 1985, *J. Mol. Biol.* 184:99-105). The PSORT computer algorithm (Nakai, K., 1991, *PROTEINS: Structure, Function, and Genetics* 11: 95-110), using networks trained on known signal sequences indicates that residues 1-26 likely function as a typical signal sequence and predicts the most likely cleavage site between amino acids 26 and 27. Thus amino acids 1-26 are predicted to be removed from HtrA during the maturation process.

[0210] The deduced amino acid sequence of the HtrA protein (SEQ ID NO: 7) was compared to other known proteins reported in GenBank by the BLASTp algorithm (Altschul, S.F et al., 1997, above) and aligned by the CLUSTAL W algorithm (Thompson, J.D. et al., 1994, *supra*). This analysis indicated HtrA belongs to the large HtrA/DegP family of periplasmic serine proteases. The reported proteins include those identified from *E. coli*, *Salmonella typhimurium*, *Campylobacter jejuni*, *Haemophilus influenzae*, *Brucella melitensis*, *Brucella abortus*, *Chlamydia trachomatis*, *Yersinia enterocolitica*, *Borrelia burgdorferi*, and *Bacillus subtilis*, among others. In some instances the HtrA homolog is referred to as a heat shock protein and has been shown by deletion analysis to be required for bacterial survival at elevated temperatures or for survival of intracellular pathogens. In other cases an HtrA homolog is not induced by temperature but is expressed in response to other physiological stress. Several HtrA homologs have been shown to possess serine protease activity and in a number of cases is important for bacterial virulence and/or intracellular survival, for example resistance to high temperature, hydrogen peroxide, oxidative and osmotic stress.

[0211] Alignment of the *L. intracellularis* HtrA protein with its most similar relative from *Pseudomonas aeruginosa* (Accn. #U32853) indicates the two proteins share 40% identical amino acid residues (as shown in Figure 6). Based on alignment of the *L. intracellularis* HtrA protein with other serine proteases, especially well conserved residues including Histidine-109, Aspartic acid-143, and the active-site Serine-217 are predicted to form the catalytic triad of residues which are highly conserved in bacterial and mammalian serine proteases. A number of HtrA homologs contain a carboxy-terminal RGD motif while others have been shown to contain an RGN motif. The *L. intracellularis* HtrA protein contains a similar motif at residues 458-460 (RNG). The RGD motif has been identified as a cell attachment site for mammalian adhesion proteins (Ruoslahti, E. et al., 1986, *Cell* 44:517-518). The HtrA/DegP family of serine proteases are induced during a range of stress responses and during infection by *L. intracellularis*, surface expression of HtrA may occur as part of a stress response mechanism. Other intracellular heat shock proteins have been shown to become surface expressed under physiological stress conditions and have been implicated as adhesion factors (Ensgraber, M. et

al., 1992, *Infect. Immun.* 60:3072-3078 and Hartmann, E. et al., 1997, *Infect. Immun.* 65:1729-1733).

Analysis of the *htrA* promoter region and induction in response to temperature

5 [0212] The gene arrangement for *L. intracellularis* Region A and Region B differ with regard to the extent of inter-genic spacing between the encoded proteins. Unlike Region A the ORF's within Region B are more distantly separated. For example, the *figE*, *ponA*, *htrA*, and *hypC* genes are separated by approximately 125, 200, and 265 nucleotides between the respective open reading frames. The 200 bp region immediately upstream of *htrA* was examined in more detail to find a promoter region, particularly since several HtrA protein homologs have been shown to be induced in
10 response to a number of different environmental signals including temperature, oxidative, and osmotic stress. Examination of the nucleotide sequence of SEQ ID NO: 2 upstream of *htrA* indicated a promoter located about nucleotide 2797-2802 (TTGATA; -35 region) and nucleotide 2824-2829 (TATAAT; -10 region). These two hexamers are separated by a 21 nucleotide space and share near perfect homology to consensus sigma 70 type promoters. Other promoter elements may exist in this region which control *htrA* expression in response to various environmental signals. Plasmid
15 pER434, which contains the *htrA* ORF and *htrA* promoter region imparts a temperature-dependent phenotype to *E. coli* host cells grown at either 30°C or 37°C. Thus, the region upstream of *htrA* can be recognized as a likely functional promoter in response to temperature. It should therefore be possible to use the *htrA* promoter to operably control expression of heterologous proteins in *E. coli* and other organisms in response to temperature. The presence of other promoter elements that control expression in response to other environmental signals would allow those other signals
20 to be used to control expression.

Example 3: Preparation of plasmids and deposit materials

Plasmids containing DNA fragments encompassing *L. intracellularis* Region A

25 [0213] Plasmids were prepared containing the *L. intracellularis* genomic region representing the *lysS*, *ycfW*, *abc1*, and *omp100* genes. A 2.6 kb fragment encompassing the *lysS* gene and a portion of the *ycfW* gene was amplified using primers ER246 (SEQ ID NO: 97) and ER254 (SEQ ID NO: 98) while a 0.87 kb fragment encompassing a portion of the *ycfW* gene and complete *abc1* gene fragment was amplified using primers ER229 (SEQ ID NO: 73) and ER206
30 (SEQ ID NO: 66). These fragments were amplified as described in Example 1 under "Specific PCR amplification of sub-genomic DNA fragments encompassing *L. intracellularis* Region A". The 2.6 kb and 0.87 kb DNA fragments were isolated by extraction with spin chromatography (QIAquick™) and inserted into the TA cloning site of pCR2.1 Topo. Single sequence extension reactions utilizing vector-specific sequencing primers confirmed the endpoints of the cloned fragments, and revealed that the genes encoding *LysS* and *YcfW* in plasmid pT068 and *YcfW* and *ABC1* in plasmid
35 pER438 were in the opposite orientation relative to the lactose promoter.

[0214] A 2.97 kb DNA fragment containing the *omp100* gene was amplified by PCR employing specific 5' and 3' primers ER187 (SEQ ID NO: 54) and ER170 (SEQ ID NO: 42). PCR reactions were carried out in triplicate and contained 1 µl DNA extract as template, 1x PCR Buffer II, 1.5 mM MgCl₂, 200 µM each deoxy-NTP, 50 pMol each primer, and 2.5 U AmpliTaq Gold thermostable polymerase in a 50 µl final sample volume. Conditions for amplification consisted of denaturation at 95° for 9 min followed by 33 cycles of denaturation (95° 30 sec), annealing (62° 30 sec), and
40 polymerization (72° 3 min). A final extension at 72° for 7 minutes completed the amplification of the target gene region. Following amplification, each of the triplicate samples were pooled and the specific product was isolated by extraction with spin chromatography (QIAquick™) and inserted into the TA cloning site of pCR2.1 Topo in the opposite orientation relative to the lactose promoter. This plasmid construct was designated pER440.

45 [0215] Plasmids pER438 and pER440 were introduced into *E. coli* TOP 10 cells (Invitrogen, Carlsbad, CA). The resulting strains, designated Pz438 and Pz440, were deposited with the ATCC (10801 University Blvd, Manassas, VA, 20110, USA) on September 9, 1999 and assigned accession numbers PTA-638 and PTA-640 respectively. Plasmid pT068 was introduced into *E. coli* TOP10 cells and the resulting strain was deposited with the ATCC on July 14, 2000 and assigned accession number PTA-2232.

Plasmids containing DNA fragments encompassing *L. intracellularis* Region B

55 [0216] Plasmids were prepared containing the *L. intracellularis* genomic region representing the *ponA*, *htrA*, and *hypC* genes. The *ponA*, *htrA*, and *hypC* gene fragments were amplified as described above in Example 2, in the section entitled "Specific PCR amplification of subgenomic DNA fragments encompassing *L. intracellularis* Region B" using primers ER228 (SEQ ID NO: 72) and ER190 (SEQ ID NO: 57), which flank the *ponA* gene; primers ER207 (SEQ ID NO: 67) and RA134 (SEQ ID NO: 78), which flank the *htrA* gene; and primers ER189 (SEQ ID NO: 56) and ER196 (SEQ ID NO: 62), which flank the *hypC* gene. The resulting 2.98 kb fragment containing *ponA* was purified following

agarose gel electrophoresis using a JETsorb™ kit and cloned into pCR2.1 Topo to generate plasmid pER432. The resulting 1.72 kb fragment containing *htrA* was isolated by extraction with spin chromatography (QIAquick™) and inserted into the TA cloning site of pCR2.1 Topo to generate plasmid pER434. The resulting 0.98 kb fragment containing *hypC* and additional flanking nucleotides encoding the C-terminal 94 amino acids of ORF1 was isolated by extraction with spin chromatography (QIAquick™) and inserted into the TA cloning site of pCR2.1 Topo to generate plasmid pER436. Single sequence extension reactions utilizing vector-specific sequencing primers confirmed the endpoints of the cloned fragments, and revealed that the genes encoding PonA and HypC were in the opposite orientation relative to the lactose promoter. The HtrA gene was cloned in the same orientation relative to the lactose promoter and cells containing such plasmids exhibited an unstable phenotype at 37°C which was relieved when growth was maintained at 30°C.

[0217] Plasmids pER432, pER434 and pER436 were introduced into *E. coli* TOP10 cells (Invitrogen, Carlsbad, CA). The resulting strains, designated Pz432, Pz434, and Pz436 were deposited with the ATCC (10801 University Blvd, Manassas, VA, 20110, USA) on September 9, 1999 and assigned the accession numbers PTA-635, PTA-636, and PTA-637, respectively.

Example 4: Expression of recombinant HtrA and Omp100 proteins in *E. coli*

Plasmid expression vectors

[0218] The expression vector used for production of recombinant HtrA and Omp100 was pET-28b (+) (Novagen, Inc., Madison, WI). The coding sequences for the HtrA and Omp100 proteins were amplified from *L. intracellularis*-infected pig mucosal DNA extract. The PCR products were purified following agarose gel electrophoresis using a JETsorb™ kit and cloned into pCR2.1 Topo to generate plasmids pRL001 (HtrA) and pER415 (Omp100). Specific PCR primers used to amplify the HtrA ORF included ER208 (SEQ ID NO: 68) and RA133 (SEQ ID NO: 77). Primer ER208 was designed to introduce an *NdeI* site (CATATG) while deleting the HtrA signal sequence. The HtrA insert present in pRL001 was subcloned into pET-28b (+) following digestion with *NdeI* and *EcoRI*. The resulting expression plasmid, designated pER405, was sequenced at both 5' and 3' ends of the inserted fragment and confirmed to encode an in-frame fusion with the vector encoded 6x His leader. Therefore the predicted amino terminal sequence of the encoded protein consisted of the sequence MGSSHHHHHSSGLVPRGSHM encoded by the vector followed immediately by the sequence ALPNFVP beginning at Alanine-27 of the HtrA open reading frame.

[0219] Specific PCR primers used to amplify the Omp100 ORF included ER216 (SEQ ID NO: 70) and RA138 (SEQ ID NO: 79). Primer ER216 was designed to introduce an *NcoI* site (CCATGG) while deleting the Omp100 signal sequence. In addition, ER216 specified a leader peptide, termed a "protective peptide" which protects recombinant proteins from proteolytic degradation, based on information from Sung et al., 1986, Proc. Natl. Acad. Sci. USA 83:561-565; Sung et al., 1987, Meth. Enzymol. 153:385-389; and U.S. Patent 5,460,954, which references are incorporated herein by reference. The protective peptide consisting of the amino acid sequence MGTTTTTTSL was encoded by the 5' proximal nucleotide sequence of ER216. The Omp100 insert present in pER415 was subcloned into pET-28b (+) following digestion with *NcoI* and *EcoRI*. The resulting expression plasmid, designated pRL029, was sequenced at both 5' and 3' ends of the inserted fragment and confirmed to encode an in-frame fusion with the protective peptide leader. Therefore the predicted amino terminal sequence of the encoded protein consisted of the sequence MGTTTTTTSL specified by the 5' proximal nucleotide sequence of ER216 followed immediately by the sequence ASKDDPSIV beginning at Alanine-26 of the Omp100 open reading frame.

Expression of recombinant proteins

[0220] The pET-28b (+) based expression vectors pER405 and pRL029, encoding recombinant HtrA and Omp100, respectively, were introduced into the expression host *E. coli* BL21(DE3). This expression host has the genotype F⁻, *ompT hsdS_B* (r_B m_B⁻) *gal dcm* (DE3) (Novagen, Inc.) which allows high level transcription of cloned genes driven by the IPTG-inducible phage T7 promoter. The *E. coli* transformants were propagated in SB#2 medium (2.4% yeast extract, 1.2% tryptone, 0.5% K₂HPO₄, 0.25% KH₂PO₄, .014% MgSO₄) containing 50 µg/ml kanamycin sulfate in a 5 L BioFlow™ 3000 fermentor (New Brunswick Scientific, Edison, NJ) at 30-37 °C until A₆₂₅ was 2.5-30.1. Recombinant protein expression was obtained following induction with 1 mM IPTG for 1-4.5 h.

[0221] Wet cells of *E. coli* expressing recombinant HtrA were lysed by homogenization at 10,000 psi (2 passes) followed by centrifugation. The pellet, which contained HtrA, was washed with 2x RIPA/TET which was in a 5:4 ratio. 2x RIPA is 20 mM Tris (pH 7.4), 0.3 M NaCl, 2.0% sodium deoxycholate, and 2% (v/v) Igepal CA-630™ (Sigma). TET is 0.1 M Tris (pH 8.0), 50 mM EDTA, and 2% (v/v) Triton X-100. The washed pellet was then solubilized in 8 M Urea, 10 mM Tris, 0.1 M NaH₂PO₄, pH 7.0. The solubilized protein was diluted 2 fold in 8 M Urea, 10 mM Tris, 0.1 M NaH₂PO₄, pH 7.0 and applied onto a Ni NTA column (QIAGEN, Santa Clarita, CA). The desired protein was eluted off this column by

reduction of pH into 8 M Urea, 10 mM Tris, 0.1 M NaH_2PO_4 , pH 4.5. The final pooled fractions were dialyzed against 4 M Guanidine HCl, 50 mM Tris, pH 6.5 and then step dialyzed to 2 M Guanidine HCl, 25 mM Tris, pH 6.5. The final product was filtered by 0.22 μM filtration. The protein concentration was 0.56 mg/ml with an estimated visual purity of 70% by SDS-PAGE.

- 5 [0222] Wet cells of *E. coli* expressing recombinant Omp100 were lysed with lysozyme and sonication in the presence of Benzonase™ (Benzonase™ (EM Industries Inc, Hawthorne, New York)), to facilitate DNA degradation, followed by centrifugation. The pellet, which contained Omp100, was washed twice with 2 M Urea, 50 mM Tris, 10 mM EDTA, 25 mM DTT, 1% Zwittergent 3-14. The pellet was resuspended with 6 M Urea, 50 mM Tris (pH 8.0) followed by centrifugation. The pellet was washed with 2x RIPA/TET which was in a 5:4 ratio and the washed pellet was then solubilized
- 10 in 8 M Urea, 50 mM Tris (pH 8.0). 25 mM DTT was added to the solubilized protein and further diluted 2:1 with 8 M Urea, 25 mM DTT, 50 mM Tris (pH 8.0). The diluted solubilized protein was applied onto a Q-Sepharose column equilibrated with 8 M Urea, 25 mM DTT, 50 mM Tris (pH 8.0). Recombinant Omp100 was eluted in a linear gradient of 0-1 M NaCl in 8 M Urea, 25 mM DTT, 50 mM Tris (pH 8.0). The pooled fractions were dialyzed against 6 M Guanidine HCl, 10 mM DTT, 50 mM Tris (pH 8.0) and then step dialyzed to 4 M Guanidine HCl, 6.7 mM DTT, 33.3 mM Tris (pH 8.0). The final
- 15 product was filtered by 0.22 μM filtration and frozen at 70°C. The purified Omp100 protein was then thawed and centrifuged (16,000 rpm, 60 min) and the supernatant was subjected to 0.22 μM filtration again to remove insoluble particles and aggregates. The protein concentration was 1.08 mg/ml with an estimated visual purity of 80% by SDS-PAGE.

20

25

30

35

40

45

50

55

SEQUENCE LISTING

5 <110> Pfizer Products Inc.

<120> LAWSONIA INTRACELLULARIS PROTEINS, AND RELATED METHODS
AND MATERIALS

10 <130> PC10589A

<140>
<141>

15 <160> 102

<170> PatentIn Ver. 2.1

20 <210> 1
<211> 6617
<212> DNA
<213> Lawsonia intracellularis

25 <400> 1
ggggaacgct acttaactta agttggtggt tatctaaaca aaaccataca gtcaagcttt 60
ttatttttca agactcattt tatcttcttg actatcaagc tcttttggac taccgctaata 120
taaatataga atacgcctta attgtattac tggagaagca ttcattgata cagaaaaaaaa 180
aatctcatcc cccaattaaa ttagctacca agtcacctca tgtatcttat tttaaaccctc 240
30 tgcttgagag ccttgacaga aaaaatgagc ttaatgaagt tatcaaaaac tgtgtagtaa 300
aatcctgtga gcttttagac tcaggaattc ctctctaccc agatgagttc gttaaagagc 360
attatgctgg tatgcttcgt gctgaatatg aagcctatag tgcattctgaa cttgaatcac 420
tagacgaaat ttttgcttgt gctggacgta ttatctctct ccggtcattt ggtaaagtaa 480
tattctttca tatcatggat agaagcggtc gcattcaatg ttatgcatct cgtgaaaata 540
35 tgggagaaga agcatttagt acattcaaaa agtttgatat tgggtgacatt gttggtgtta 600
atggaaaact tttccgtaca aaaatgggag aattaactct caactgctcc actatcacat 660
tattagctaa gtccttccgt tctttaccag aaaaacataa tggccttact aacatagaac 720
ttaggtatcg ccagcgatat atagatctta ttgttaatcc taaaacaaga gatattctta 780
40 gaaagcgtag taaaattatt catgaaatta gagcattctt agaagaaaat ggctttatag 840
aagtagaaac acctattctt caacctattc caggtggtgc aatggcgcgt ccatttacta 900
cacataataa tgcaatggat atgacccttt atatgcgcat tgctcctgaa ctctatttaa 960
agcggcttct tgttggtggt ttgaaaaaac tatttgaatt aaatcgtagc ttccgtaatg 1020
aaggaatctc tatccaacat aatccagaat ttacatgtg tgaattttac tgggcctatg 1080
45 caacatatct agatcttatg gaacttacag aagaaatggt tgcatacctt acaaaaaaaaa 1140
tctgtggtac tatgactata tcttaccgaag gaaatacaat cgattttaca cctgggacat 1200
ggcaaaaata tacatttcat gagtctcttg aaaaaattgg tgggcattct ccagagtttt 1260
ataataactt tgaaaaaggt agtgaatata ttaaagaaca tggagaaaaa gttctgacaa 1320
ctgacaaaat aggaaaactt caagctaaac tctttgacct tgacgtagaa aacaaaactga 1380
50 ttcaaccac atttatctat cactatccta ctgatattct tccactctcc aaaaaaata 1440
aagataaccc agaagtaaca gatcgttttg agctttttat tgcaggaaaa gaaattgcta 1500
atgcatttct agaacttaat gatcctattg atcaacgtct gcgttttgaa gaacaagtgc 1560

55

ttgagaaagc acgtggagac gaagaagcat gtcccatgga tgaagattat cttcgtgcat 1620
 tagaatatgg aatgccacca gcagcagggg aaggatttgg aattgatcga ctcgttatgc 1680
 5 tctttacaga ctctccttcc atacgagagg ttatcctttt ccctctatta cgaacagaac 1740
 gctaataag tttgaacttt ttattgtctc acattatctc tttgcaagac gaaaacaagc 1800
 tttcatttat cttatttcat taatgtcaat tttaggagtt gctattgggtg ttgcctctct 1860
 tgtagttgta ttaggggttt ataatgggtt tactatagat atccgtgaca aaattcttgg 1920
 agctaatagca catattatta ttacagggaa ctttgattca cctatagaag aacctacaag 1980
 10 ttttactcag ctgtcaacta cttctatgct gtcccaaat gctcttatta tcctaaataa 2040
 acttcaacaa acttctgcga taataggtgc tactcccttt atttatgcag aatgtatgat 2100
 atcctctcct catggagtaa aaggctcttat ttaaggggg atagatccct catcagcaca 2160
 aaatgtcatt tctatgcttt ctcactcaac aaaaggaaat ctggaagatc ttatccctaa 2220
 agttttaggg actccagacg gtattattat tggtaatgag ctgcccacaa gactcaatgt 2280
 15 aacaataggt agtcgtgtaa acttactctc accaacagga caaaaaacat cttcaggatt 2340
 tcagccacgg atacgaccac ttattgtaac aggaatcttt catacaggta tgtttgaata 2400
 tgacacttct cttgcattta cttctcttaa tgcagcaaga gaacttcttg gactacctca 2460
 caattatatt tctggaatag aagtcagtat tcatgatgtg tatcaagcaa attatatcac 2520
 aaaccaactg caacaagagt taggtcataa ttttctgta cgaagctgga tggatatgaa 2580
 20 tgcaaattta tttgcagcac ttaagcttga aaaaattgga atgtttatta tattagctat 2640
 ggttgttctc attggttctt tttctattgt tacaacatta attatgcttg taatggaaaa 2700
 aacaagagat attgctatc taacctccat gggggctaca agccaaatga tccgtcgtat 2760
 tttcatttta caaggaaacta ttattggtat tgtaggaaact ttgctagggtt atctacttgg 2820
 25 aattactctt gcacttttat tgcagaaata tcaattcatt aaacttcccc ctgggggtata 2880
 tacaatagat cacttgccag tattacttaa ttggctagat atattcatta ttgggtacttc 2940
 tgccatgcta ctatgttttt ttgctactct ctacctgcc catcaagcgg ctcgactaca 3000
 gcctattgaa ggattaagggt acgagtaaaa atgtcacaat atctattaga aaatatagta 3060
 aaacagtatg acagtccttc tgaacctatt tgtgtcttac ataaaaataa tctttctata 3120
 30 gctcacggag aatcattagc tattattggt gcactggtt ctgggaaatc aaccttattg 3180
 catatccttg gagcattaga tataccatct tctggcactg tgttatttaa taataaaaat 3240
 ttaagtcata tgggcccacaa tgaaaaagca tgctttcgta ataaactact gggatttatt 3300
 ttccaatttc acaacttact tccagaatc tctgctgaag aaaatgttgc aatgaaagct 3360
 35 cttattgctg gtataccaaa aaagaagct cttctgcttg cagagaagc acttggtagt 3420
 gtaggacttg aaaataaata ccatcacaga ataacaatgt tgtcaggagg tgaacgtcaa 3480
 cgtgtagcca tagctagagc tattttatta gaaccccaag ttcttcttgc agatgaacca 3540
 acaggcaacc ttgatcaaaa aacaggtgaa cacattgccca atcttctaat ctacttaat 3600
 aaaaacttta atataactct tattgtagtc acacataata atgatattgc ccattctatg 3660
 40 ggacgtgcc ttgagctgaa gtccggagat ctacatgaca aaacgcctga atatatctct 3720
 tctactgtta ctgtgtaata tactttattg taatataata gccaatgctg cttcaaaaga 3780
 cgatccttct attgtggttc tcccatttca aattaatggc tcatcaaatg atgaagagtt 3840
 acaaacagaa ctaccaatgc ttcttgcaac tgcattaaag aataagggat ttcgtgtcat 3900
 ccttaataaa tctgcattaa atcttctata taaacaaaat atctcccaac ttaatatctc 3960
 45 tactgcaaaa aaggtagctc aacaactcca tgctgactat gtagtatacg gcagtttcaa 4020
 tcaaacaggt gaaaatttta gtattgatag taggcttatt gatagtacag gtgtagcatc 4080
 tgcacgtcca ttatcacatag aaaaaccaa atttaatgag ctaaatattg ctgtaacaga 4140
 acttgcgtgaa cgtataagta atggccttat aaagaaaaac actattgctg atgtacgtat 4200
 tcatgggctt aaagtctctg atcctgatgt aatccttaca cgactcacta ttaataaggg 4260
 50 agatcatact gatcatgccca aaattaatgc agaaatcaaa aaaatatggg aattaggata 4320
 ttttagtgat gtctctgcaa gtattgaaga aagcggggaa ggacgattac ttgtatttac 4380
 tgtacaagaa aagcctaaaa ttacagatgt tgttgttcaa ggctcaaaag ctgtaagtat 4440

55

cgataacatt cttgctgcaa tgagttctaa aaaaggatca gttattagt atagactatt 4500
 gtcccaagat attcaaaaaa ttaccgacct ctatagaaaa gaaggctact atctcgctga 4560
 5 agttaattat gaaataaaag agaaagaaaa tacttcttct gcaacactat tgtaacagt 4620
 aatgaaggg aaaaaacttt atattaaaga tgtccgaatt gaaggacttg aaacaataaa 4680
 agctaaaact ttaaaaaaag agttagcatt aacagaacgt aattttttat catgggttac 4740
 rggaacagg gtattacgtg aagaatatct tgaacgtgac tctatagcaa tctctgccta 4800
 tgccatgaat catggctatg tagatattca agttgcttca cctgaagtaa cattcaatga 4860
 10 aaaaaggaatt gttattacat ttagagtaaa agaaggtaag cgctataaaa taggaaaaat 4920
 agactttaaa ggagatctta ttgagacaaa tgaacaactc cttaaagtaa caaaaattga 4980
 tgatcataaa aactatgagc agtatttttc tctttctgtt atgcaagatg atgtaaaagc 5040
 attaacagat ttttattcag attatgggta tgcatttgct gaagtagatc ttgaaacaac 5100
 caaaaatgaa gaagatgcaa caattgatgt tactttcctt attgataaaa aacaaaaagt 5160
 15 ctttcttctg agaataattg ttgaaggaaa tactcgact agagataatg ttatctctcg 5220
 tgaattacgc cttgctgatg gagatctttt taatgggtcaa catctccgac gctctaata 5280
 atgccttaac cgccttggtt attttaacca agtagataga gatacactgc ctacaggga 5340
 agatgatgaa gttgatctac ttgtaaaagt tcaagaagct cgaacagggt caatcacagg 5400
 20 tgggtgttgg tactcaacac attctaaatt tgggtgttca ggaagtatct cagaaagaaa 5460
 cttatgggga aaagggtata ttttaagtat tgaagggttt atttctagta agtcatcttc 5520
 tcttgatctt tcttttacca atcctcgtgt ttatgataca gactttggct ttagtaataa 5580
 catttatacg ctacgagatg aatgggatga cttccgtaaa aaaacttatg gagataccat 5640
 acgtctatct caccctatag gagaatattc atctatcttt gttggctatc gaattgatca 5700
 25 atatcgtcta tatgatattc catctacagc accacgctct tatcttgact atcaagggaa 5760
 aaatatttct agttagtaga gtgggtgggt tacttttgat tctacagaca gtcgtgagag 5820
 accatctaaa gggcatattg caaaactaat tgttgaatat ggaggtggtg gtcctggtg 5880
 taatgataac ttcttcaagc caattgctga actacaagga ttttactcaa tttcaagaag 5940
 taaaaacat ataatacatt ggcgtacacg tgcagggtgca gcttataaga atagtaaaaa 6000
 30 acctgtgcca gtatttgacc gattttttat tgggtggata gatagtatta gaggatatga 6060
 tacagaagat cttgcaccaa aagatcctcg ctttgagat gaaattggtg gtgataggat 6120
 ggcttttctt aacctagagt atatttggac attccagcca gagctagggtc ttgcattagt 6180
 tccattctat gacataggat tccaaacaga ttctgtacaa acttctaacc cattctctaa 6240
 actcaaaaca tcatatggcc ttgaacttcg ctggcggttca ccaatgggag atttgcgatt 6300
 35 tgcctatggt ataccactca ataaaaatgt tagtggcaaa aaaactcgtg gtagatttga 6360
 attttcaatg gggcaattct tctaataaca taatataact cataaaataa gagatactat 6420
 aaattttaaag atgagaggtg caggagagccg ccccataaaa atgttggttat gccataacta 6480
 ctgcactagg aaatagatga atataacata ttctcttcaa tgcaagcatg agcaacatca 6540
 40 tttgtcgaca agccattgca attttatcca atttatatta ttggaaaaaa ctgttatgga 6600
 tacctatcct agcttac 6617

<210> 2

45 <211> 5445

<212> DNA

<213> *Lawsonia intracellularis*

<400> 2

50 ctaacgtaga catgagcaga gaaatgggta atatgattat tattcaacgt ggttttcaga 60
 tgaatagtaa atctgttaca acagcagaca caatgctaca aaaagcactt gaactaaagc 120
 gtaaatatgt attttattgt taattttgta ttttttaatc tattgtaatc ttagtatgta 180

55

5 ttatatatta atagtatttc aacttataat tatttatttt gatatgttac tactttttct 240
 ttacgtcaag gatgaaacag gttatcagct ttgacatgaa aaagtttttt ctgaatattg 300
 ttattttttg ttttggtatt attttactat ctattatagg actaataggt ctttattttt 360
 gggttagtag agatcttcct aatattacaa agcttaatga ctatagacca gctttagtaa 420
 caacagttct tgctagagat ggaacactta ttgggtatat atatcgagag aagcgttttc 480
 ttatcccatt aagcgaatg tctccttttt tgcctaaggc atttttagct gcagaagatg 540
 10 ctgagtttta tgaacatgaa ggtgttaatc cgcttgctat tatccgggct tttttaataa 600
 atcttcaatc agggacaaca cgccaagggtg gaagtacgat tactcaacaa gtcattaaac 660
 gtcttttgtt aagccctgaa agaagttatg agcgttaagat aaaagaggca attcttgctt 720
 accgtctaga gaaatatctt tctaaagatg aaattttaac tatatactta aatcagacat 780
 ttttagggtc tcattcttat ggggttgagg cagccgcaag gacttatttt gctaagcatg 840
 ctaaagatct ttcatatagc gaatgtgctc ttcttgagg acttcacaa gcaccttctc 900
 15 ggtataatcc ctataaagat cctgaggctg caaaaattag acaacgttat gctcttcgta 960
 ggctacatga tgttggttgg attaccagg ctgaatatga ggaggctctt caagaaccac 1020
 tatatttttc ttcaatgaaa gaagggttag gagctgaatc aagttggtat atggaagaag 1080
 tccgtaagca gcttggttcc tttcttagta aagaaaatat ttctcagtat ggaattgtgc 1140
 20 tccctttata tggagaagat gcactttatg aacttggtt tactatccag acagcaattg 1200
 atectcaggc acaacttgtg gcatatgatg ttttaagaaa tggacttgaa aatttttagta 1260
 aacgacaagg ttggaaggga cctattgagc acatttcttc aacaatgatt cagcattacc 1320
 tagaaaatgc tacatttaca cctgaaaaac ttgatgggtg tgcatgggct aaagcaattg 1380
 ttagtaaaat tagtcaagaa ggtgcagaag tatctcttag tagcatttat aaagggtttg 1440
 25 ttagtgtaga gactatgggt tgggcacgta aacctaatcc agaagttcga tcagcttatt 1500
 gtgctcctat caaagatgca cgtagtgttt taaatcctgg agatattata tgggtatctg 1560
 gagttggccc agactctaca cataggtata gttctaaaac actagatact tctaaacctt 1620
 ttcctttagc tcttcaacag ttaccacaaa tccaaggagc attaatctt atagagccaa 1680
 atacaggcga tgtgatagct atgattgggt gttatgagtt tggaaagagc caatttaata 1740
 30 gagctgtaca ggcaatgagg caaccagggt ctgcatttaa gccaatgtta tactctgcag 1800
 cacttgatca tgattataca tctgcaacta tgggtgcttga tgcacctata gtagaattta 1860
 tggaaagtgg ggatatttgg agaccaggta attacgaaaa aaatttttaa ggaccaatgt 1920
 tatttagcaa tgctcttgca ctttcaagaa atttatgtac agtaagaatt gcacagtcta 1980
 35 taggattacc tgctgttatt gaaagagcta aggccttagg atttaattgg aatttccctg 2040
 aattttttc tattagttta ggtgcagttg aagtaactcc tattegtctt gtaaattgct 2100
 atcacgcatt tgcaaatggt ggttaacttag ccacgccagc gtttattctt tctattaaag 2160
 attctaataa tactgttatt taccgccagg aaatagaaca acatcctgtt atttcaccac 2220
 agaatgcgta tattatggct tcactattaa aaaatgttgt taatattggt acagcaagaa 2280
 40 aagcaaaaagt acttgagcgt cctctagcag gaaagacagg aactacaaat ggggagcatg 2340
 atgcatgggt tattggattt acaccctatc ttgttacagg tgtttatggt ggtaatgatc 2400
 atccacagac attaggtaaa gatggcacag gtgctgttgc tgctcttctt atttttacag 2460
 aatattcaaa agtagtattg aaaaaatatc ctgaaagtga ctttctgtt cctgatggga 2520
 45 ttacttttgc ttcaatagat actcagacag ggaatagagc aactgctaatt agtaccaata 2580
 gtgttgatc acccttttat gtaggtacag ttccagaata ttttgatagt aaagataatg 2640
 aggatgaatac tattgaacgt ggtgaggatt tattaaaca atttttttaa ccatttttat 2700
 gtagctgatt ataaaaatgg agtttggtac atattttttg ttatcattat cataagttat 2760
 atttatatac tcaaatattg aggcaagtta gtatccttga taatatttca taagagctag 2820
 50 atttataata tacgtttatc ttatttttaa tccctaatta ttcaagggtg atagttttta 2880
 ggagagttat atgttttgta agttaagggt gataatatgc ataactctta tgtttattat 2940
 aactgtggtt ccaacaattg cagaaagtgc cttaccaaac tttgtacccc ttgtaaaaga 3000
 tgctagtaaa gctgttgta atattagtagc agaaaaaaaa attcctcgtg gtcgtacaga 3060

55

```

gtccctatg gaaatgttcc gtggtcttcc cccagggtttt gaacgctttt ttgaacaatt 3120
tgaacctaaa gggcctgata gtcagataca taaacaacgt tcattaggaa ctgggttttat 3180
catttcttca gatggatata ttgttaccaa taatcatgtg atagaaggag cagattctgt 3240
tagagtaaat cttgaaggta cctcaggcaa agaagaatca ctacctgcag aagtgatagg 3300
tagagatgaa gaaacagatc ttgctttatt aaaagttaaa agtaaagact cattacctta 3360
tcttatattt ggaaattcag atactatgga agttggtgaa tgggtgctag ctattggtaa 3420
tccttttggg ttaggccata cagttacagc aggtatatta agtgctaaag gacgtgatat 3480
tcatgctgga ccatttgata actttttaca aactgatgca tctatcaatc ctgggaatag 3540
tgggtggtcca ttaatcaata tgtcaggaca agttgtaggc attaacacag ctattatggc 3600
aagtgggcaa ggtattggtt tcgctatccc aagtagtatg gcagatcgta ttatagagca 3660
gttaaagaca aataaaaagg taagtagagg ttggataggt gtaacaattc aggatgtaga 3720
tactaataca gctaaagctc ttggattatc tcaggcaaaa ggtgcgcttg taggttctgt 3780
tgttcctgga gatcctgctg ataaggcttg tcttaaagtt ggcgatattg taacacaagc 3840
tgatggtaaa caaattgata gtgcaagctc attgttaaaa gctattgcta ctaaactccc 3900
ttttctgtt gtgaaattaa aagtttggcg tgatggaaag agtaaagata tatccattac 3960
actaggagag cgtaagacaa cttcaagtca aaaacaaagc tcaccagaat ctttaccagg 4020
tgctcttggg ttatctgtac gtcctttaac acaagaagag tctaaatctt ttgatgttaa 4080
gcttggata ggcttgttag ttgtaagcgt tgagcctaata aagccagcgt cagaagctgg 4140
tatcagagag caagatataa tcctttctgc taacttaaaa cctcttcaat cggctgatga 4200
ccttgcaaat attatttgtg gagatgctaa gaagaaaggg gttattatgt tacaattaca 4260
aagaaatgga caaacgtttt ttaaaacatt gtctttaact gaagatagca actaactctt 4320
ccttatttat taaacttata acaagtataa agaatactct ttacttttgt aaggagtatt 4380
cttttttata gtttgagctt gttagaggta tattaatact atttttatct atcaatttta 4440
taaaataatat gtttagatat aagaaaagga taaatgatt ttcatagata tagttattgt 4500
attccatata gttactaatt attatgtgat acaagagggt aaaagtttgt ttaaaataat 4560
atagaataaaa ggataagttg atgtgtcatg ctatccctgt aaaagttatt gaactgttgg 4620
ataatgatat tattcgtgct acggttggcg atagtacaac aatattgact gtttcaggta 4680
tgttacttcc agaaccagta actgttggag attatattat tgtgcatgct ggatttgcta 4740
tacataaact ggaggcaact gaagctgaag aaagtttacg gttattcaga gagctttcta 4800
ttgccgttgg tgatacacct aatttttaat tattaatcta attaatagat aaagtagtta 4860
gatacagtaa aagaaaaata ctagataggt gcaatgaatt ttagttatt attatttgtt 4920
agttctatta tgttgaatag tgcttgttgc ttcaggactt aatgcattat atacatttac 4980
tgcttgttct tttgcttga gaagtaaagg agtcagtggt ggctttgggc gtttttcaat 5040
acgcattcca acgtatgtcc ctataggaaa agaaagaata atacggttaa gtttagacca 5100
tgaagagggt acatcccaag tacgcttagg acctagtaaa gtagagcgac aataaattct 5160
acattcagga taaagctgct ttgttagacg aataagttgc caaggactca cccattgact 5220
gtcttttttt ggttttttat gaagcagctg taatgtacta ttaatgatat gatttataga 5280
ccattttatt gtgaatccaa caataatacc atcagatgca acacgaaatg cttctgctaa 5340
aatttttttt ggatcttcaa catattctaa aatagtcact aatgatgcgt agttaaact 5400
ttcatcttca aatggaagat catctaaggc acctaatggg aattc 5445

```

<210> 3

<211> 427

<212> PRT

<213> *Lawsonia intracellularis*

<400> 3

EP 1 094 070 A2

Met Lys Phe Glu Leu Phe Ile Ala Leu His Tyr Leu Phe Ala Arg Arg
1 5 10 15

5 Lys Gln Ala Phe Ile Tyr Leu Ile Ser Leu Met Ser Ile Leu Gly Val
20 25 30

Ala Ile Gly Val Ala Ser Leu Val Val Val Leu Gly Val Tyr Asn Gly
10 35 40 45

Phe Thr Ile Asp Ile Arg Asp Lys Ile Leu Gly Ala Asn Ala His Ile
50 55 60

15 Ile Ile Thr Gly Asn Phe Asp Ser Pro Ile Glu Glu Pro Thr Ser Phe
65 70 75 80

Thr Gln Leu Ser Thr Thr Ser Met Leu Ser Gln Asn Ala Leu Ile Ile
20 85 90 95

Leu Asn Lys Leu Gln Gln Thr Ser Ala Ile Ile Gly Ala Thr Pro Phe
100 105 110

25 Ile Tyr Ala Glu Cys Met Ile Ser Ser Pro His Gly Val Lys Gly Leu
115 120 125

Ile Leu Arg Gly Ile Asp Pro Ser Ser Ala Gln Asn Val Ile Ser Met
30 130 135 140

Leu Ser His Leu Thr Lys Gly Asn Leu Glu Asp Leu Ile Pro Lys Val
145 150 155 160

35 Leu Gly Thr Pro Asp Gly Ile Ile Ile Gly Asn Glu Leu Ala Gln Arg
165 170 175

Leu Asn Val Thr Ile Gly Ser Arg Val Asn Leu Leu Ser Pro Thr Gly
40 180 185 190

Gln Lys Thr Ser Ser Gly Phe Gln Pro Arg Ile Arg Pro Leu Ile Val
195 200 205

45 Thr Gly Ile Phe His Thr Gly Met Phe Glu Tyr Asp Thr Ser Leu Ala
210 215 220

Phe Thr Ser Leu Asn Ala Ala Arg Glu Leu Leu Gly Leu Pro His Asn
225 230 235 240

50 Tyr Ile Ser Gly Ile Glu Val Ser Ile His Asp Val Tyr Gln Ala Asn
245 250 255

55

EP 1 094 070 A2

1 Tyr Ile Thr Asn Gln Leu Gln Gln Glu Leu Gly His Asn Phe Ser Val
260 265 270

5 Arg Ser Trp Met Asp Met Asn Ala Asn Leu Phe Ala Ala Leu Lys Leu
275 280 285

10 Glu Lys Ile Gly Met Phe Ile Ile Leu Ala Met Val Val Leu Ile Gly
290 295 300

15 Ser Phe Ser Ile Val Thr Thr Leu Ile Met Leu Val Met Glu Lys Thr
305 310 315 320

20 Arg Asp Ile Ala Ile Leu Thr Ser Met Gly Ala Thr Ser Gln Met Ile
325 330 335

Arg Arg Ile Phe Ile Leu Gln Gly Thr Ile Ile Gly Ile Val Gly Thr
340 345 350

25 Leu Leu Gly Tyr Leu Leu Gly Ile Thr Leu Ala Leu Leu Leu Gln Lys
355 360 365

Tyr Gln Phe Ile Lys Leu Pro Pro Gly Val Tyr Thr Ile Asp His Leu
370 375 380

30 Pro Val Leu Leu Asn Trp Leu Asp Ile Phe Ile Ile Gly Thr Ser Ala
385 390 395 400

Met Leu Leu Cys Phe Phe Ala Thr Leu Tyr Pro Ala His Gln Ala Ala
405 410 415

35 Arg Leu Gln Pro Ile Glu Gly Leu Arg Tyr Glu
420 425

40 <210> 4
<211> 235
<212> PRT
<213> Lawsonia intracellularis

45 <400> 4
Met Ser Gln Tyr Leu Leu Glu Asn Ile Val Lys Gln Tyr Asp Ser Pro
1 5 10 15

50 Ser Glu Pro Ile Cys Val Leu His Lys Ile Asn Leu Ser Ile Ala His
20 25 30

Gly Glu Ser Leu Ala Ile Ile Gly Ala Ser Gly Ser Gly Lys Ser Thr
35 40 45

55

EP 1 094 070 A2

Leu Leu His Ile Leu Gly Ala Leu Asp Ile Pro Ser Ser Gly Thr Val
50 55 60

5 Leu Phe Asn Asn Lys Asn Leu Ser His Met Gly Pro Asn Glu Lys Ala
65 70 75 80

10 Cys Phe Arg Asn Lys Leu Leu Gly Phe Ile Phe Gln Phe His Asn Leu
85 90 95

Leu Pro Glu Phe Ser Ala Glu Glu Asn Val Ala Met Lys Ala Leu Ile
100 105 110

15 Ala Gly Ile Pro Lys Lys Lys Ala Leu Leu Leu Ala Arg Glu Ala Leu
115 120 125

20 Gly Ser Val Gly Leu Glu Asn Lys Tyr His His Arg Ile Thr Met Leu
130 135 140

Ser Gly Gly Glu Arg Gln Arg Val Ala Ile Ala Arg Ala Ile Leu Leu
145 150 155 160

25 Glu Pro Gln Val Leu Leu Ala Asp Glu Pro Thr Gly Asn Leu Asp Gln
165 170 175

30 Lys Thr Gly Glu His Ile Ala Asn Leu Leu Ile Ser Leu Asn Lys Thr
180 185 190

Phe Asn Ile Thr Leu Ile Val Val Thr His Asn Asn Asp Ile Ala His
195 200 205

35 Ser Met Gly Arg Cys Leu Glu Leu Lys Ser Gly Asp Leu His Asp Lys
210 215 220

Thr Pro Glu Tyr Ile Ser Ser Thr Val Thr Val
225 230 235

40

<210> 5
<211> 896
<212> PRT
45 <213> Lawsonia intracellularis

<400> 5
Met Thr Lys Arg Leu Asn Ile Phe Leu Leu Leu Leu Cys Asn Ile
50 1 5 10 15

Leu Tyr Cys Asn Ile Ile Ala Asn Ala Ala Ser Lys Asp Asp Pro Ser

55

EP 1 094 070 A2

	20	25	30
5	Ile Val Val Leu Pro Phe Gln Ile Asn Gly Ser Ser Asn Asp Glu Glu 35 40 45		
	Leu Gln Thr Glu Leu Pro Met Leu Leu Ala Thr Ala Leu Lys Asn Lys 50 55 60		
10	Gly Phe Arg Val Ile Pro Asn Lys Ser Ala Leu Asn Leu Leu Tyr Lys 65 70 75 80		
	Gln Asn Ile Ser Gln Leu Asn Ile Ser Thr Ala Lys Lys Val Ala Gln 85 90 95		
	Gln Leu His Ala Asp Tyr Val Val Tyr Gly Ser Phe Asn Gln Thr Gly 100 105 110		
20	Glu Asn Phe Ser Ile Asp Ser Arg Leu Ile Asp Ser Thr Gly Val Ala 115 120 125		
	Ser Ala Arg Pro Leu Tyr Ile Glu Lys Pro Lys Phe Asn Glu Leu Asn 130 135 140		
25	Ile Ala Val Thr Glu Leu Ala Glu Arg Ile Ser Asn Gly Leu Ile Lys 145 150 155 160		
	Lys Asn Thr Ile Ala Asp Val Arg Ile His Gly Leu Lys Val Leu Asp 165 170 175		
	Pro Asp Val Ile Leu Thr Arg Leu Thr Ile Asn Lys Gly Asp His Thr 180 185 190		
35	Asp His Ala Lys Ile Asn Ala Glu Ile Lys Lys Ile Trp Glu Leu Gly 195 200 205		
	Tyr Phe Ser Asp Val Ser Ala Ser Ile Glu Glu Ser Gly Glu Gly Arg 210 215 220		
	Leu Leu Val Phe Thr Val Gln Glu Lys Pro Lys Ile Thr Asp Val Val 225 230 235 240		
45	Val Gln Gly Ser Lys Ala Val Ser Ile Asp Asn Ile Leu Ala Ala Met 245 250 255		
	Ser Ser Lys Lys Gly Ser Val Ile Ser Asp Arg Leu Leu Ser Gln Asp 260 265 270		
	Ile Gln Lys Ile Thr Asp Leu Tyr Arg Lys Glu Gly Tyr Tyr Leu Ala		

55

	275	280	285
5	Glu Val Asn Tyr Glu Ile Lys Glu Lys Glu Asn Thr Ser Ser Ala Thr 290	295	300
	Leu Leu Leu Thr Val Asn Glu Gly Lys Lys Leu Tyr Ile Lys Asp Val 305	310	315 320
10	Arg Ile Glu Gly Leu Glu Thr Ile Lys Ala Lys Thr Leu Lys Lys Glu 325	330	335
15	Leu Ala Leu Thr Glu Arg Asn Phe Leu Ser Trp Phe Thr Gly Thr Gly 340	345	350
	Val Leu Arg Glu Glu Tyr Leu Glu Arg Asp Ser Ile Ala Ile Ser Ala 355	360	365
20	Tyr Ala Met Asn His Gly Tyr Val Asp Ile Gln Val Ala Ser Pro Glu 370	375	380
25	Val Thr Phe Asn Glu Lys Gly Ile Val Ile Thr Phe Arg Val Lys Glu 385	390	395 400
	Gly Lys Arg Tyr Lys Ile Gly Lys Ile Asp Phe Lys Gly Asp Leu Ile 405	410	415
30	Glu Thr Asn Glu Gln Leu Leu Lys Val Thr Lys Ile Asp Asp His Lys 420	425	430
35	Asn Tyr Glu Gln Tyr Phe Ser Leu Ser Val Met Gln Asp Asp Val Lys 435	440	445
	Ala Leu Thr Asp Phe Tyr Ser Asp Tyr Gly Tyr Ala Phe Ala Glu Val 450	455	460
40	Asp Leu Glu Thr Thr Lys Asn Glu Glu Asp Ala Thr Ile Asp Val Thr 465	470	475 480
	Phe Leu Ile Asp Lys Lys Gln Lys Val Phe Leu Arg Arg Ile Ile Val 485	490	495
45	Glu Gly Asn Thr Arg Thr Arg Asp Asn Val Ile Leu Arg Glu Leu Arg 500	505	510
50	Leu Ala Asp Gly Asp Leu Phe Asn Gly Gln His Leu Arg Arg Ser Asn 515	520	525
55	Glu Cys Leu Asn Arg Leu Gly Tyr Phe Asn Gln Val Asp Thr Asp Thr		

EP 1 094 070 A2

	530	535	540
5	Leu Pro Thr Gly Lys Asp Asp Glu Val Asp Leu Leu Val Lys Val Gln 545	550	555 560
	Glu Ala Arg Thr Gly Ala Ile Thr Gly Gly Val Gly Tyr Ser Thr His 565	570	575
10	Ser Lys Phe Gly Val Ser Gly Ser Ile Ser Glu Arg Asn Leu Trp Gly 580	585	590
	Lys Gly Tyr Ile Leu Ser Ile Glu Gly Phe Ile Ser Ser Lys Ser Ser 595	600	605
15	Ser Leu Asp Leu Ser Phe Thr Asn Pro Arg Val Tyr Asp Thr Asp Phe 610	615	620
20	Gly Phe Ser Asn Asn Ile Tyr Thr Leu Arg Asp Glu Trp Asp Asp Phe 625	630	635 640
	Arg Lys Lys Thr Tyr Gly Asp Thr Ile Arg Leu Phe His Pro Ile Gly 645	650	655
25	Glu Tyr Ser Ser Ile Phe Val Gly Tyr Arg Ile Asp Gln Tyr Arg Leu 660	665	670
30	Tyr Asp Ile Pro Ser Thr Ala Pro Arg Ser Tyr Leu Asp Tyr Gln Gly 675	680	685
	Lys Asn Ile Ser Ser Val Val Ser Gly Gly Phe Thr Phe Asp Ser Thr 690	695	700
35	Asp Ser Arg Glu Arg Pro Ser Lys Gly His Ile Ala Lys Leu Ile Val 705	710	715 720
40	Glu Tyr Gly Gly Gly Gly Leu Gly Gly Asn Asp Asn Phe Phe Lys Pro 725	730	735
	Ile Ala Glu Leu Gln Gly Phe Tyr Ser Ile Ser Arg Ser Lys Asn His 740	745	750
45	Ile Ile His Trp Arg Thr Arg Ala Gly Ala Ala Tyr Lys Asn Ser Lys 755	760	765
50	Lys Pro Val Pro Val Phe Asp Arg Phe Phe Ile Gly Gly Ile Asp Ser 770	775	780
	Ile Arg Gly Tyr Asp Thr Glu Asp Leu Ala Pro Lys Asp Pro Arg Phe		
55			

EP 1 094 070 A2

	785		790		795		800
5	Gly Asp Glu Ile Gly Gly Asp Arg Met Ala Phe Leu Asn Leu Glu Tyr						
		805		810		815	
	Ile Trp Thr Phe Gln Pro Glu Leu Gly Leu Ala Leu Val Pro Phe Tyr						
		820		825		830	
10	Asp Ile Gly Phe Gln Thr Asp Ser Val Gln Thr Ser Asn Pro Phe Ser						
		835		840		845	
	Lys Leu Lys Gln Ser Tyr Gly Leu Glu Leu Arg Trp Arg Ser Pro Met						
15		850		855		860	
	Gly Asp Leu Arg Phe Ala Tyr Gly Ile Pro Leu Asn Lys Asn Val Ser						
	865		870		875		880
20	Gly Lys Lys Thr Arg Gly Arg Phe Glu Phe Ser Met Gly Gln Phe Phe						
		885		890		895	
25							
	<210> 6						
	<211> 812						
30	<212> PRT						
	<213> Lawsonia intracellularis						
	<400> 6						
35	Met Lys Gln Val Ile Ser Phe Asp Met Lys Lys Phe Phe Leu Asn Ile						
	1		5		10		15
	Val Ile Phe Cys Phe Gly Ile Ile Leu Leu Ser Ile Ile Gly Leu Ile						
		20		25		30	
40	Gly Leu Tyr Phe Trp Val Ser Arg Asp Leu Pro Asn Ile Thr Lys Leu						
		35		40		45	
	Asn Asp Tyr Arg Pro Ala Leu Val Thr Thr Val Leu Ala Arg Asp Gly						
45		50		55		60	
	Thr Leu Ile Gly Tyr Ile Tyr Arg Glu Lys Arg Phe Leu Ile Pro Leu						
		65		70		75	80
50	Ser Glu Met Ser Pro Phe Leu Pro Lys Ala Phe Leu Ala Ala Glu Asp						
		85		90		95	
55							

EP 1 094 070 A2

Ala Glu Phe Tyr Glu His Glu Gly Val Asn Pro Leu Ala Ile Ile Arg
100 105 110

5 Ala Phe Leu Ile Asn Leu Gln Ser Gly Thr Thr Arg Gln Gly Gly Ser
115 120 125

10 Thr Ile Thr Gln Gln Val Ile Lys Arg Leu Leu Leu Ser Pro Glu Arg
130 135 140

Ser Tyr Glu Arg Lys Ile Lys Glu Ala Ile Leu Ala Tyr Arg Leu Glu
145 150 155 160

15 Lys Tyr Leu Ser Lys Asp Glu Ile Leu Thr Ile Tyr Leu Asn Gln Thr
165 170 175

20 Phe Leu Gly Ala His Ser Tyr Gly Val Glu Ala Ala Ala Arg Thr Tyr
180 185 190

Phe Ala Lys His Ala Lys Asp Leu Ser Leu Ala Glu Cys Ala Leu Leu
195 200 205

25 Ala Gly Leu Pro Gln Ala Pro Ser Arg Tyr Asn Pro Tyr Lys Asp Pro
210 215 220

30 Glu Ala Ala Lys Ile Arg Gln Arg Tyr Ala Leu Arg Arg Leu His Asp
225 230 235 240

Val Gly Trp Ile Thr Gln Ala Glu Tyr Glu Glu Ala Leu Gln Glu Pro
245 250 255

35 Leu Tyr Phe Ser Ser Met Lys Glu Gly Leu Gly Ala Glu Ser Ser Trp
260 265 270

Tyr Met Glu Glu Val Arg Lys Gln Leu Val Ser Phe Leu Ser Lys Glu
275 280 285

40 Asn Ile Ser Gln Tyr Gly Ile Val Leu Pro Leu Tyr Gly Glu Asp Ala
290 295 300

45 Leu Tyr Glu Leu Gly Phe Thr Ile Gln Thr Ala Met Asp Pro Gln Ala
305 310 315 320

Gln Leu Val Ala Tyr Asp Val Leu Arg Asn Gly Leu Glu Asn Phe Ser
325 330 335

50 Lys Arg Gln Gly Trp Lys Gly Pro Ile Glu His Ile Ser Ser Thr Met
340 345 350

55

Ile Gln His Tyr Leu Glu Asn Ala Thr Phe Thr Pro Glu Lys Leu Asp
 355 360 365
 5 Gly Gly Ala Trp Ala Lys Ala Ile Val Ser Lys Val Ser Gln Glu Gly
 370 375 380
 10 Ala Glu Val Phe Leu Ser Ser Ile Tyr Lys Gly Phe Val Ser Val Glu
 385 390 395 400
 Thr Met Gly Trp Ala Arg Lys Pro Asn Pro Glu Val Arg Ser Ala Tyr
 405 410 415
 15 Cys Ala Pro Ile Lys Asp Ala Arg Ser Val Leu Asn Pro Gly Asp Ile
 420 425 430
 20 Ile Trp Val Ser Gly Val Gly Pro Asp Ser Thr His Arg Tyr Ser Ser
 435 440 445
 Lys Thr Leu Asp Thr Ser Lys Pro Ile Pro Leu Ala Leu Gln Gln Leu
 450 455 460
 25 Pro Gln Ile Gln Gly Ala Leu Ile Ser Ile Glu Pro Asn Thr Gly Asp
 465 470 475 480
 30 Val Ile Ala Met Ile Gly Gly Tyr Glu Phe Gly Lys Ser Gln Phe Asn
 485 490 495
 Arg Ala Val Gln Ala Met Arg Gln Pro Gly Ser Ala Phe Lys Pro Ile
 500 505 510
 35 Val Tyr Ser Ala Ala Leu Asp His Asp Tyr Thr Ser Ala Thr Met Val
 515 520 525
 40 Leu Asp Ala Pro Ile Val Glu Phe Met Glu Ser Gly Asp Ile Trp Arg
 530 535 540
 Pro Gly Asn Tyr Glu Lys Asn Phe Lys Gly Pro Met Leu Phe Ser Asn
 545 550 555 560
 45 Ala Leu Ala Leu Ser Arg Asn Leu Cys Thr Val Arg Ile Ala Gln Ser
 565 570 575
 50 Ile Gly Leu Pro Ala Val Ile Glu Arg Ala Lys Ala Leu Gly Phe Asn
 580 585 590
 Gly Asn Phe Pro Glu Phe Phe Ser Ile Ser Leu Gly Ala Val Glu Val
 595 600 605
 55

EP 1 094 070 A2

Thr Pro Ile Arg Leu Val Asn Ala Tyr Thr Ala Phe Ala Asn Gly Gly
 610 615 620
 5 Asn Leu Ala Thr Pro Arg Phe Ile Leu Ser Ile Lys Asp Ser Asn Asn
 625 630 635 640
 Thr Val Ile Tyr Arg Gln Glu Ile Glu Gln His Pro Val Ile Ser Pro
 10 645 650 655
 Gln Asn Ala Tyr Ile Met Ala Ser Leu Leu Lys Asn Val Val Asn Ile
 660 665 670
 15 Gly Thr Ala Arg Lys Ala Lys Val Leu Glu Arg Pro Leu Ala Gly Lys
 675 680 685
 Thr Gly Thr Thr Asn Gly Glu His Asp Ala Trp Phe Ile Gly Phe Thr
 20 690 695 700
 Pro Tyr Leu Val Thr Gly Val Tyr Val Gly Asn Asp His Pro Gln Thr
 705 710 715 720
 25 Leu Gly Lys Asp Gly Thr Gly Ala Val Ala Ala Leu Pro Ile Phe Thr
 725 730 735
 Glu Tyr Ser Lys Val Val Leu Lys Lys Tyr Pro Glu Ser Asp Phe Pro
 30 740 745 750
 Val Pro Asp Gly Ile Thr Phe Ala Ser Ile Asp Thr Gln Thr Gly Asn
 755 760 765
 35 Arg Ala Thr Ala Asn Ser Thr Asn Ser Val Val Leu Pro Phe Tyr Val
 770 775 780
 Gly Thr Val Pro Glu Tyr Phe Asp Ser Lys Asp Asn Glu Val Asn Thr
 785 790 795 800
 40 Ile Glu Arg Gly Glu Asp Leu Leu Lys Gln Phe Phe
 805 810
 45 <210> 7
 <211> 474
 <212> PRT
 <213> Lawsonia intracellularis
 50 <400> 7
 Met Phe Cys Lys Leu Lys Val Ile Ile Cys Ile Thr Leu Met Phe Ile
 1 5 10 15
 55

Ile Thr Val Val Pro Thr Ile Ala Glu Ser Ala Leu Pro Asn Phe Val
 20 25 30
 5 Pro Leu Val Lys Asp Ala Ser Lys Ala Val Val Asn Ile Ser Thr Glu
 35 40 45
 10 Lys Lys Ile Pro Arg Gly Arg Thr Glu Phe Pro Met Glu Met Phe Arg
 50 55 60
 Gly Leu Pro Pro Gly Phe Glu Arg Phe Phe Glu Gln Phe Glu Pro Lys
 65 70 75 80
 15 Gly Pro Asp Ser Gln Ile His Lys Gln Arg Ser Leu Gly Thr Gly Phe
 85 90 95
 20 Ile Ile Ser Ser Asp Gly Tyr Ile Val Thr Asn Asn His Val Ile Glu
 100 105 110
 Gly Ala Asp Ser Val Arg Val Asn Leu Glu Gly Thr Ser Gly Lys Glu
 115 120 125
 25 Glu Ser Leu Pro Ala Glu Val Ile Gly Arg Asp Glu Glu Thr Asp Leu
 130 135 140
 30 Ala Leu Leu Lys Val Lys Ser Lys Asp Ser Leu Pro Tyr Leu Ile Phe
 145 150 155 160
 Gly Asn Ser Asp Thr Met Glu Val Gly Glu Trp Val Leu Ala Ile Gly
 165 170 175
 35 Asn Pro Phe Gly Leu Gly His Thr Val Thr Ala Gly Ile Leu Ser Ala
 180 185 190
 40 Lys Gly Arg Asp Ile His Ala Gly Pro Phe Asp Asn Phe Leu Gln Thr
 195 200 205
 Asp Ala Ser Ile Asn Pro Gly Asn Ser Gly Gly Pro Leu Ile Asn Met
 210 215 220
 45 Ser Gly Gln Val Val Gly Ile Asn Thr Ala Ile Met Ala Ser Gly Gln
 225 230 235 240
 Gly Ile Gly Phe Ala Ile Pro Ser Ser Met Ala Asp Arg Ile Ile Glu
 245 250 255
 50 Gln Leu Lys Thr Asn Lys Lys Val Ser Arg Gly Trp Ile Gly Val Thr
 260 265 270
 55

EP 1 094 070 A2

5
 10
 15
 20
 25
 30
 35
 40
 45
 50
 55

Ile Gln Asp Val Asp Thr Asn Thr Ala Lys Ala Leu Gly Leu Ser Gln
 275 280 285

Ala Lys Gly Ala Leu Val Gly Ser Val Val Pro Gly Asp Pro Ala Asp
 290 295 300

Lys Ala Gly Leu Lys Val Gly Asp Ile Val Thr Gln Ala Asp Gly Lys
 305 310 315 320

Gln Ile Asp Ser Ala Ser Ser Leu Leu Lys Ala Ile Ala Thr Lys Pro
 325 330 335

Pro Phe Ser Val Val Lys Leu Lys Val Trp Arg Asp Gly Lys Ser Lys
 340 345 350

Asp Ile Ser Ile Thr Leu Gly Glu Arg Lys Thr Thr Ser Ser Gln Lys
 355 360 365

Gln Ser Ser Pro Glu Ser Leu Pro Gly Ala Leu Gly Leu Ser Val Arg
 370 375 380

Pro Leu Thr Gln Glu Glu Ser Lys Ser Phe Asp Val Lys Leu Gly Ile
 385 390 395 400

Gly Leu Leu Val Val Ser Val Glu Pro Asn Lys Pro Ala Ser Glu Ala
 405 410 415

Gly Ile Arg Glu Gln Asp Ile Ile Leu Ser Ala Asn Leu Lys Pro Leu
 420 425 430

Gln Ser Ala Asp Asp Leu Ala Asn Ile Ile Cys Gly Asp Ala Lys Lys
 435 440 445

Lys Gly Val Ile Met Leu Gln Leu Gln Arg Asn Gly Gln Thr Phe Phe
 450 455 460

Lys Thr Leu Ser Leu Thr Glu Asp Ser Asn
 465 470

<210> 8
 <211> 82
 <212> PRT
 <213> Lawsonia intracellularis

<400> 8
 Met Cys His Ala Ile Pro Val Lys Val Ile Glu Leu Leu Asp Asn Asp

1 5 10 15

5 Ile Ile Arg Ala Thr Val Gly Asp Ser Thr Thr Ile Leu Thr Val Ser
20 25 30

Gly Met Leu Leu Pro Glu Pro Val Thr Val Gly Asp Tyr Ile Ile Val
35 40 45

10 His Ala Gly Phe Ala Ile His Lys Leu Glu Ala Thr Glu Ala Glu Glu
50 55 60

15 Ser Leu Arg Leu Phe Arg Glu Leu Ser Ile Ala Val Gly Asp Thr Pro
65 70 75 80

Asn Phe

20

<210> 9
211 177
<212> PRT
25 <213> Lawsonia intracellularis

<400> 9
Glu Phe Gln Leu Gly Ala Leu Asp Asp Leu Pro Phe Glu Asp Glu Ser
1 5 10 15

30 Phe Asn Tyr Ala Ser Leu Val Thr Ile Leu Glu Tyr Val Glu Asp Pro
20 25 30

35 Lys Lys Ile Leu Ala Glu Ala Phe Arg Val Ala Ser Asp Gly Ile Ile
35 40 45

Val Gly Phe Thr Asn Lys Trp Ser Ile Asn His Ile Ile Asn Ser Thr
50 55 60

40 Leu Gln Leu Leu His Lys Lys Pro Lys Lys Asp Ser Gln Trp Val Ser
65 70 75 80

45 Pro Trp Gln Leu Ile Arg Leu Thr Lys Gln Leu Tyr Pro Glu Cys Arg
85 90 95

Ile Tyr Cys Arg Ser Thr Leu Leu Gly Pro Lys Arg Thr Trp Asp Val
100 105 110

50 Thr Ser Ser Trp Ser Lys Leu Asn Arg Ile Ile Leu Ser Phe Pro Ile
115 120 125

55

EP 1 094 070 A2

Gly Thr Tyr Val Gly Met Arg Ile Glu Lys Arg Pro Lys Pro Thr Leu
130 135 140

5 Thr Pro Leu Leu Leu Lys Ala Lys Glu Gln Ala Val Asn Val Tyr Asn
145 150 155 160

Ala Leu Ser Pro Glu Ala Thr Ser Thr Ile Gln His Asn Arg Thr Asn
10 165 170 175

Lys

15

<210> 10
<211> 20
<212> DNA
20 <213> Lawsonia intracellularis

<400> 10
agagtctggg ccaactccag 20

25

<210> 11
<211> 20
<212> DNA
30 <213> Lawsonia intracellularis

<400> 11
tacaccctat cttgttacag 20

35

<210> 12
<211> 20
<212> DNA
40 <213> Lawsonia intracellularis

<400> 12
aacttgccctc aatatttgag 20

45

<210> 13
<211> 20
<212> DNA
50 <213> Lawsonia intracellularis

<400> 13
tccatctcta gcaagaactg 20

55

<210> 14
 <211> 20
 <212> DNA
 5 <213> *Lawsonia intracellularis*

 <400> 14
 ttcttgcccta ccgtctagag 20
 10

 <210> 15
 <211> 20
 <212> DNA
 15 <213> *Lawsonia intracellularis*

 <400> 15
 ataccaactt gattcagctc 20
 20

 <210> 16
 <211> 20
 <212> DNA
 25 <213> *Lawsonia intracellularis*

 <400> 16
 aacttgggtt tactatccag 20
 30

 <210> 17
 <211> 20
 <212> DNA
 35 <213> *Lawsonia intracellularis*

 <400> 17
 aatgaggcaa ccaggttctg 20
 40

 <210> 18
 <211> 20
 <212> DNA
 45 <213> *Lawsonia intracellularis*

 <400> 18
 attaccaaca taaacacctg 20
 50

 <210> 19
 <211> 20
 55

212. DNA
 213. *Lawsonia intracellularis*

5 <400> 19
 caaggatact aacttgctc 20

10 <210> 20
 <211> 20
 <212> DNA
 213. *Lawsonia intracellularis*

15 400. 20
 atttcttgaa agtgcaagag 20

20 <210> 21
 <211> 20
 <212> DNA
 <213> *Lawsonia intracellularis*

25 <400> 21
 tcttgctgat aaggctggc 20

30 <210> 22
 <211> 20
 <212> DNA
 <213> *Lawsonia intracellularis*

35 400. 22
 aaatcttgaa ggtacctcag 20

40 <210> 23
 <211> 20
 <212> DNA
 <213> *Lawsonia intracellularis*

45 <400> 23
 tgtcttacgc tctcctagtg 20

50 <210> 24
 <211> 20
 <212> DNA
 <213> *Lawsonia intracellularis*

55

	<400> 24	
	tccaacagtt actggttctg	20
5		
	<210> 25	
	<211> 19	
	<212> DNA	
10	<213> Lawsonia intracellularis	
	<400> 25	
	acaaagcagc tttatcctg	19
15		
	<210> 26	
	<211> 20	
	<212> DNA	
20	<213> Lawsonia intracellularis	
	<400> 26	
	ttcatttggg cccatatgac	20
25		
	<210> 27	
	<211> 20	
	<212> DNA	
30	<213> Lawsonia intracellularis	
	<400> 27	
	cagaataaca atgttgtcag	20
35		
	<210> 28	
	<211> 20	
	<212> DNA	
40	<213> Lawsonia intracellularis	
	<400> 28	
	attacgcctt gctgatggag	20
45		
	<210> 29	
	<211> 20	
	<212> DNA	
50	<213> Lawsonia intracellularis	
	<400> 29	
	tcgaattgat caatatcgtc	20
55		

BNSDOCID: <EP_____1094070A2_1_>

	<212> DNA	
	<213> <i>Lawsonia intracellularis</i>	
5	<400> 35	
	ggatgaaaca gggtatcagc ttgacatg	29
10	<210> 36	
	<211> 25	
	<212> DNA	
	<213> <i>Lawsonia intracellularis</i>	
15	<400> 36	
	ggctcttatt ttggggttag tagag	25
20	<210> 37	
	<211> 31	
	<212> DNA	
	<213> <i>Lawsonia intracellularis</i>	
25	<400> 37	
	cagcatcaga aactgtgaaa gaatgttttg c	31
30	<210> 38	
	<211> 23	
	<212> DNA	
	<213> <i>Lawsonia intracellularis</i>	
35	<400> 38	
	ggatatttag ttatgacaga ttg	23
40	<210> 39	
	<211> 24	
	<212> DNA	
	<213> <i>Lawsonia intracellularis</i>	
45	<400> 39	
	ggcatcatta gggttatgaa gtcg	24
50	<210> 40	
	<211> 25	
	<212> DNA	
	<213> <i>Lawsonia intracellularis</i>	
55		

5	<400> 40 gttagtgtag agactatggg ttggg	25
10	<210> 41 <211> 26 <212> DNA <213> <i>Lawsonia intracellularis</i>	
15	<400> 41 ccttaaagta acaaaaattg atgac	26
20	<210> 42 <211> 20 <212> DNA <213> <i>Lawsonia intracellularis</i>	
25	<400> 42 gtaagctagg ataggtatcc	20
30	<210> 43 <211> 22 <212> DNA <213> <i>Lawsonia intracellularis</i>	
35	<400> 43 ggtgcttgat gcacctatag ta	22
40	<210> 44 <211> 22 <212> DNA <213> <i>Lawsonia intracellularis</i>	
45	<400> 44 tgccatacta cttgggatag cg	22
50	<210> 45 <211> 27 <212> DNA <213> <i>Lawsonia intracellularis</i>	
55	<400> 45 gctcaccaga atctttacca ggtgctc	27

5 <210> 46
 <211> 26
 <212> DNA
 <213> *Lawsonia intracellularis*

 <400> 46
 gtttcaagtc cttcaattcg gacatc 26
 10

 <210> 47
 <211> 26
 <212> DNA
 15 <213> *Lawsonia intracellularis*

 <400> 47
 gtttagctt ttattgtttc aagtcc 26
 20

 <210> 48
 <211> 20
 <212> DNA
 25 <213> *Lawsonia intracellularis*

 <400> 48
 aggtgcaatc acaggtggtg 20
 30

 <210> 49
 <211> 20
 <212> DNA
 35 <213> *Lawsonia intracellularis*

 <400> 49
 gagtttagag aatgggtag 20
 40

 <210> 50
 <211> 21
 <212> DNA
 45 <213> *Lawsonia intracellularis*

 <400> 50
 ttggtacagc aagaaaagca a 21
 50

 <210> 51
 <211> 21
 55

<212> DNA
 <213> *Lawsonia intracellularis*
 5 <400> 51
 atctgaagaa atgattaaac c 21

10 <210> 52
 <211> 20
 <212> DNA
 <213> *Lawsonia intracellularis*

15 <400> 52
 actaaaatat cctaattccc 20

20 <210> 53
 <211> 22
 <212> DNA
 <213> *Lawsonia intracellularis*

25 <400> 53
 ttgagctaaa tattgctgta ac 22

30 <210> 54
 <211> 21
 <212> DNA
 <213> *Lawsonia intracellularis*

35 <400> 54
 tgcccattct atgggacgct g 21

40 <210> 55
 <211> 29
 <212> DNA
 <213> *Lawsonia intracellularis*

45 <400> 55
 ggtataaccag caataagagc tttcattgc 29

50 <210> 56
 <211> 22
 <212> DNA
 <213> *Lawsonia intracellularis*

55

5 <400> 56
 ggggatgcta agaagaaagg gg 22

10 <210> 57
 <211> 21
 <212> DNA
 <213> Lawsonia intracellularis

15 <400> 57
 agtttggtaa ggcactttct g 21

20 <210> 58
 <211> 20
 <212> DNA
 <213> Lawsonia intracellularis

25 <400> 58
 gaaagtgact ttctgttcc 20

30 <210> 59
 <211> 20
 <212> DNA
 <213> Lawsonia intracellularis

35 <400> 59
 ttagggtgctc attcttatgg 20

40 <210> 60
 <211> 18
 <212> DNA
 <213> Lawsonia intracellularis

45 <400> 60
 tcctttccaa ccttgtcg 18

50 <210> 61
 <211> 22
 <212> DNA
 <213> Lawsonia intracellularis

55 <400> 61
 gatacaagag ggtaaaagtt tg 22

5 <210> 62
<211> 22
<212> DNA
<213> *Lawsonia intracellularis*

<400> 62
cttattcgtc taacaaagca gc 22
10

<210> 63
<211> 32
<212> DNA
15 <213> *Lawsonia intracellularis*

<400> 63
cgaccatgga acagggttatc agctttgaca tg 32
20

<210> 64
<211> 35
<212> DNA
25 <213> *Lawsonia intracellularis*

<400> 64
gggactagtt ttataatca gctacataaa aatgg 35
30

<210> 65
<211> 33
<212> DNA
35 <213> *Lawsonia intracellularis*

<400> 65
cgaccatggc acaatatcta ttagaaaata tag 33
40

<210> 66
<211> 34
<212> DNA
45 <213> *Lawsonia intracellularis*

<400> 66
gggtctagac gttattacac agtaacagta gaag 34
50

<210> 67
<211> 30
55

<212> DNA
 <213> *Lawsonia intracellularis*
 5 <400> 67
 aagccatggg agctgattat aaaaatggag 30
 10 <210> 68
 <211> 31
 <212> DNA
 <213> *Lawsonia intracellularis*
 15 <400> 68
 caccatattg ccttaccaaa ctttgtaccc c 31
 20 <210> 69
 <211> 27
 <212> DNA
 <213> *Lawsonia intracellularis*
 25 <400> 69
 caatcctggg aatgctgggtg gtccatt 27
 30 <210> 70
 <211> 62
 <212> DNA
 <213> *Lawsonia intracellularis*
 35 <400> 70
 ggccatgggt accaccacca ccaccacctc tctggcttca aaagacgatc cttctattgt 60
 gg 62
 40 <210> 71
 <211> 35
 <212> DNA
 <213> *Lawsonia intracellularis*
 45 <400> 71
 ggccatgggt tcaaaagacg atccttctat tgtgg 35
 50 <210> 72
 <211> 27
 <212> DNA
 <213> *Lawsonia intracellularis*
 55

	<400> 72 ctaacgtaga catgagcaga gaaatgg	27
5		
	<210> 73 <211> 24 <212> DNA <213> Lawsonia intracellularis	
10		
	<400> 73 ggggtatata caatagatca cttg	24
15		
	<210> 74 <211> 28 <212> DNA <213> Lawsonia intracellularis	
20		
	<400> 74 tataactac tgcactagga aatagatg	28
25		
	<210> 75 <211> 27 <212> DNA <213> Lawsonia intracellularis	
30		
	<400> 75 gcccattcta tgggacgctg ccttgag	27
35		
	<210> 76 <211> 27 <212> DNA <213> Lawsonia intracellularis	
40		
	<400> 76 gtaagctagg ataggtatcc ataacag	27
45		
	<210> 77 <211> 33 <212> DNA <213> Lawsonia intracellularis	
50		
	<400> 77 ggctctagag ctagttgcta tcttcagtta aag	33
55		

<210> 78
 <211> 32
 <212> DNA
 <213> *Lawsonia intracellularis*
 <400> 78
 ggctctagag tattaatata cctctaaca gc 32
 <210> 79
 <211> 33
 <212> DNA
 <213> *Lawsonia intracellularis*
 <400> 79
 ggctctagag ttattagaag aattgcccc ttg 33
 <210> 80
 <211> 57
 <212> DNA
 <213> *Lawsonia intracellularis*
 <400> 80
 ggccatgggt accaccacca ccaccacctc tctgctattg ttaacagtaa atgaagg 57
 <210> 81
 <211> 35
 <212> DNA
 <213> *Lawsonia intracellularis*
 <400> 81
 ggctctagag ttaaataataa ccttttcccc ataag 35
 <210> 82
 <211> 22
 <212> DNA
 <213> *Lawsonia intracellularis*
 <400> 82
 tacaaaatta acaataaaat ac 22
 <210> 83

	· 211 · 20	
	· 212 · DNA	
5	<213> <i>Lawsonia intracellularis</i>	
	<400> 83	
	agaatgtatg atatcctctc	20
10	<210> 84	
	<211> 20	
	· 212 · DNA	
	· 213 · <i>Lawsonia intracellularis</i>	
15	<400> 84	
	aggtattgga attgatcgac	20
20	<210> 85	
	<211> 20	
	<212> DNA	
	<213> <i>Lawsonia intracellularis</i>	
25	<400> 85	
	ggagagtgga gagatatcag	20
30	<210> 86	
	<211> 20	
	<212> DNA	
	<213> <i>Lawsonia intracellularis</i>	
35	· 400 · 86	
	ctaaactctt tgacctgac	20
40	<210> 87	
	<211> 20	
	<212> DNA	
	<213> <i>Lawsonia intracellularis</i>	
45	<400> 87	
	aaagtttgta ggtatatctc	20
50	· 210 · 88	
	· 211 · 20	
	<212> DNA	
	<213> <i>Lawsonia intracellularis</i>	

<400> 88
 aataagatac atgaggtgac 20
 5

<210> 89
 <211> 20
 <212> DNA
 10 <213> Lawsonia intracellularis

<400> 89
 gcagttgaga gttaattctc 20
 15

<210> 90
 <211> 20
 <212> DNA
 20 <213> Lawsonia intracellularis

<400> 90
 tccagaattt accatgtgtg 20
 25

<210> 91
 <211> 20
 <212> DNA
 30 <213> Lawsonia intracellularis

<400> 91
 gatatgttgc ataggcccag 20
 35

<210> 92
 <211> 20
 <212> DNA
 40 <213> Lawsonia intracellularis

<400> 92
 atagratccc ataccatgac 20
 45

<210> 93
 <211> 20
 <212> DNA
 50 <213> Lawsonia intracellularis

<400> 93
 tgcataacat tgaatgagac 20
 55

BNSDOCID: <EP_____1094070A2_1_>

<211> 24
 <212> DNA
 <213> *Lawsonia intracellularis*
 5
 <400> 99
 gtaagtttac acgactacct attg 24
 10
 <210> 100
 <211> 20
 <212> DNA
 <213> *Lawsonia intracellularis*
 15
 <400> 100
 gctggacgta ttatctctct 20
 20
 <210> 101
 <211> 19
 <212> DNA
 <213> *Lawsonia intracellularis*
 25
 <400> 101
 ttgtaggttc ttctatagg 19
 30
 <210> 102
 <211> 526
 <212> PRT
 <213> *Lawsonia intracellularis*
 35
 <400> 102
 Leu Ile Gln Lys Lys Lys Ser His Pro Pro Ile Lys Leu Ala Thr Lys
 1 5 10 15
 40
 Ser Pro His Val Ser Tyr Phe Lys Pro Leu Leu Glu Ser Leu Ala Glu
 20 25 30
 Lys Asn Glu Leu Asn Glu Val Ile Lys Asn Cys Val Val Lys Ser Cys
 35 40 45
 45
 Glu Leu Leu Asp Ser Gly Ile Pro Leu Tyr Pro Asp Glu Phe Val Lys
 50 55 60
 50
 Glu His Tyr Ala Gly Met Leu Arg Ala Glu Tyr Glu Ala Tyr Ser Ala
 65 70 75 80
 Ser Glu Leu Glu Ser Leu Asp Glu Ile Phe Ala Cys Ala Gly Arg Ile
 55

EP 1 094 070 A2

	85	90	95
5	Ile Ser Leu Arg Ser Phe Gly Lys Val Ile Phe Phe His Ile Met Asp 100 105 110		
	Arg Ser Gly Arg Ile Gln Cys Tyr Ala Ser Arg Glu Asn Met Gly Glu 115 120 125		
10	Glu Ala Phe Ser Thr Phe Lys Lys Phe Asp Ile Gly Asp Ile Val Gly 130 135 140		
	Val Asn Gly Lys Leu Phe Arg Thr Lys Met Gly Glu Leu Thr Leu Asn 145 150 155 160		
15	Cys Ser Thr Ile Thr Leu Leu Ala Lys Ser Phe Arg Ser Leu Pro Glu 165 170 175		
20	Lys His Asn Gly Leu Thr Asn Ile Glu Leu Arg Tyr Arg Gln Arg Tyr 180 185 190		
	Ile Asp Leu Ile Val Asn Pro Lys Thr Arg Asp Ile Phe Arg Lys Arg 195 200 205		
25	Ser Lys Ile Ile His Glu Ile Arg Ala Phe Leu Glu Glu Asn Gly Phe 210 215 220		
30	Ile Glu Val Glu Thr Pro Ile Leu Gln Pro Ile Pro Gly Gly Ala Met 225 230 235 240		
	Ala Arg Pro Phe Thr Thr His Asn Asn Ala Met Asp Met Thr Leu Tyr 245 250 255		
35	Met Arg Ile Ala Pro Glu Leu Tyr Leu Lys Arg Leu Leu Val Gly Gly 260 265 270		
40	Phe Glu Lys Leu Phe Glu Leu Asn Arg Ser Phe Arg Asn Glu Gly Ile 275 280 285		
	Ser Ile Gln His Asn Pro Glu Phe Thr Met Cys Glu Phe Tyr Trp Ala 290 295 300		
45	Tyr Ala Thr Tyr Leu Asp Leu Met Glu Leu Thr Glu Glu Met Phe Ala 305 310 315 320		
	Tyr Leu Thr Lys Lys Ile Cys Gly Thr Met Thr Ile Ser Tyr Gln Gly 325 330 335		
50	Asn Thr Ile Asp Phe Thr Pro Gly Thr Trp Gln Lys Tyr Thr Phe His		

55

	340	345	350
5	Glu Ser Leu Glu Lys Ile Gly Gly His Ser Pro Glu Phe Tyr Asn Asn		
	355	360	365
10	Phe Glu Lys Val Ser Glu Tyr Ile Lys Glu His Gly Glu Lys Val Leu		
	370	375	380
	Thr Thr Asp Lys Ile Gly Lys Leu Gln Ala Lys Leu Phe Asp Leu Asp		
	385	390	395 400
15	Val Glu Asn Lys Leu Ile Gln Pro Thr Phe Ile Tyr His Tyr Pro Thr		
	405	410	415
20	Asp Ile Ser Pro Leu Ser Lys Lys Asn Lys Asp Asn Pro Glu Val Thr		
	420	425	430
	Asp Arg Phe Glu Leu Phe Ile Ala Gly Lys Glu Ile Ala Asn Ala Phe		
	435	440	445
25	Ser Glu Leu Asn Asp Pro Ile Asp Gln Arg Leu Arg Phe Glu Glu Gln		
	450	455	460
30	Val Leu Glu Lys Ala Arg Gly Asp Glu Glu Ala Cys Pro Met Asp Glu		
	465	470	475 480
	Asp Tyr Leu Arg Ala Leu Glu Tyr Gly Met Pro Pro Ala Ala Gly Glu		
	485	490	495
35	Gly Ile Gly Ile Asp Arg Leu Val Met Leu Leu Thr Asp Ser Pro Ser		
	500	505	510
40	Ile Arg Glu Val Ile Leu Phe Pro Leu Leu Arg Thr Glu Arg		
	515	520	525

45 Claims

1. An isolated polynucleotide molecule comprising a nucleotide sequence that is selected from the group consisting of
 - a) a nucleotide sequence encoding *L. intracellularis* HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100 protein;
 - 50 b) a nucleotide sequence that is a substantial part of said nucleotide sequence encoding said *L. intracellularis* HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100 protein; and
 - c) a nucleotide sequence that is homologous to the nucleotide sequence of a) or b).
2. The isolated polynucleotide molecule of claim 1 comprising said nucleotide sequence encoding said *L. intracellularis* HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100 protein.
- 55 3. The isolated polynucleotide molecule of claim 1 comprising a nucleotide sequence consisting of the open reading frame selected from the group consisting of the open reading frame of SEQ ID NO: 1 from about nt 165 to about nt

1745, the open reading frame of SEQ ID NO: 1 from about nt 3031 to about nt 3738, the open reading frame of SEQ ID NO: 1 from about nt 3695 to about nt 6385, the open reading frame of SEQ ID NO: 2 from about nt 252 to about nt 2690, the open reading frame of SEQ ID NO: 2 from about nt 2891 to about nt 4315, and the open reading frame of SEQ ID NO: 2 from about nt 4581 to about nt 4829.

4. A polynucleotide molecule comprising a nucleotide sequence of greater than 20 nucleotides having promoter activity and found within SEQ ID NO: 2 from about nt 2691 to about nt 2890, or its complement.
5. A recombinant vector comprising the polynucleotide molecule of claim 1.
6. The recombinant vector of claim 5 consisting of a plasmid selected from the group consisting of plasmid pER432 containing the *ponA* gene (ATCC accession number PTA-635), plasmid pER434 containing the *htrA* gene (ATCC accession number PTA-636), plasmid pER436 containing the *hypC* gene (ATCC accession number PTA-637), plasmid pT068 containing the *lysS* and *ycfW* genes (ATCC accession number PTA-2232), plasmid pER438 containing the *ycfW* and *abc1* genes (ATCC accession number PTA-638), and plasmid pER440 containing the *Omp100* gene (ATCC accession number PTA-639).
7. A transformed host cell comprising the recombinant vector of claim 5.
8. A polypeptide produced by the transformed host cell of claim 7.
9. A genetic construct comprising a polynucleotide molecule that can be used to alter a *Lawsonia* gene, comprising:
 - (a) a polynucleotide molecule comprising a nucleotide sequence that is otherwise the same as a nucleotide sequence of a *htrA*, *ponA*, *hypC*, *lysS*, *ycfW*, *abc1*, or *omp100* gene, or that is otherwise the same as a nucleotide sequence that is homologous thereto, or a substantial portion of said nucleotide sequence, but which nucleotide sequence further comprises one or more mutations capable of altering the *htrA*, *ponA*, *hypC*, *lysS*, *ycfW*, *abc1*, or *omp100* gene; or
 - (b) a polynucleotide molecule comprising a nucleotide sequence that naturally flanks *in situ* the ORF of said *htrA*, *ponA*, *hypC*, *lysS*, *ycfW*, *abc1*, or *omp100* gene, or a nucleotide sequence that is homologous to said flanking sequence; such that transformation of a *Lawsonia* cell with the genetic construct of (a) or (b) results in altering the *htrA*, *ponA*, *hypC*, *lysS*, *ycfW*, *abc1*, or *omp100* gene.
10. A transformed cell comprising the genetic construct of claim 9.
11. An isolated polypeptide, said polypeptide being selected from the group consisting of:
 - (a) *L. intracellularis* HtrA, PonA, HypC, YcfW, ABC1, or Omp100 protein;
 - (b) a polypeptide having an amino acid sequence that is homologous to that of said *L. intracellularis* HtrA, PonA, HypC, YcfW, ABC1, or Omp100 protein;
 - (c) a polypeptide consisting of a substantial portion of said *L. intracellularis* HtrA, PonA, HypC, YcfW, ABC1, or Omp100 protein or of said polypeptide having an amino acid sequence that is homologous to that of said *L. intracellularis* HtrA, PonA, HypC, YcfW, ABC1, or Omp100 protein;
 - (d) a fusion protein comprising the protein or polypeptide of (a), (b) or (c) fused to another protein or polypeptide; and
 - (e) an analog or derivative of the protein or polypeptide of (a), (b), (c) or (d).
12. The isolated polypeptide of claim 11 wherein said *L. intracellularis* protein has an amino acid sequence that comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 102.
13. The isolated polypeptide of claim 11 comprising a polypeptide that consists of said *L. intracellularis* HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100 protein having between 1 and 10 amino acids inserted, deleted, or substituted, including combinations thereof.
14. A substantially pure polypeptide comprising an epitope of HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100 protein that is specifically reactive with anti-*Lawsonia* antibodies.
15. An isolated polypeptide comprising an amino acid sequence encoded by the polynucleotide molecule of claim 1.

16. An isolated antibody that specifically reacts with *L. intracellularis* HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100 protein.

5

17. A live attenuated vaccine comprising the transformed cell of claim 10.

18. A killed cell vaccine comprising transformed cells of claim 10 in killed form.

10

19. An immunogenic composition comprising an immunogenically effective amount of the polypeptide of claim 11 in combination with a pharmaceutically acceptable carrier.

20. An immunogenic composition comprising an immunogenically effective amount of a polynucleotide molecule comprising a nucleotide sequence encoding the polypeptide of claim 11 in combination with a pharmaceutically acceptable carrier.

15

20

25

30

35

40

45

50

55

FIG. 1




FIG. 2

```

Li_Ycfw  ---MKFELFIALHYLFARRKQAFIYLISLMSILGVAIGVASLVVVLGVYNGFTIDIRDKI  57
AJ235272 MINNNFSFNIAFRYFRAKKNEKFVSIIAAFSLVGMIGVAALIVVMSVMNGFHLELTKNI  60
      :*.: **::*: *::: *: *: :*:** ***:**:* ** *:: :.*

Li_Ycfw  LGANAHIITGNFDSPIEPTSFTQLSTTSMLSQNALIILNKLQOTSAAIGATPFIYAEC  117
AJ235272 IGLNGDIVINRQGDN-----IDNYEEIKTTLKQDYVKHVITYIAHQALALGK-----  158
      :* *..*:* : *.      . : .*:**:* : .. : : .* ..

Li_Ycfw  MISSPHGVKGLILRGIDPSSAQNVISMLSHLTGKNGLEDLIPKVLGTPDGIIGNELAQRL  177
AJ235272 ---SNN--SGVLVKGIKLNDSLNRNGIFKNVNFSGFDNPHGKNV-----IALGEQLASNL  158
      * : .*:***. . . . : : : .*:*** : * : * :*:***..*

Li_Ycfw  NVTIGSRVNLLSPTGQKTSSGFQPRIRPLIVTGIFHTGMFEYDTSLAFTSLNAARELLGL  237
AJ235272 GVTVGEKLRLLISPSVSTAFGSI PRSKEFQIIAIFNSGMYDYDLTTILMPLTAAQNFLSL  218
      .**.*.:**.*.. *: * ** : : : .*:***:*** : : .*:***:***

Li_Ycfw  PHYTISGIEVSIHDVYQANYITNQLQOELGHNFSVRSWMDMNANLFAALKLEKIGMFIL  297
AJ235272 G-NDINSIEINSLDPDQAITYSYKIQSLGPNLYVFNWKTLSQFLSALAVERTAMFTIL  277
      * *..*:. * ** : :*. ** *: * . * :*:***:*** :*:*** **

Li_Ycfw  AMVVLIGSFSIVTTLIMLVMEKTRDIAILTSMGATSQIMIRRIFFILOGTIIGIVGTLLGYL  357
AJ235272 SLIITVAAFNIISNLFMLVKDKTSDIAILRTMGASTKQIMVIFIYNGMFIGLGLTTLGLV  337
      :*: :*:**.*:*** :** ***** :***: : * *** :* :*:*****

Li_Ycfw  LGITLALLLQKYQ-----FIKLPPGVYTIDHLPVLLNWLDIFIIGTSAMLLCFFATL  409
AJ235272 LGVTFSYNIQTIKNYLERITGIKIFEAAIYFLYSLPSKVKTDDIILITSLSIILCFLATI  397
      **:*. :*. : : : :*: : ** : : **:*. : :*:***:***

Li_Ycfw  YPAHQARLQPIEGLRYE 427
AJ235272 YPSYRASKLNPVDALRYE 415
      **:***:***:***.****

```

FIG. 3

```

Li_ABC1      MSQYLLENIVKQYDSPSEPICVLHKINLSIAHGESLAIIGASGSGKSTLLHLGALDIPS 60
AE000212    ---MQCDNLCRRYQEGSVQTDVLHNVFSVGEGETMAIVGSSGSGKSTLLHLGGLDTPT 57
           :*: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *:
           :*: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *:
Li_ABC1      SGTVLFNKNLSHMGPNEKACFRNKLGLFIFQFHNLLPEFSAEENVAMKALIAGIPKKKA 120
AE000212    SGDVI FNGQPM SKLSSAAKAE LRNQKLGFIYQFHHLLPDPFTALENVAMP LLIGKKKPAEI 117
           ** *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *:
           ** *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *:
Li_ABC1      LLLAREALG SVGLE NKYHHRITMLSGGERQ RVAIARA ILLEPQVLLADEPTGNLDQKTGE 180
AE000212    NSRALEMLKAVGLDHRANHRPSELSGGERQ RVAIARA LVNPNRVLADEPTGNLDARNAD 177
           * * * *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *:
           * * * *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *:
Li_ABC1      HIANLLISLNKTFNITLIVVTHNNDIAHSMGRCL ELKSGDLHDKTP EYISSTVTV 235
AE000212    SIFQLLGELNRLQGTAFLV VTHDLQLAKRMSRQLEMRDGRLLTAELSLMGAE --- 228
           * *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *:
           * *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *: *:

```

FIG. 4

```

Li_OMP100 MTKRLNIFLLLLLCNILYCNIANAASKDDPSIVLVPFQINGSSNDEELQTELPMLLATA 60
U70214 -----
Li_OMP100 LKNKGFRVIPNKSALNLLYQONISQLNISTAKKVAQQLHADYVVYGSFNQTGENFSIDSR 120
U70214 -----
Li_OMP100 LIDSTGVASARPLYIEKPKFNELNIAVTELAERISNGLIKKNTIADVRIHGLKVLPDVI 180
U70214 -----MAMKKLLIASLLFSSATVYG-AEGFVVKDIHFEGLRVAVGAA 42
      : : * * * : : * : : * : : * : :
Li_OMP100 LTRLTINKGDHTDHAKINAEIKKIWELGYFSDVSASIEESGEGRLLVFTVQEKPKITDVV 240
U70214 LLSMPVRTGDTVNDENISNTIRALFATGNFEDVRVLRD---GDTLLVQVKERPTIASIT 98
      * : : : * * * : : * : : * * * : : * : : * : : * : :
Li_OMP100 VQGSKAVSIDNILAAMSSK--KGSVISDRLLSQDIQK-ITDLYRKEGYLLAEVNYEIKEK 297
U70214 FSGNKSVDKDDMLKQNLASGVRVGSGLDRTTIADIEKGLEDFYYSVGKYSASVKAVVTPL 158
      . : * : * : : : : : * * * : : * : : * : : * : :
Li_OMP100 ENTSSATLLLTVNEGKKLYIKDVRIELETIKAKTLKKELALTERNFLSWFTGTG--VLR 355
U70214 P-RNRVDLKLVFQEGVSAEIQQINIVGNHAGTTDELISHFQL--RDEVPWWNVVGDRLKYQ 215
      . : * * : : * * : : : * * : : : * : : * : : * : :
Li_OMP100 EEYLERDSIAISAYAMNHGYVDIQVASPEVTFN--EKGIVITFRVKEGKRYKIGKIDFKG 413
U70214 KQKLAGDLETLRSYLLDRGYARFNIDSTQVSLTPDKKGIYVTVNITEGDQYKLSGVEVSG 275
      : : * * : : * : : * : : * : : : : * * : : : * : :
Li_OMP100 DLIETNEQLLKVTIKIDDHKNYEQYFSLVMDQDDVKALTDYFSDYGYAAAEVDLETTKNEE 473
U70214 NLAGHSAEIEQLTKIEPGE-LYNGTKVTKMEDDIKKLLG---RYGYAYPRVQSMPEINDA 331
      : * : : : * : : : : * : : * * : : * : : * : : * : :
Li_OMP100 DATIDVTFLIDKKQKQVFLRRIIVEGNTRTRDNVILRELRLADGDLENGQHLRBSNECLNR 533
U70214 DKTVKLRVNVVDAGNRGYVRKIRFEGNDTSKDAVLRREMROMEGAWLGSELVDQGERLNR 391
      * * : : . : * : : : * : * * * : : * : : * : : * : :
Li_OMP100 LGYFNQVDTDFTLPT-GKDDEVLLVKVQEARTGAITGGVGYSTHSGFGVSGSISERNLWG 592
U70214 LGFFETVDTDTQRPVSPDQVDVYKVKERNVTSFNGIGYGTESGVSFQAGVQDQDNWLW 451
      * : : * : : * : : * : : * : : * : : * : : * : : * : :
Li_OMP100 KGYILSIEGFISSKSSSLDLSFTNP--RVYDTDFG---FSNNIYTLRDEWDDFRKKTGYD 647
U70214 TGYAVGINGTKNDYQTYAELSVTNPYFTVDGVSLLGGRLFYNDFQADDADLSYTNKSYGT 511
      . * : : * : : : : * : * * : : * : : * : : * : :
Li_OMP100 TIRLFHPIGEYSSIFVGYRIDQYRLYDI-PSTAPRSYLDYQGNISSVSVSG-----FT 700
U70214 DVTLGFPINEYNSLRAGLGYVHNSLSNMQPQVAMWRYLYSMGEHPSTSDQDNSFKTDDFT 571
      : * * * * : : * : : * : : * * : : * : : * : :
Li_OMP100 FDSTDSRERPSKGHIK---LIVEYGGGGLGNDN-FFKPIAELQGFYSISRKNHIIHW 756
U70214 FNYGWTYNKLDRGYFPTDGSRVNLTGKVTIPGSDNEYKVTLDATYVPIDDDHKWVVLG 631
      * : : : : * : : : : * : : * : : * : : * : : * : :
Li_OMP100 RTRAGAAYKNSKKPVVDFRFFIGGIDSIRGYDTEDLAPK-----DP----- 798
U70214 RTRWGYGDGLGGKEMPFYENFYAGGSSTVRGFSNTIGPKAVYFPHQASNYDPDYDECA 691
      * * * . : * : : * : * : : * : : * : : * : :
Li_OMP100 -----RFGDEIGGDRMAFLNLEYIWF-----QPELGLALVPFYDIGFQTDTSVQTS 844
U70214 TQDGAKDLCKSDDAVCGNAMAVASLEFITPTPFISDKYANSVRTSFFWDMGTVWDTNWD 751
      : * : * : * : * : : : : : : : * : : * : :
Li_OMP100 NPFS-----KLKQSYGLELRWRSPMGDLRFAYGIPLKNVSGKKTRGRFEFSMGQF 895
U70214 SQYSGYPDYS DPSNIRMSAGIALQWMSPLGPLVFSYAQPFKKYDGDK--AEQFQFNIGKT 809
      . : * : : * : * : * * : : * : : * : : * : :
Li_OMP100 F 896
U70214 W 810
      :

```

FIG. 5

Li_PonA -MKQVISFDMKKFFLNIVIFCFGIILLSIIGLIGLYFWVSRDLPNITKLNDRPALVTTV 59
 AF087677 MIKKIITTCMG---LNNGLALFGVGLIAIALV-----TYPKLPSLDSLQHYKPKLPLTI 52
 :*: *: * : *: *: * . :*: *: *: *: *: *

Li_PonA LARDGTLIGYIYREKRFLIPLSEMSPFPLPKAFLAAEDAEFYEHGVNPLAIRAFILNLO 119
 AF087677 YSSDGQVIGVYGEQRREFTKIDDFPKILKDAVIAAEDKRFYDHWGVDVWGVAVRIGNVM 112
 : * : * : * : * : * : * : * : * : * : * : *

Li_PonA SGTTRQGGSTITQQVIKRLLLSPERSYERKIKEAILAYRLEKYLKDEILTIYLNQTFGL 179
 AF087677 AGGVQSGASTITQQVAKNFYLSSESRFTRKFNEALLAYKIEQSLSKDKILELYFNQIYLG 172
 : * : * : * : * : * : * : * : * : * : * : *

Li_PonA AHSYGVEAAARTYFAKHAKDLSLAECALLAGLPQAPSRYNPYKDEAAKIRQRYALRRLH 239
 AF087677 QRAYGFASAAQTYFNKNVNDLTAEAAMLAGLPKAPSAYNPVPERAKLRQAYILNNML 232
 : * : * : * : * : * : * : * : * : * : * : *

Li_PonA DVGWITQAEYEEALQEPLYFSSMKEGLGAESSWYMEEVKQLVSLKENISQYGIVLPL 299
 AF087677 EEGMITLQQRDQALKEELHYERFVQNIQDSALVAEMARQEL--F-----EK 277
 : * * : : * : * : * : * : * : * : * : *

Li_PonA YGEDALYELGFTIQTAMPQALVAYDVLRLNGLENFSK---RQWKGPIEHISSTMIQHY 356
 AF087677 YGEDA-YTQGFVYTTVDTAHQRVATEALRKVLNRNDRGSSYRGAENYIDLSKSDNVEET 336
 * * * * * : * : * : * : * : * : * : * : *

Li_PonA LENATFTPEKLDGGAWAKAIVSKVSQEGAEVFLSSIIYKGFVSVETMGWARKPNPEVRSAY 416
 AF087677 VSQYLSTLYTVD--KMIPAVVLEASRKGVQIQLPSGRKVTLNHALGFA-----ARAVN 388
 : : * : * : * : * : * : * : * : * : *

Li_PonA CAPIKDARSVLNPGDIWVSGVGPDSHRYSSKTLDTSKPIPLALQQLPQILOGALISIEP 476
 AF087677 NEKMGDDR--IRRGSVIRVKGSG-D-----TFTTVQEPQLQALVSLDA 429
 : * * : * : * : * : * : * : * : * : *

Li_PonA NTGDVIAMIGGYEFGKSQFNRAVQAMRQPGSAFKPIVYSAALDHDYTSATMVLDAPIVEF 536
 AF087677 KTGAVRALVGGYDYHSKTFNRATQAMRQPGSTFKPFIYSAALAKGMTASTMINDAPISLP 489
 : * * : * : * : * : * : * : * : * : *

Li_PonA ME--SGDIWRPGNYEKNFKGPMFLSNALALSRNLCTVRIAQSIGLPAVIERAKALGFNGN 594
 AF087677 GKGANGKAWNPKNSDGRYAGYITLRQALTASKNMVSIRILMSIGIGYAQQYIQRFGFKPS 549
 : * : * : * : * : * : * : * : * : *

Li_PonA -FPEFFSISLGAVEVTPIRLVNAYTAFANGGNLATPRFILSIKDSNN-TVIYRQEIEQHP 652
 AF087677 EIPASLSMALGAGETTPLRIAEGYSVFANGGYKVSAAHVIDKIYDSQGRRLRAQMQLVAGE 609
 : * : * : * : * : * : * : * : * : *

Li_PonA ----VISPQAYIMASLLKNVVNIGTARKAKVLERP-LAGKTGTNGEHDWFIGFTPYL 707
 AF087677 NAPQAIDPRNAYIMYKIMQDVVRVGTARGAATLGRSDIAGKTGTNDNKDAWFGVGNPNV 669
 : * : * : * : * : * : * : * : * : *

Li_PonA VTGVYVGNLHPQTLGKDGTVGAVALPIFTEYSKVVLKYPESDFPVPDGITFASIDTQGT 767
 AF087677 VTAVYIGFDKPRSMGRAGYGGTIAVPVWVEYIGFALKGTSVKPMKAPEGVVTNGGEVYMR 729
 * : * : * : * : * : * : * : * : *

Li_PonA NRATANS----TNSVVLV-----FYVGTVPYFDSKDNEVNTIERGED 806
 AF087677 ERMTTSSDLALDNSGIRPRPTQPARRAVPNENRRRAESNTAPAREESDET PVLPSNTGN 789
 : * * : * : * : * : * : * : * : *

Li_PonA ---LLKQFF 816
 AF087677 NRQQLDSL 798
 * : * : *

FIG. 6

```

Li_HtrA  MFCKLKVIICITLMFIITVVPPTAESALPNFVPLVKDASKAVVNISTEKKIPR---GRTE  57
U32853    -MHTLKRCMAAMVALLALSLAMTARAELPDFTPLVEQASPAVVNISTRQKLPDRAMARGQ  59
          : .**  :.  : ::  :.  *.: **:*.***:.* *****.:*:*  .*  :

Li_HtrA  FPMEMFRGLPPGFERFFEQFEPKGPDSQIHKQR---SLGTGFIISDGYIVTNNHVIEGA  114
U32853    LSIPDLEGLPPMFRDFLERSIPOVPRNPRGQOREAQSLGSGFIISNDGYILTNNHVVADA  119
          :.:  :.**** * .*:.*: * : * .  :**  ***.*****.*****.*****.: *

Li_HtrA  DSVRVNLEGTSGKEESLPAEVIGRDEETDLALLKVKSKDSLPLYLIFGNSDTMEVGEWVLA  174
U32853    DEILVRLSDRS--E--HKAKLIGADPRSDVAVLKIEAKN-LPTLKLGD SNKLVGEWVLA  174
          *: *.*. * *  *.:** * .:*.***:.*: ** * .*:.*.:*****

Li_HtrA  IGNPFGLGHTVTAGILSAKGRDIHAGPFDNFLQTDASINPGNSGGPLINMSGQVVGINTA  234
U32853    IGSPFGFDH SVTAGIVSAKGRSLPNESYVFFIQTDVA INPGNSGGPLLNLOGEVVGINSQ  234
          **.*.*:.*.*****.*****.:  :  *.*.*.*****.*****.:*.*.*.*:

Li_HtrA  IMAS-G--QGIGFAIPSSMADRIIEQLKTNKKVSTGWIGVTIQDVTNTAKALGLSQAKG  291
U32853    IFTRSGGFMGLSFAIPIDVALNVADQLKKAGKVSTGWLGVVIOEVNKDLAESFGLDKPSG  294
          *: *  *.*.*. :.*  :.:***.  *****:.*.*.*. :.:**.*. :.*

Li_HtrA  ALVGSVVPGD PADKAGLVGDIVTQADGKQIDSASSLLKAIATKPPFSVVKLKVWRDGKS  351
U32853    ALVAQLVEDGPAAKGGLQVGDVILSLNQSINESADLPHLVGNMKPGDKINLDVIRNGQR  354
          ***.:.*  ..** *.*.*.*.:.  :*:.*.:.*: * :.. * . :*:.* *.*:

Li_HtrA  KDISITLGER---KTTSSQKQSSPESLPGALGLSVRPLTQEESKSFVDVKLGIGLLVVSV  407
U32853    KSLSMVAGSLPDDDEEIASMGAPGAERSSNRLGVTVADLTAEQRKSLDIQG--GVVIKEV  402
          *:.*.:.*.  :  :*  ...*  .. **:.*  ** *: **.*:  *.:. :*

Li_HtrA  EPNKPASEAGIREQDIILSANLKPLQSADDLANIICGDAKKKGVIMLQLQRNGQTFFKTL  467
U32853    Q-DGPAAVIGLRPGDVITHLDNKAVTSTKVFADVAKALPKNR-SVSMRVLROGRASFITF  470
          : : **:  *: *  *:  : *: *.: :*:  . .*:  : :*:  *:.*:  * *:

Li_HtrA  SLTEDSN  474
U32853    KLAE---  474
          .*:

```

79

Fig. 8

Li_ORF1	U67555	----- MNVFDKYAEEYDKWFDENEI IYKSEIEALKRHI PKGRGLEIGVGTGRFAKPFNIKIGVDI 60 -----
Li_ORF1	U67555	-----EFQLGALDDLPPFEDESFNyasLVtILEYVEDPKKILAEAFRVASDG- 46 SKEMAKIAEKRGIKVII AKGEDLPFKDEEDFFLINTVLFEAPENPKKMIEEAKRVLKRG 120 :. : . : ****:***: * : * : * : * : * : *
Li_ORF1	U67555	-IIVGFTNKWSINHIINSTLQLLHKKPKKDSQWVSPWQLIRLTQLYPECRIYCRSTLLG 105 KIIIGIIDRDSFLGKMYEEKQKSK - FYKDANFLSAKEVI EMLKELG ----- FKN 169 **:* : : * : * : * : * : * : * : *
Li_ORF1	U67555	PKRTWDVTSSWSKLNRIILSFPPIG --TYVGMRIEKRPKPTLTPLLKAQEAVNVYNALS 153 IKATQTIFKEIDKVCKVEVKEGYGEGFVAISAEKI ----- 205 * * : .. *: :: : . : * : * : *
Li_ORF1	U67555	PEATSTIQHNRTNK 177 -----

80

[illegible]

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 094 070 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
09.01.2002 Bulletin 2002/02

(51) Int Cl.7: **C07K 14/205, C12N 15/31**

(43) Date of publication A2:
25.04.2001 Bulletin 2001/17

(21) Application number: **00309125.3**

(22) Date of filing: **17.10.2000**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**
Designated Extension States:
AL LT LV MK RO SI

(71) Applicant: **Pfizer Products Inc.**
Groton, Connecticut 06340 (US)

(72) Inventor: **Rosey, Everett Lee,**
Pfizer Central Research
Groton, Connecticut 06340 (US)

(30) Priority: **22.10.1999 US 160922 P**

(83) Declaration under Rule 28(4) EPC (expert
solution)


(74) Representative: **Eddowes, Simon et al**
Urquhart-Dykes & Lord, 30 Welbeck Street
London W1G 8ER (GB)

(54) **Lawsonia intracellularis proteins, and related methods and materials**

(57) Isolated polynucleotide molecules contain a
nucleotide sequence that encodes a *L. intracellularis*
HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100 pro-

tein, a substantial portion of the sequences, or a homol-
ogous sequence. Related polypeptides, immunogenic
compositions and assays are described.

FIG. 1



EP 1 094 070 A3



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 00 30 9125

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
D,X	WO 97 20050 A (PIG RESEARCH AND DEV CORP ;HASSE DETLEF (AU); DARATECH PTY LTD (AU) 5 June 1997 (1997-06-05)	1-3	C07K14/205 C12N15/31
A	* the whole document *	5-20	
X	DALE C JANE H ET AL: "Identification and sequencing of the groE operon and flanking genes of Lawsonia intracellularis: Use in phylogeny." MICROBIOLOGY (READING), vol. 144, no. 8, August 1998 (1998-08), pages 2073-2084, XP002156652 ISSN: 1350-0872	1-3	
A	* the whole document *	5-20	
A	BOUCHER J C ET AL: "Two distinct loci affecting conversion to mucoidy in Pseudomonas aeruginosa in cystic fibrosis encode homologs of the serine protease HtrA." JOURNAL OF BACTERIOLOGY, vol. 178, no. 2, 1996, pages 511-523, XP002117832 ISSN: 0021-9193 * abstract; figure 7 *		TECHNICAL FIELDS SEARCHED (Int.Cl.7) C07K
-The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 17 January 2001	Examiner Morawetz, R
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 (3.82 (Pdc01))

European Patent
OfficeLACK OF UNITY OF INVENTION
SHEET B

Application Number

EP 00 30 9125

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

1. Claims: 1-3, 5-20 (all partially), 4 (completely)

A nucleotide sequence encoding L. intracellularis HtrA protein (SEQ ID NO:2, nt 2891 - nt 4315) and subject-matter relating thereto.

2. Claims: 1-3, 5-20 (all partially)

A nucleotide sequence encoding L. intracellularis PonA protein (SEQ ID NO:2, nt 252 - nt 2690) and subject-matter relating thereto.

3. Claims: 1-3, 5-20 (all partially)

A nucleotide sequence encoding L. intracellularis HypC protein (SEQ ID NO:2, nt 4581 - nt 4829) and subject-matter relating thereto.

4. Claims: 1-3, 5-10, 12-18 (all partially)

A nucleotide sequence encoding L. intracellularis LysC protein (SEQ ID NO:1, nt 165 - nt 1745) and subject-matter relating thereto.

5. Claims: 1-2, 5-20 (all partially)

A nucleotide sequence encoding L. intracellularis YcfW protein (SEQ ID NO:1, nt 1745 - nt 3028) and subject-matter relating thereto.

6. Claims: 1-3, 5-20 (all partially)

A nucleotide sequence encoding L. intracellularis ABC1 protein (SEQ ID NO:1, nt 3031 - nt 3738) and subject-matter relating thereto.

7. Claims: 1-3, 5-20 (all partially)

A nucleotide sequence encoding L. intracellularis Omp100 protein (SEQ ID NO:1, nt 3695 - nt 6385) and subject-matter relating thereto.

Article 82 EPC stipulates that the European patent application shall relate to one invention only or to a group so linked as to form a single general inventive concept. Where a group of inventions is claimed in one and the same European patent application, the requirement of unity of invention shall be fulfilled only when there is a technical relationship among those inventions involving one or more of the same or corresponding "special technical features", i.e. technical features that define a novel and inventive contribution over the prior art (Rule 30 EPC).



European Patent
Office

**LACK OF UNITY OF INVENTION
SHEET B**

Application Number
EP 00 30 9125

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

The present application discloses the identification of seven nucleotide sequences encoding seven different *Lawsonia intracellularis* proteins (HtrA, PonA, HypC, LysC, YcfW, ABC1 and Omp100).

Nucleotide sequences encoding various *Lawsonia intracellularis* proteins are already known from the prior art (see e.g. Dale C.J.H. et al., Microbiology (1998), 144, 2073-2084 or WO9720050).

The problem underlying the present application can, thus, be seen as the provision of further nucleotide sequences encoding alternative *Lawsonia intracellularis* proteins.

The solutions as disclosed and claimed in the present application can be summarised as the provision of the 7 sequences and the polypeptides they encode (SEQ ID Nos:1-8 and 102).

Due to the fact that nucleotide sequences encoding *Lawsonia intracellularis* proteins are already known from the prior art, due to the essential differences between the primary structures of the sequences claimed and due to the fact that no other technical feature can be distinguished which in light of the prior art could be regarded as a special, common technical feature, the Search Division is of the opinion that there is no single inventive concept underlying the plurality of different inventions of the present application in the sense of Rule 30 EPC.

Consequently there is lack of unity, and the different inventions not belonging to a common inventive concept are formulated as the different subjects in the communication pursuant to Rule 46 EPC.

ANNEX TO THE EUROPEAN SEARCH REPORT ON EUROPEAN PATENT APPLICATION NO.

EP 00 30 9125

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

17-01-2001

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9720050 A	05-06-1997	AU 718333 B2	13-04-2000
		AU 7614196 A	19-06-1997
		WO 9720050 A1	05-06-1997
		BR 9611623 A	28-12-1999
		CA 2236574 A1	05-06-1997
		CN 1203630 A	30-12-1998
		EP 0871735 A1	21-10-1998
		JP 2000502054 T	22-02-2000

EPO FORM P0439

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82